[COMPANY_001] Research and Development
LOU064/remibrutinib
Clinical Trial Protocol CLOU064A2301 / [STUDY_ID_REMOVED]
A multicenter, randomized, double- blind, 
placebo -controlled Phase 3 study of remibrutinib (LOU064) 
to inv estigate the efficacy , safety and tolerability for 52 
weeks in adult chronic spontaneous urticaria patients 
inadequately controlled by H1 -antihistamines
Document type: Global Amended Protocol Version
EUDRACT number: 2021 -000471 -37
Version number: 01 (Clean )
Clinical Trial Phase: III
Release date: 23-May-2022 (content final)
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Template Version 4.0 dated 15 -Feb-2021

[COMPANY_001] Confidential Page 2of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Table of contents
Table of contents ................................................................................................................. [ADDRESS_181910] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 11
Protocol summary .............................................................................................................. 17
1Introduction ....................................................................................................................... 23
1.1 Background ............................................................................................................ 23
1.2 Purpose .................................................................................................................. 24
2
Objectives, endpoints and estimands................................................................................. 24
2.1 Primary  estimands ................................................................................................. 29
2.2 Secondary  estimands
............................................................................................. 30
3Study  design ................................ ................................ ................................ ...................... 31
4Rationale ............................................................................................................................ 32
4.1 Rationale for stud y design ................................ ................................ ..................... 32
4.1.1 Rationale for choice of background therap y ......................................... 34
4.2
Rationale for dose/regimen and duration of treatment .......................................... 34
4.3 Rationale for choice of control drugs (comparator/p
lacebo) or combination 
drugs ...................................................................................................................... 37
4.4 Purpose and timing of interim anal yses/design adaptations .................................. 38
4.5 Risks and benefits .................................................................................................. 39
4.6 Rationale for Public Health Emergency  mitigation procedures
............................ 43
5Study  Population ............................................................................................................... 43
5.1 Inclusion criteria .................................................................................................... 44
5.2 Exclusion criteria ................................................................................................... 44
6Treatment ........................................................................................................................... 47
6.1 Study  treatment ...................................................................................................... 47
6.1.1 Investigational and control drugs .......................................................... 48
6.1.2 Additional study  treatments .................................................................. 48
6.1.3 Treatment arms/group ........................................................................... 48
6.1.4 Treatment duration ................................................................................ 48
6.2 Other treatment(s) .................................................................................................. 48
6.2.1 Concomitant therap y
............................................................................. 48
6.2.2 Permitted concomitant therap y requiring caution and/or action ........... 49
6.2.3
Prohibited medication ........................................................................... 49
6.2.4
Rescue medication ................................................................................ 52

[COMPANY_001] Confidential Page 3of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
6.3 Preparation and dispensation ................................................................................. 53
6.3.1 Handling of study  treatment and other treatment .................................. 53
6.3.2 Instruction for prescribing and taking stud y treatment ......................... 54
6.4
Participant numbe ring, treatment assignment, randomization .............................. 54
6.4.1 Participant numbering ........................................................................... 54
6.4.2 Treatment assignment, randomization .................................................. 55
6.5 Treatment blinding ................................................................................................. 55
6.6
Dose escalation and dose modification.................................................................. 56
6.6.1 Follow -up for toxicities ......................................................................... 56
6.7 Additional treatment guidance ............................................................................... 56
6.7.1 Treatment compliance ........................................................................... 56
6.7.2 Emergency  breaking of assigned treatment code .................................. 57
6.7.3 Treatment of overdose ........................................................................... 57
7Informed consent procedures
............................................................................................ 58
8
Visit schedule and assessments ......................................................................................... 59
8.1 Screening ............................................................................................................... 66
8.1.1 Information to be collected on screening failures ................................. 66
8.2
Participant demographics/other baseline characteristics ....................................... 66
8.3 Efficacy .................................................................................................................. 67
8.3.1 eDiary  assessments ................................................................................ 67
8.3.2
Other Patient Reported Outcomes (PRO) assessments......................... 70
8.3.3 Appropriateness of efficacy  assessments .............................................. 72
8.3.4 Other assessments: eviden ce of urticaria .............................................. 72
73
8.4 Safet y
..................................................................................................................... 73
8.4.1 Laboratory  evaluations .......................................................................... 75
8.4.2 Electrocardiogram (ECG) ..................................................................... 76
8.4.3 Pregnancy  and assessments of fertility ................................................. 77
8.4.4 Appropriateness of safety  measurements .............................................. 78
8.5
Additional assessments.......................................................................................... 78
8.5.1 Clinical Outcome Assessments (COAs) ............................................... 78
78
79
9
Discontinuation and completion................................ ................................ ........................ 80
9.1 Discontinuation from study  treatment and from study .......................................... 80
9.1.1 Discontinuation from study  treatm ent................................................... 80

[COMPANY_001] Confidential Page 4of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
9.1.[ADDRESS_181911] to follow -
up................................................................................... 82
9.2
Withdrawal of informed consent/Opposition to use data/biological samples .......[ADDRESS_181912] -study  treatment .......................................................... 83
9.4 Early study termination by [CONTACT_456] ................................................................. 83
10Safety  monitoring, reporting and committees ................................................................... 84
10.1 Definition of adverse events and reporting requirements ...................................... 84
10.1.1 Adverse events ...................................................................................... 84
10.1.2 Serious adverse events .......................................................................... 85
10.1.3 SAE report ing........................................................................................ 86
10.1.4 Pregnancy  reporting .............................................................................. 87
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 88
10.2 Additional Safety  Monito ring................................................................................ 88
10.2.1 Liver safety  monitoring ......................................................................... 88
10.2.2 Renal safet y monitor ing........................................................................ 89
10.3 Committees ............................................................................................................ 89
10.3.1 Data Monitoring Committee ................................................................. 89
10.3.2 Steering Committee ............................................................................... 90
11Data Collection and Database management ................................ ................................ ......90
11.1 Data collection....................................................................................................... 90
11.2 Database management and quality  control ............................................................ 90
11.3 Site monitoring ...................................................................................................... 91
12Data analy sis and statistical methods ................................ ................................ ................ 91
12.1 Analy sis sets .......................................................................................................... 92
12.2 Participant demographics and other baseline characteristics ................................. 92
12.3 Treatments ............................................................................................................. 92
12.4 Analy sis supporting primary  objectives ................................................................ 93
12.4.1 Definition of primary  endpoint(s) ......................................................... 93
12.4.2 Statistical model, hy pothesis, and method of a nalysis.......................... 93
12.4.3 Handling of intercurrent events of primary  estimand ........................... 94
12.4.4 Handling of missing values not related to intercurrent event ............... 95
12.4.5 Sensitivity  analy ses............................................................................... 96
12.4.6 Supplementary  anal ysis......................................................................... 96
12.5 Analy sis supporting secondary  objectives ............................................................. 97
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) .................................... 97
12.5.2 Safety  endpoints .................................................................................. 101

[COMPANY_001] Confidential Page 5of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
102
102
103
103
103
104
12.7 Interim anal yses................................................................................................... 105
12.8
Sample size calculation........................................................................................ 105
12.8.1 Primary  endpoint(s) ............................................................................. 105
12.8.2 Secondary  endpoint(s) ......................................................................... 106
13Ethical considerations and administrative procedures .................................................... 107
13.1 Regulatory  and ethical complianc e
...................................................................... 107
13.2 Responsibilities of the investigator and IRB/ IEC................................................ 107
13.3 Publication of study  protocol and results ............................................................. 107
13.4 Quality  Control and Quality  Assurance ............................................................... 107
13.5 Participant Engagement ....................................................................................... 108
14Protocol adherence .......................................................................................................... 108
14.1 Protocol amendments ........................................................................................... 108
15References ....................................................................................................................... 109
16Appendices ................................ ................................ ................................ ...................... 113
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ....................... 113
16.2 Appendix 2: L iver event and laboratory  trigger definitions & follow -up 
requirements ........................................................................................................ 114
16.3
Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow -up.... 118
16.4 Appendix 4: PRO Tools ....................................................................................... [ADDRESS_181913] of tables
Table 2
-1 Objectives and related endpoints –Scenario with UAS7 as the 
primary  efficacy  endpoint ..................................................................... 25
Table 2
-2 Objectives and related endpoints -Scenario with ISS7 and HSS7 as 
the co- primary  efficacy  endpoints ......................................................... 28
Table 6
-1 Investigational and control drug............................................................ 48
Table 6
-2 Permitted concomitant therap y requiring caution and/or action ........... 49
Table 6-3 Prohibited me dication ................................ ................................ ........... 49
Table 8-1 Assessment Schedule ................................ ................................ ............ 61
Table 8-2 UPDD .................................................................................................... 67
Table 8
-3 Hives Severit y Score ............................................................................. 68

[COMPANY_001] Confidential Page 6of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Table 8-[ADDRESS_181914] on patient's life ..................................... 70
Table 8
-8 Physical assessments ............................................................................. 74
Table 8
-9 Laboratory  assessments ......................................................................... 75
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... 88
Table 16
-1 Liver event and laboratory  trigger definitions .................................... 114
Table 16
-2 Follow up requirements for liver laboratory  triggers: AL T, AST 
and TBL ................................ ................................ .............................. [ADDRESS_181915] repeated measurement anal ysis, by  [CONTACT_1570] 
(FAS) ..................................................................................................... 36
Figure 4 -
2 UAS7 = 0 and UAS7 <= 6 response rate over time by  [CONTACT_6490] (as observed) (FAS).................................................................... 36
73
Figure 12 -
1 Testing s trategy  with UAS7 as the primary  endpoint ........................... 99
Figure 12 -2 Testing strategy  with I SS7/HSS7 as the co- primary  endpoints .......... 101

[COMPANY_001] Confidential Page 7of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
List of abbreviations
AAS Angioedema Activity Score
AD Atopic Dermatitis
AE Adverse Event
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
APTT Activated Partial Thromboplastin Time
AST Aspartate Aminotransferase
ATC Anatomical Therapeutic Chemical
b.i.d. bis in die/twice a day
BCR B cell receptor
BCRP Breast Cancer Resistance Protein
BP Blood Pressure
BTK Bruton's T yrosine Kinase
BTKi Bruton's T yrosine Kinase inhibitor
BUN Blood Urea Nitrogen
CINDU Chronic Inducible Urticaria
CIU Chronic Idiopathic Urticaria
CK Creatine Kinase
CMO&PS Chief Medical Office and Patient Safety
COA Clinical Outcome Assessment
COVID -19 Coronavirus disease 2019
CRA Clinical Research Associate
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CSR Clinical Study Report
CSU Chronic Spontaneous Urticaria
CU Chronic Urticaria
CV Coefficient of Variation
CYP Cytochrome P
DBP Diastolic Blood Pressure
DIN Drug Inducted Nephrotoxicity
DLQI Dermatology Life Quality Index
DMC Data Monitoring Committee
DNA Deoxyribonucleic Acid
ECG Electrocardiogram
EDC Electronic Data Capture
eDiar y Electronic Diar y
eGFR Estimated Glomerular Filtration Rate
eSAE Electronic Serious Adverse Event
eSource Electronic Source

[COMPANY_001] Confidential Page 8of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
FAS Full Analysis Set
FcγR Fc gamma receptor
FcεR Fc epsilon Receptor
FSH Follicle -stimulating Hormone
GCP Good Clinical Practice
GCS Global Clinical Supply
GGT Gamma -glutam yl transferase
GLDH Glutamate dehydrogenase
h Hour
HBc Hepatitis B core
HBcAb Antibodies against hepatitis B core antigen (anti -HBcAg antibodies)
HBsAb Antibodies against hepatitis B surface antigen (anti -HBsAg antibodies)
HBsAg Hepatitis B virus surface antigen
HBV Hepatitis B Virus
HCP Healthcare Professional
HCV Hepatitis C Virus
HCVAb Hepatitis C Virus Antibody
HDL High-Density Lipoprotein
hERG Human ether -a-go-go related gene
HIV Human immunodeficiency virus
HRQoL Health -Related Quality of Life
HSS Hives Severity Score
HSS7 Weekly Hives Severity Score
i.v. Intravenous
IA Intra-articular
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use
IEC Independent Ethics Committee
Ig Immunoglobulin
IMP Investigational Medicinal Product
IN Investigator Notification
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology
ISS Itch Severity Score
ISS7 Weekly Itch Severity Score
J2R Jump to Reference
KDIGO Kidney Disease Improving Global Outcome

[COMPANY_001] Confidential Page 9of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
LC-
MS/MSLiquid Chromatography –Mass Spectrometry
LDH Lactate Dehy drogenase
LDL Low-Density Lipoprotein
LFT Liver Function Test
LLOQ Lower Limit of Quantification
LTRA Leukotriene Receptor Antagonists
MAR Missing At Random
MCH Mean Corpuscular Hemoglobin
MCHC Mean Corpuscular Hemoglobin Concentration
MCV Mean Corpuscular Volume
MedDRA Medical dictionary for regulatory activities 
mg Milligram(s)
MI Multiple Imputation
ml Milliliter(s)
MMRM Mixed effect Model for Repeated Measurements
NOAC Novel Oral Anti Coagulant
NSAID Nonsteroidal Anti -Inflammatory Drug
PA Primary analysis
Pbo Placebo
PCR Protein -creatinine ratio
PD Pharmacodynamic(s)
PE Primary endpoint
PK Pharmacokinetic(s)
PRO Patient Reported Outcomes
PT Prothrombin Time
q.d. Once a Day
QMS Quality Management System
QTcF QT interval corrected by [CONTACT_6550]’s formula
RAS Randomized Set
RDO Retrieved Drop Out
RNA Ribonucleic Acid
s.c. Subcutaneous
SAE Serious Adverse Event
SAF Safety Set
SBP Systolic Blood Pressure
SD Standard Deviation
SjS Sjoegren’s Syndrome
SMQ Standardized MedDRA Query
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction

[COMPANY_001] Confidential Page 10of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
TBL Total Bilirubin
UAS Urticaria Activity Score
UAS7 Weekly Urticaria Activity Score
ULN Upper Limit of Normal
UPDD Urticaria Patient Daily Diar y
UV Ultraviolet
WHO World Health Organization 
WoCBP Women of Child -Bearing Potential

[COMPANY_001] Confidential Page 11of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Glossary  of terms
Additional treatment Medicinal products that may be used during the clinical trial as 
described in the protocol, but not as an investigational medicinal 
product (e.g. ,any background therapy)
Assessment A procedure used to generate data required by [CONTACT_49382] A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. taken from a study participant 
Clinical Outcome 
Assessment (COA)A measure that describes or reflects how a participant feels, functions, 
or survives
Coded Data Personal Data which has been de -identified by [CONTACT_30760] a code.
Cohort A group of individuals who share a common exposure,
experience or characteristic, or a group of individuals followed up
or traced over time
Control drug A study drug (active or placebo) used as a comparator to reduce 
assessment bias, preserve blinding of investigational drug, assess 
internal study validity, and/or evaluate comparative effects of the 
investigational drug
Discontinuation from 
studyPoint/time when the participant permanently stops receiving the study 
treatment and further protocol required assessments or follow -up, for 
any reason. No specific request is made to stop the use of their 
samples or data.
Discontinuation from 
study treatmentPoint/time when the participant permanently stops receiving the study 
treatment for any reason (prior to the planned completion of study drug 
administration, if any). Participant agrees to the other protocol required 
assessments including follow -up. No specific request is made to stop 
the use of their samples or data.
Dosage Dose of the study treatment given to the participant in a time unit (e.g. ,
100 mg once a day, 75 mg twice a day)
Electronic Data Capture 
(EDC)Electronic data capture (EDC) is the electronic acquisition of clinical 
study data using data collection s ystems, such as Web-based 
applications, interactive voice response s ystems and clinical laboratory 
interfaces. EDC include s the use of Electronic Case Report Forms 
(eCRFs) which are used to capture data transcribed from source 
data/documents used at the point of care
End of the clinical trial The end of the clinical trial is defined as the last visit of the last 
participant or at a later point in time as defined by [CONTACT_157057]/time of participant entry into the study at which informed consent 
must be obtained. The action of enrolling one or more participants
eSource (DDE) eSource Direct Data Entry (DDE) refers to the capture of clinical study 
data electronically, at the point of care. eSource Platform/Applications 
combines source documents and case report forms (eCRFs) into one 
application, allowing for the real time collection of clinical trial 
informati on to sponsors and other oversight authorities, as appropriate
Estimand As defined in the ICH E9(R1) addendum, estimand is a precise 
description of the treatment effect reflecting the clinical question posed 
by [CONTACT_6553]. It summarizes at a population -level what the 
outcomes would be in the same participants under di fferent treatment 
conditions being compared. Attributes of an estimand include the 
population, variable (or endpoint) and treatment of interest, as well as 

[COMPANY_001] Confidential Page 12of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
the specification of how the remaining intercurrent events are 
addressed and a population- level summ ary for the variable.
Healthy volunteer A person with no known significant health problems who volunteers to 
be a study participant 
Intercurrent events Events occurring after treatment initiation that affect either the 
interpretation or the existence ofthe measurements associated with the 
clinical question of interest.
Investigational drug/ 
treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Mis-randomized 
participant sMis-randomized participants are those who were not qualified for 
randomization and who did not take study treatment, but have been 
inadvertently randomized into the study 
Off-site Describes trial activities that are performed at remote location by [CONTACT_106623]-
site healthcare professional, such as procedures performed at the 
participant's home.
Other treatment Treatment that may be needed/allowed during the conduct of the study 
(i.e., concomitant or rescue therapy)
Part A sub -division of a study used to e valuate specific objectives or contain 
different populations. For example, one study could contain a single 
dose part and a multiple dose part, or a part in participants with 
established disease and in those with newly diagnosed disease
Participant A tria l participant (can be a healthy volunteer or a patient). "Participant" 
terminology is used in the protocol whereas term "Subject" is used in 
data collection
Participant number A unique number assigned to each participant upon signing the 
informed consent. This number is the definitive, unique identifier for the 
participant and should be used to identify the participant throughout the 
study for all data collected, sample labels, etc.
Patient- Reported 
Outcome (PRO)A measurement based on a report that comes directly from the patient 
about the status of a participant's health condition without amendment 
or interpretation of the patient's report by a clinician or anyone else
Period The subdivisions of the trial design (e.g., Screening, Treatment, Follow -
up) w hich are described in the Protocol. Periods define the study 
phases and will be used in clinical trial database setup and eventually in 
analysis
Personal data Participant information collected by [CONTACT_157058]. This data 
includes participant identifier information, study information and 
biological samples.
Premature participant 
withdrawalPoint/time when the participant exits from the study prior to the planned 
completion o f all study drug administration and/or assessments; at this 
time all study drug administration is discontinued and no further 
assessments are planned
Randomization The process of assigning trial participants to investigational drug or 
control/comparator drug using an element of chance to determine the 
assignments in order to reduce bias.
Randomization number A unique identifier assigned to each randomized participant

[COMPANY_001] Confidential Page 13of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Re-screening If a participant fails the initial screening and is considered as a Screen
Failure, he/she can be invited once for a new Screening visit after 
medical judgment and as specified by [CONTACT_157059] a location that is not the 
investigative site where the investigator will conduct the trial, but is for 
example a home or another appropriate location
Screen Failure A participant who did not meet one or more criteria that were required 
for participation in the study
Source Data/Document Source data refers to the initial record, document, or primary  location 
from where data comes. The data source can be a database, a dataset, 
a spreadsheet or even hard -coded data, such as paper or eSource
Start of the clinical trial The start of the clinical trial is defined as the signature [CONTACT_30832] [CONTACT_157060]; includes 
investigational drug(s), control(s) or background therapy
Study treatment 
discontinuationWhen the participant permanently stops taking any of the study drug(s) 
prior to the defined study treatment completion date (if any ) for any 
reason; may or may not also be the point/time of study discontinuation 
Tele-visit Procedures or communications conducted using technology such as 
telephone or video -conference, whereby [CONTACT_131327].
Treatment arm/group A treatment arm/group defines the dose and regimen or the 
combination, and may consist of [ADDRESS_181916], which might or might not be the same as the study treatment.
Variable (or endpoint) The variable (or endpoint) to be obtained for each participant that is 
required to address the clinical question. The specification of the 
variable might include whether the participant experiences an 
intercurrent event.
Withdrawal of study 
consent (W oC) / 
Opposition to use of data 
/biological samplesWithdrawal of consent from the study occurs when the participant 
explicitly requests to stop use of their data and biological samples 
(opposition to use data and biological samples) AND no longer wishes 
to receive study treatment, AND does not agree to further protocol 
required assessments. This request should be in writing (depending on 
local regulations) and recorded in the source documentation.
Opposition to use data/biological samples occurs in the countries where 
collection and processing of personal data is justified by a different legal 
reason than consent.

[COMPANY_001] Confidential Page 14of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Amendment 1 ( 23-May-2022 ) 
Amendment rationale 
Amendment 1 implements recommendations from the US FDA regarding statistical analy sis 
for covering intercurrent event handling for COVID -19 related reasons for treatment 
discontinuation and the use of the same covariates in both primar y and secondary  endpoints. I n 
addition, feedback received from Health Authorities and Institutional Review Boards 
(IRBs)/Independent Ethics Committees (IECs) for both pi[INVESTIGATOR_9205] 3 trials (CLOU064A2301 
and CLOU064A2302) was considered to ensure consisten cy across the program and the 
protocol amended as indicated below.
Furthermore, clarifications and corrections were made, and Section 4.5 Risks and benefits has 
been amended to include updates from the LOU064 I nvestigator Br ochure Edition 9 ( 03-May-
2022) as indicated below. 
At the time of this amendment (V01) release, enrollment is ongoing with 205patients screened 
and 114patients randomized. 
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
 
Section 
2.1: Methods for handling of intercurrent events have been updated considering US 
FDA feedback.
Section 
2.2: Methods for handling of intercurrent events have been updated considering US 
FDA feedback.
Section 4.5 : Risks and benefits has been amended to include updates from the LOU064 
Investigator Brochure Edition 9. No change to risk- benefit assessment of the study .
Section 5.2: Exclusion criteria [ADDRESS_181917] the feedback received from 
Health Authorities, exclusion criteria 19 updated to clarify
 maximum dose of clopi[INVESTIGATOR_7745].
Section 6.2.3: Clarification that immunomodulating biologic s are considered prohibited 
medication under immunosuppressive medications; prohibition period for live attenuated 
vaccines updated to reflect feedback from Health Authorities; maximum dose for long-term 
clopi[INVESTIGATOR_157029]. Clarification that 
live attenuated vaccines are prohibited [ADDRESS_181918] dose of study treatment as consistent 
with exclusion criteria and Investigator Brochure. Remibrutinib updated with study  
treatment for clarification.
Section 6.6: Clarification that interruptions are permitted related to study  treatment.
Section 
6.7.3: New section added regarding treatment of overdose, to align with the updated 
[COMPANY_001] protocol template merged with the TransCelerate Common Protocol Template
developed 
with input from industry , regulators, sites, CROs and I RBs

[COMPANY_001] Confidential Page 15of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Section 8: Order of assessments clarified.
Table 8-1:Dispense participants' eDiary  and Subject's eDiary  review removed for Week 
56/Safety  FU/Study  completion visit considering eDiary  completion ends at Week 52/Study  
discontinuation; Weight added at Randomization/Baseline and Week 24 to allow for eGFR 
calculation; Rescue medication dispensation and usage removed from Week 56/Safety 
FU/Study  completion visit considering eDiary completion ends at Week 52/Study  
discontinuation; Footnotes 1, 3, and 7 updated for additional clarity ; Footnote [ADDRESS_181919] feedback from Health Authorities; Footnotes 17 and 18 added for clarity .
Section 8.3.1: Duration of eDiary  completion clarified.
 .
Table 8-8: Body temperature added to Physical Examination assessments to reflect feedback 
from Health Authorities.
Table 8-9: Hepatitis screening and Hepatitis re-activation monitoring amended as aligned 
with central laboratory  testing procedures.
Section 9.1.1: Clarified that participant can request discontinuation from study treatment in 
writing or verbally , definition of severe/serious infections removed to reflect feedback from 
Health Authorities.
Section 
9.1.2: Clarified that participant can request discontinuation from study  in writing or 
verball y to reflect feedback from Health Authorities.
Section 
9.2: Clarified that participant can request withdrawal of consent in writing or 
verball y to reflect feedback from Health Authorities.
Section 10.1.1: “Dose Reduced/increased” removed as dose modifications not permitted 
Section 
10.1.3: Reporting timelines and follow - up for SAEs clarified to reflect feedback 
from Health Authorities.
Section 12.4.3: Handling of intercurrent events amended considering US FDA feedback.
Section 
12.4.5: Tippi[INVESTIGATOR_157030].
Section 12.4.6 : Handling of intercurrent events amended considering US FDA feedback.
Section 12.5.1: Analy sis method for absolute change from baseline in ISS7 and HSS7 at 
Week 12 amended considering US FDA feedback.

Section 15: Additional references added and tworeference sremoved to align with updated 
Investigator Brochure and Section 4.5.
Section 
16.1: QTcF increase ≥60 msec from baseline added to the definition of a notable 
QTc value for ECGs for clarification.

[COMPANY_001] Confidential Page 16of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Additional minor changes (e.g., correction of typographical errors) have been incorporated 
directly  in the protocol with track changes, even if not listed specifically  in this section.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Co mmittee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 17of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Protocol summary
Protocol number CLOU064A2301
Full Title A multicenter, randomized, double- blind, placebo -controlled Phase 3 study of 
remibrutinib (LOU064) to investigate the efficacy , safety and tolerability for 
52 weeks in adult chronic spontaneous urticaria patients inadequately 
controlled by H1 -antihistamines
Brief title A Phase 3 study of efficacy and safety of remibrutinib in the treatment of 
chronic spontaneous urti caria in adults inadequately controlled by 
H1-antihistamines
Sponsor and 
Clinical Phase[COMPANY_001]
Phase 3
Investigation type Drug
Study type Interventional
Purpose The purpose of this study is to establish the efficacy, safety, and tolerability 
of remibrutinib (LOU064) 25 mg b.i.d. in adult participants suffering from 
chronic spontaneous urticaria (CSU) inadequately controlled by 
H1-antihistamines in comparison to placebo.
Primary 
Objective(s) The primary  objective of this study is to demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with respect to change from baseline in 
Weekly Urticaria Activity Score (UAS7) in W eekly Itch Severity Score (ISS7) 
and W eekly Hive Severity Score (HSS7) for the second primary  endpoint 
scenari o) at Week 12.
The primary  clinical question of interest is: What is the effect of remibrutinib 
treatment versus placebo on the change from baseline in UAS7 score (in 
HSS7 and ISS7 for the second primary endpoint scenario) after 12 weeks of 
treatment in adult participants with CSU who are inadequately controlled by 
H1-antihistamine and receiving a stable locally label approved dose of a 
second generation H1 -antihistamine, regardless of discontinuation from study 
treatment for any reason and regardless of intake of a different second 
generation H1-antihistamine as rescue medication and considering strongly 
confounding prohibited medication as an unfavourable outcome?
Secondary 
ObjectivesScenario #1 with UA S7 as the primary endpoint
To demonstrate that a greater proportion of participants achieve disease 
activity control (UAS7 ≤ 6) at W eek 12 when treated with remibrutinib (25 mg 
b.i.d.) compared to placebo -treated participants.
The secondary clinical question of interest is: What is the effect of 
remibrutinib treatment versus placebo on the UAS7 ≤ [ADDRESS_181920] amine, regardless of 
treatment discontinuation for any reason and regardless of intake of a 
different second generation H1-antihistamine as rescue medication and 
considering strongly confounding prohibited medication as an 
unfavourable outcome?

[COMPANY_001] Confidential Page 18of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
To demonstr ate that a greater proportion of participants achieve complete 
absence of hives and itch (UAS7 = 0) at Week 12 when treated with 
remibrutinib (25 mg b.i.d.) compared to placebo -treated participants 
The secondary clinical question of interest is: What is the effect of 
remibrutinib treatment versus placebo on the UAS7 = 0 response after 12 
weeks treatment in adult participants with CSU who are inadequately 
controlled by H1-antihistamine and receiving a stable locally label 
approved dose of a second generatio n H1-antihistamine, regardless of 
treatment discontinuation for any reason and regardless of intake of a 
different second generation H1-antihistamine as rescue medication and 
considering strongly confounding prohibited medication as an 
unfavourable outcome ?
To demonstrate the superiority of remibrutinib (25 mg b.i.d.) versus placebo 
with respect to a reduction from baseline in the weekly  itch severity score 
(ISS7) at W eek 12
To demonstrate the superiority of remibrutinib (25 mg b.i.d.) versus placebo 
with respect to a reduction from baseline in the weekly hive severity score 
(HSS7) at W eek 12
To demonstrate that a greater proportion of participants achieve UAS7 ≤ 6 at 
Week 2 when treated with remibrutinib (25 mg b.i.d.) compared to placebo -
treated participan ts
To demonstrate that a greater proportion of participants who are treated with 
remibrutinib (25 mg b.i.d.) achieve dermatology life quality index (DLQI) = 0 -1 
at Week 12 com pared to placebo -treated participants
To demonstrate that remibrutinib (25 mg b.i.d.) treated participants maintain 
disease activity control (defined as UAS7 ≤ 6) for more weeks compared to 
placebo treated participants over a total of 12 weeks
To demonstrate that rem ibrutinib (25 m g b.i.d.) treated participants have m ore 
angioedema occurrence -free weeks over a total of 12 weeks compared with 
placebo -treated participants
To demonstrate the safety and tolerability of remibrutinib (25 mg b.i.d.)
Scenario #2 with ISS7 and HSS7 as the co -primary endpoints
To demonstrate that remibrutinib (2 5 mg b.i.d.) is superior to placebo in CSU 
with respect to change from baseline in UAS7 at Week 12
To demonstrate that a greater proportion of participants achieve disease 
activity  control (UAS7 ≤ 6) at Week 12 who are treated with remibrutinib (25 
mg b.i.d.) compared to placebo -treated participants
The secondary clinical question of interest is: What is the effect of 
remibrutinib treatment versus placebo on the UAS7 ≤ 6 response after 12 
weeks treatment in adult participants with CSU who are inadequately 
controlled by H1-antihistamine and receiving a stable locally label 
approved dose of a second generation H1-antihistamine, regardless of 
treatment discontinuation for any reason and regardless of intake of a 
different second generation H1-antihistamine as rescue medication and 
considering strongly confounding prohibited medication as an 
unfavourable outcome?

[COMPANY_001] Confidential Page 19of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
To demonstrate that a greater proportion of participants achieve complete 
absence of hives and itch (UAS7 = 0) at Week 12 who are treated with 
remibruti nib (25 mg b.i.d.) compared to placebo -treated participants
The secondary clinical question of interest is: What is the effect of 
remibrutinib treatment versus placebo on the UAS7=0 response after 12 
weeks treatment in adult participants with CSU who are inadequately 
controlled by H1-antihistamine and receiving a stable locally label 
approved dose of a second generation H1-antihistamine, regardless of 
treatment discontinuation for any reason and regardless of intake of a 
different second generation H1-antih istamine as rescue medication and 
considering strongly confounding prohibited medication as an 
unfavourable outcome?
To demonstrate that a greater proportion of participants achieve UAS7 ≤ 6 at 
Week 2 who are treated with rem ibrutinib (25 mg b.i.d.) compared to placebo -
treated participants
To demonstrate that a greater proportion of participants who are treated with 
remibrutinib (25 mg b.i.d.) achieve DLQI = 0-1 at Week 12 compared to 
placebo -treated participants
To demonstrate that remibrutinib (25 mg b.i.d.) treated participants maintain 
disease activity control (defined as UAS7 ≤ 6) for more weeks compared to 
placebo treated participants over 12 weeks
To demonstrate that rem ibrutinib (25 m g b.i.d.) treated participants have m ore 
angioedema occurrenc e-free weeks over 12 weeks compared with placebo -
treated participants
To demonstrate the safety and tolerability of remibrutinib (25 mg b.i.d.)
Study design This is a global Phase 3 multicenter, randomized, double -blind, parallel -group, 
placebo -controlled study  investigating the safety , tolerability, and efficacy  of 
remibrutinib (25 mg b.i.d.) in participants with CSU inadequately controlled by 
[CONTACT_157061] H1 -antihistamines. The study consists of four periods, the 
total study  duration is up to 60 weeks: screening period of up to [ADDRESS_181921] cell 
degranulation with release of inflammatory  mediators including histamine. 
Bruton’s tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase which is 
indispensable for Fc epsilon receptor (FcεR1), Fc gamma receptor (FcγR) as 
well as B c ell receptor (BCR) signaling and a central signaling kinase in mast 
cell activation. It has been demonstrated that BTK inhibition can effectively 
inhibit mast cell activation. Remibrutinib (LOU064) is a low molecular weight 
compound for oral administration that covalently binds and inhibits BTK with 
high selectivity. In Phase 1, remibrutinib was well tolerated at all doses without 
any dose -limiting toxicity and showed encouraging blood and skin 
pharmacodynamics (PD) with a favorable safety profile, fully supporting further 
development. The Phase 2b clinical trial CLOU064A2201 demonstrated 
clinical efficacy  of remibrutinib [ADDRESS_181922] onset of action and a favorable safety profile. This Phase 3 study is 
designed to confirm and further evaluate the efficacy and safety of remibrutinib 
in adult CSU patients at a dose of 25 mg b.i.d. A second, nearly identical 
Phase 3 study will be conducted in parallel.

[COMPANY_001] Confidential Page 20of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Study population The study population will consist of approximat ely 450 randomized female and 
male adult participants (300 in the active arm and 150 in placebo arm) with 
CSU inadequately controlled by [CONTACT_157061] H1 -antihistamines.
The screen failure rate is estimated to be 30%, meaning approximately 645 
particip ants are expected to be screened.
Participants will be stratified based on prior exposure to anti-immunoglobulin 
(Ig) E biologics and geographic region. Maximum number of participants with 
prior exposure to anti -IgE biologics will be limited to approximate ly 30% of the 
total study population.
Key Inclusion 
criteriaSigned informed consent must be obtained prior to participation in the 
study.
Male and female adult participants ≥18 y ears of age at the time of 
screening .
CSU duration for ≥ 6 months prior to s creening (defined as the onset of 
CSU determined by [CONTACT_157062]).
Diagnosis of CSU inadequately controlled by [CONTACT_157061] 
H1-antihistamines at the time of randomization defined as: 
The presence of itch and hives for ≥6 consecutive weeks prior to 
screening despi[INVESTIGATOR_157031] H1 -antihistamines 
during this time period
UAS7 score (range 0 -42) ≥16, ISS7 score (range 0 -21) ≥ 6 and 
HSS7 score (range 0 -21) ≥ 6 during the 7 days prior to 
random ization (Day 1)
Documentation of hives within three months before randomization (either 
at screening and/or at randomization; or documented in the participants 
medical histor y).
Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for 
the duration of the study and adhere to the study protocol.
Participants must not have had more than one missing UPDD entr y 
(either morning or evening) in the 7 days prior to randomization (Day 1).
Key Exclusion 
criteriaParticipants having a clearly defi ned predominant or sole trigger of their 
chronic urticaria (chronic inducible urticaria) including urticaria factitia 
(symptomatic dermographism), cold- , heat- , solar -, pressure -, delayed 
pressure -, aquagenic -, cholinergic -, or contact -urticaria
Other dise ases with sy mptoms of urticaria or angioedema, including but 
not limited to urticaria vasculitis, urticaria pi[INVESTIGATOR_1802], erythema 
multiforme, mastocy tosis, hereditary urticaria, or drug -induced urticaria
Any other skin disease associated with chronic itching that might 
influence in the investigator’s opi[INVESTIGATOR_157032], 
e.g.,atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, 
senile pruritus or psoriasis
Evidence of clinically significant cardiovascular (such as but not l imited 
to myocardial infarction, unstable ischemic heart disease, [LOCATION_001] 
heart association (NYHA) Class III/IV left ventricular failure, arrhythmia 
and uncontrolled hypertension within 12 months prior to Visit 1), 
neurological, psychiatric, pulmonary, re nal, hepatic, endocrine, 
metabolic, hematological disorders, gastrointestinal disease or 
immunodeficiency that, in the investigator's opi[INVESTIGATOR_1649], would compromise 
the safety of the participant, interfere with the interpretation of the study 

[COMPANY_001] Confidential Page 21of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
results or otherwi se preclude participation or protocol adherence of the 
participant
Significant bleeding risk or coagulation disorders
History of gastrointestinal bleeding, e.g., in association with use of 
nonsteroidal anti -inflammatory drugs (NSAID), that was clinically r elevant 
(e.g., where intervention was indicated or requiring hospi[INVESTIGATOR_157033])
Requirement for anti -platelet medication, except for acetylsalicylic acid 
up to 100 mg/d or clopi[INVESTIGATOR_157034] 75 mg/d. The use of dual anti -platelet 
therapy (e.g., acetylsalicylic acid + clopi[INVESTIGATOR_7745]) is prohibited.
Requirement for anticoagulant medication (for example, warfarin or 
Novel Oral Anti -Coagulants (NOAC))
History or current hepatic disease including but not limited to acute or 
chronic hepatitis, cirrhosis or hepatic failure or Aspartate 
Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels of more 
than 1.5 x upper limit of normal (ULN) or International Normalized Ratio 
(INR) of more than 1.5 at screening
Study treatmentLOU064 25mg film -coated tablets (blinded)
LOU064 25mg placebo film -coated tablets (blinded)
LOU064 25mg film -coated tablets (open -label)
Efficacy 
assessmentsAll efficacy  measures are Patient Reported Outcomes (PROs):
Electronic Diary (eDiary) assessments
Urticaria Patient s Daily Diary (UPDD), which assesses: 
Hives Severity Score (HSS)
Itch Severity Score (ISS)
Urticaria Activity Score (UAS)
angioedema occurrence
number of calls to doctor, nurse or nurse practitioner
Angioedema Activity Score (AAS)
  
Key safety 
assessmentsAdverse event (AE) monitoring
Physical examinations
Vital signs
Monitoring of laborator y markers in blood and urine
Central electrocardiogram (ECG) monitoring
Other 
assessments Other PROs assessments
Dermatology Life Quality Index (DLQI)

[COMPANY_001] Confidential Page 22of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
 
 
Data analysis The main purpose of this study is to demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with respect to change from baseline in 
UAS7 at Week 12 (for second scenario, in ISS7 and HSS7). A linear mixed 
model with repeated measures (MMRM) will be used to estimate treatment 
differences for change from baseline in UAS7 score (ISS7 and HSS7 for 
second scenario) at W eek 12, based on the full analysis set (FAS).
For secondary endpoints, a logistic regression model will be used to estimate 
treatment differences for disease activity control at weeks 2 and 12, complete 
response and DLQI =0/1 endpoints at week 12. Negative binom ial regression 
model will be used to estimate treatment differences for the cumulative 
number of weeks achieving AAS7 = 0 response and UAS7<= 6 between 
baseline and Week 12.
The primary  and secondary endp oints analy ses are planned to use the 
multiple testing strategy to control the family -wise error at α =0.025 (one-
sided).
Summary  tables will be presented by [CONTACT_6982] (as 
applicable) using descriptive statistics, which include absolute and relative 
frequencies for categorical variables and arithm etic mean, standard deviation, 
minimum, maximum, median and 25thand 75thpercentiles for continuous 
variables.
Key words BTK inhibitor; Chronic spontaneous urticaria; Urticaria activity score; Hi ves 
severit y score; Itch severity score

[COMPANY_001] Confidential Page 23of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
1 Introduction
1.1 Background
Chronic Spontaneous Urticaria (CSU), also known as Chronic Idiopathic Urticaria (CIU), is 
defined as the spontaneous occurrence of itchy  wheals (hives), angioedema or both, lasting for 
at least 6 weeks (Zuberbier et al 2014, Zuberbier etal2018). The classic description of urticaria 
is a wheal and flare with a pale elevated lesion and surroundin
g ery thema, ranging in size from 
a few millimeters to a few centimeters across, usually occurring in groups and often coalescing 
to form large confluent lesions. Wheals and angioedema in CSU involve the degranulation of 
mast cells, which release histamine, proteases and cytokin es. These mediators induce 
vasodilatation, increase vascular permeability , and stimulate sensory  nerve endings leading to 
swelling, redness and itch ( Kaplan et al 1978, Saini andKaplan2018).
CSU can be debilitating, is associated with intense itching and has a major impact on patient’s 
quality  of life, comparable to that of severe coronary  artery  disease (Greaves 2003, 
Powell et
al2007). The overall burden of CSU and CSU -associated angioedema for affected 
patients is substantial: CSU and its symptoms have a negative impact on numerous aspects of 
their daily  life, including mental health, work productivity , sleep, partnership and famil y life 
(O'Donnell et
al1997, Maurer et al 2017, Gonçalo et al 2021).
Second generation H1
-antihistamines are recommended as first -line treatment for patients with 
CSU, but less than 40% of patients respond adequately  (Guillén- Aguinaga et al2016). While 
uptitration of second generation H1-antihistamines up to 4-fold the approv ed dose is 
recommended by [CONTACT_157063] -line therapy  (Zuberbier et
al2018), 
the efficacy  of uptitrated H1-antihistamines in CSU has not been studied in larger clinical trials, 
and uptitration is considered off -label. The use of H2
-antihistamines and Leukotriene Receptor 
Antagonists (LTRAs) has in the past been recommended by [CONTACT_157064][INVESTIGATOR_12847] H1-antihistamines (Zuberbier et al 2009, 
Bernstein et
al2014), although their use has not been well supported by  [CONTACT_157065]. In the 
latest version of the treatment guidelines ( Zuberbier et
al2018), neither H2 -antihistamines nor 
LTRAs are perceived to have sufficient evidence to maintain them as recommendable in the 
algorithm. Short courses of systemic corticosteroids are sometimes added to the treatment 
regimen; however, they ar e not recommended in treatment guidelines for long -term use, as this 
would expose patients to the well-known risk of adverse effects associated with chronic 
systemic corticosteroid use. Omalizumab is an effective third- line therap y for CSU patients. 
Howeve r, less than 50% of patients treated with omalizumab reach complete control of signs 
and symptoms (Kaplan et al 2016). Therefore, there is a high unmet medical need for new 
treatment options for CSU patients inadequatel y controlled by  H1-antihistamines.
Bruton’s tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase and member of the TEC kinase 
family . BTK is expressed in selected cells of the adaptive and innate immune system including 
B cells, macrophages and mast cell
s/basophils. BTK is indispensable for signaling through the 
Fc epsilon receptor (FcεR1 for IgE), the activating Fc gamma receptors (FcγR for IgG), as well 
as the B cell antigen receptor (BCR) and therefore an important signaling node in the 
activation/degr anulation of B cells, macrophages, mast cells or basophils ( Ripet al 2018).

[COMPANY_001] Confidential Page 24of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
BTK inhibitors (BTKi) like ibrutinib have been first approved for the treatment of B cell 
malignancies (Hendriks etal2014). Due to the above described role of BTK in adaptive as well 
as innate immune signaling and associated with that, its role in immune -mediated diseases, 
targeting BTK is regarded as a promising new approach for the treatment of various im
mune -
mediated conditions. 
 
Mast cells and basophil s play a  key role in the pathophy siology  of CSU, and it has been 
demonstrated that BTK inhibition leads to blockade of mast cell and basophil 
activation/degranulation in vitro and to reduced wheal sizes in skin prick tests with patients 
suffering from IgE-mediated allergies (Smiljkovic et al2017, Regan et al2017, 
Dispenza et
al2017). Thus, BTK inhibition is a promising therapeutic concept for the treatment 
of CSU.
Remibrutinib (LOU064) is a low molecular weight compound for oral administration that 
covalentl y binds and inhibits BTK with high selectivity (Angst et al 2020, 
Gabizon andLondon 2020 ). In Phase 1, remibrutinib was well-tolerated at all doses without 
any dose-limiting toxicity  and showed encouraging blood and skin pharmacod ynamics with a 
favorable safet y pro file, fully  supporting further development for diseases d riven by [CONTACT_157066], 
basophils, and B cells, such as chronic spontaneous urticaria (Kaul et
al2021). The Phase 2b 
clinical trial CLOU064A2201 primary  endpoint analy sis demonstrated clinical efficacy  and a 
fast onset ofaction of remibrutinib in the treatment of CSU patients as well as a favorable safet y 
profile (for detailed information please refer to the I nvestigator`s Brochure (IB)).
Taken together, remibrutinib may  offer a novel therapeutic approach for patients wit h CSU and 
is advanced to Phase 3 clinical development.
1.2 Purpose
The purpose of this study  is to establish the efficacy , safety , and tolerability  of remibrutinib 
(LOU064) 25 mg b.i.d. in adult participants suffering from chronic spontaneous urticaria (CSU) 
inadequatel y controlled by H1 -antihistamines in comparison to placebo.
Inadequate control of CSU by  H1-antihistamines is defined as:
The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despi[INVESTIGATOR_157035] H1-antihistamines during this time period
UAS7 score (range 0 -42) ≥ 16, I SS7 score (range 0
-21) ≥6 and HSS7 score (range 0- 21) 
≥ 6 during the 7 day s prior to randomization (Day 1).
2 Objectives, endpoints and estimands
There are two primary  objective scenar ios based on regional regulatory  precedent and Health 
Authorities’ feedback. These two primary  objective scenarios will be tested in two distinct 
testing strategies ( Table 2-1and Table 2 -2). Distinctions in the secondary  objectives reflect the 
corresponding scenario: the primary  objective in one scenario is presented as secondary 
objective( -s) in another. The other secondary   objectives are identical in both 
scenarios.

[COMPANY_001] Confidential Page 25of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Table 2-1 Objectives and related endpoints –Scenario with UA S7 as the primary 
efficacy  endpoint
Objective(s) Endpoint(s)
Primary objective(s) Endpoint(s) for primary objective(s)
To demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with 
respect to change from baseline in UAS7 
at Week 12Absolute change from baseline in UAS7 at 
Week 12
Secondary objective(s) Endpoint(s) for secondary objective(s)
To demonstrate that a greater proportion 
of participants achieve disease activity 
control (UAS7 ≤ 6) at Week 12 who are 
treated with remibrutinib (25 mg b.i.d.) 
compared to placebo -treated participantsAchievement of UAS7 ≤ 6 (y es/no) at W eek12
To demonstrate that a greater proportion 
of participants achieve complete absence 
of hives and itch (UAS7 = 0) at Week 12 
who are treated with remibrutinib (25 mg 
b.i.d.) compared to placebo -treated 
participantsAchievement of UAS7 = 0 (yes/no) at Week 12
To demonstrate the superiority of 
remibrutinib (25 mg b.i.d.) treated 
participants with respect to a reduction 
from baseline in the weekly itch severity 
score at Week 12 com pared to placebo -
treated participantsImprovement of severity of itch, ass essed as 
absolute change from baseline in ISS7 score at 
Week 12
To demonstrate the superiority of 
remibrutinib (25 mg b.i.d.) treated 
participants with respect to a reduction 
from baseline in the weekly hive severity 
score at Week 12 com pared to placebo -
treated participantsImprovement of severity of hives, assessed as 
absolute change from baseline in HSS7 score 
at Week 12
To demonstrate that a greater proportion 
of participants achieve UAS7 ≤ 6 at W eek 
2 who are treated with remibrutinib (25 
mg b.i.d.) compared to placebo -treated 
participantsAchieving early onset of disease activity 
control, as defined as achievement of UAS7≤ 6 
(yes/no) at W eek 2
To demonstrate that a greater proportion 
of participants who are treated with 
remibrutinib (25 mg b.i.d.) achieve DLQI 
= 0-1 at W eek 12 compared to placebo-
treated participantsNo im pact on participants' dermatology -quality 
of life, as defined by [CONTACT_157067] = 0- 1 
(yes/no) at W eek 12
To demonstrate that remibrutinib (25 mg 
b.i.d.) treated participants maintain 
disease activity control (defined as UAS7
≤6) for more weeks compared to placebo 
treated participants over 12 weeksAchieving sustained disease activity control, 
assessed as cumulative number of weeks with 
an UAS7 ≤6 response between baseline and 
Week12
To demonstrate that remibrutinib (25 mg 
b.i.d.) treated participants have more Number of weeks without angioedema, 
assessed by [CONTACT_157068] 26of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Objective(s) Endpoint(s)
angioedema occurrence- free weeks over 
12 weeks compared with placebo -treated 
participantswith an AAS7 = 0 response between baseline 
and W eek12
To demonstrate the safety and tolerability 
of remibrutinib (25 mg b.i.d.)Occurrence of treatment emergent adverse 
events and serious adverse events during the 
study

[COMPANY_001] Confidential Page 27of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Objective(s) Endpoint(s)

[COMPANY_001] Confidential Page 28of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Table 2-2 Objectives and related endpoints -Scenario with ISS7 and HSS7 as 
the co -primary  efficacy endpoints
Objective(s) Endpoint(s)
Primary objective(s) Endpoint(s) for primary objective(s)
To demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with 
respect to change from baseline in ISS7 and 
HSS7 at Week 12Absolute change from baseline in ISS7 at 
Week 12
Absolute change from baseline in HSS7 at 
Week 12
Secondary objective(s) Endpoint(s) for secondary objective(s)
To demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with 
respect to change from baseline in UAS7 at 
Week 12Absolute change from baseline in UAS7 at 
Week 12
To demonstrate that a greater proportion of 
participants achieve disease activity control 
(UAS7 ≤ 6) at W eek 12 who are treated with 
remibrutinib (25 mg b.i.d.) compared to 
placebo -treated participantsAchievement of UAS7 ≤ 6 (y es/no) at W eek 
12
To demonstrate that a greater proportion of 
participants achieve complete absence o f 
hives and itch (UAS7 = 0) at Week 12 who 
are treated with remibrutinib (25 mg b.i.d.) 
compared to placebo -treated participantsAchievement of UAS7 = 0 (yes/no) at W eek 
12
To demonstrate that a greater proportion of 
participants achieve UAS7 ≤ 6 at W eek 2 
who are treated with remibrutinib (25 mg 
b.i.d.) compared to placebo -treated 
participantsAchieving early onset of disease activity 
control, as defined as achievement of UAS7
≤ 6 (yes/no) at W eek 2
To demonstrate that a greater proportion of 
participants who are treated with 
remibrutinib (25 mg b.i.d.) achieve DLQI = 0 -
1 at W eek 12 compared to placebo- treated 
participantsNo im pact on participants' dermatology 
qualit y of life as defined by [CONTACT_157069] = 0 -1 (yes/no) at W eek 12.
To dem onstrate that remibrutinib (25 mg 
b.i.d.) treated participants maintain disease 
activity control (defined as UAS7 ≤6) for 
more weeks compared to placebo treated 
participants over 12 weeksAchieving sustained disease activity control, 
assessed as cumulativ e number of weeks 
with an UAS7 ≤6 response between 
baseline and Week12
To demonstrate that remibrutinib (25 mg 
b.i.d.) treated participants have more 
angioedema occurrence- free weeks over 12 
weeks compared with placebo -treated 
participantsNumber of wee ks without angioedema, 
assessed by [CONTACT_157070]7 = 0 response between 
baseline and Week12
To demonstrate the safety and tolerability of 
remibrutinib (25 mg b.i.d.)Occurrence of treatment emergent adverse 
events and serious adverse events (SAEs)
during the study

[COMPANY_001] Confidential Page 29of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Objective(s) Endpoint(s)
2.[ADDRESS_181923] the interpretation of the trial results 
(e.g., premature discontinuation of treatment).
Primary estimand for scenario with UAS7 as primary efficacy endpoint
The primary  clinical question of interest is: What is the effect of remibrutinib treatment versus 
placebo on the change from baseline in UAS7 score after 12 weeks treatment in adult 
participants with CSU who are inadequatel y controlled by H1-antihistamine and receiving a 
stable locally  label approved dose of a second generation H1-antihistamine, regardless of 
discontinuation from study  treatment for any reason and regardless of intake of a different 
second generation H1-antihistamine as rescue medication and considering strongl y 
confounding prohibited medication as an unfavourable outco me?
The primary  estimand is described by  [CONTACT_6570]:
1.Population : participants with inadequatel y controlled CSU despi[INVESTIGATOR_157036] H1 -antihistamine who have CSU duration 
≥ 6 months, a UAS7 score ≥ 16, 
ISS7 ≥ 6 and HSS7 sc ore ≥ [ADDRESS_181924] 7 day s prior to randomization.
2.Endpoint: Change in UAS7 from baseline at Week 12.
3.Treatment of interest: the randomized study  treatment (remibrutinib 25 mg b.i.d. or 
placebo) regardless of treatment compliance, with background medicatio n of locally  label 
approved dose second generation H1 -antihistamine, and a different second generation 
H1-antihistamine as rescue medication.
4.Summary Measurement: the mean difference between treatment groups.
5.Handling of intercurrent events:
Discontinuation of study  treatment due to any:Treatment policy  strategy
Intake of strongl y confounding prohibited medication (e.g. ,biologics treatment at any  
time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8): 
Composite strategy  (irrespective of potential occurrence of other intercurrent events)
Intake of rescue medication, switch of background medication, intake of other prohibited 
medication: Treatment policy  strategy

[COMPANY_001] Confidential Page 30of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Primary estimand for scenario with ISS7/HSS7 as co- primary efficacy endpoints
The primary  clinical question of interest is: What is the effect of remibrutinib treatment versus 
placebo on the co-primary  endpoints change from baseline in ISS7 score and change from 
baseline in HSS7 score after treatment in adult participants with CSU who are inadequatel y 
controlled by H1-antihistamine and receiving a stable locall y label approved dose of a second 
generation H1 -antihistamine, regardless of discontinuation from study  treatment for any reason 
and regardless of intake of a different second generation H1-antihistamine as rescue medication 
and considering strongl y confounding prohibited medication as an unfavourable outcome?
The primary  estimand is described by  [CONTACT_6570]:
1.Population : participants with inadequatel y controlled CSU despi[INVESTIGATOR_157036] H1 -antihistamine who have CSU duration 
≥ 6 months, a UAS7 score ≥ 16, 
ISS7 ≥ 6 and HSS7 score ≥ [ADDRESS_181925] 7 day s prior to randomization.
2.Endpoint (co- primary): Change in ISS7 from ba seline at Week [ADDRESS_181926]: the randomized study  treatment (remibrutinib 25 mg b.i.d. or 
placebo) regardless of treatment compliance, with background medication of locally label 
approved dose second generation H1 -antihistamine, and a different second generation 
H1-antihistamine as rescue medication.
4.Summary Measurement: the mean difference between treatment groups.
5.Handling of intercurrent events:
Discontinuation of study  treatment due to any reason: Treatment policy  strategy
Intake of strongl y confounding prohibited medication (e .g., biologics treatment at any  
time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 
8): Composite strategy  (irrespective of potential occurrenc eof other intercurrent 
events)
Intake of rescue medication, switch of background medication, intake of other 
prohibited medication: Treatment policy  strategy
2.2 Secondary  estimands
Secondary estimand on the secondary endpoint UAS7 ≤ [ADDRESS_181927] is: What is the effect of remibrutinib treatment versus 
placebo on the UAS7 ≤ 6 response after 12 weeks treatment in adult participants with CSU who 
are inadequatel y controlled by H1-antihistamine and receiving a stable locally  label approved 
dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any 
reason and regardless of intake of a different second generation H1-antihistamine as rescue 
medication and considering strongl y confou nding prohibited medication as an unfavourable 
outcome?
The secondary  estimand is described by  [CONTACT_6570]:
1. Population : patients with inadequatel y controlled CSU despi[INVESTIGATOR_157036] H1 -antihistamine who have CSU duration ≥6 months, a UAS7 score ≥ 16, 
ISS7 score ≥ 6 and HSS7 score ≥ [ADDRESS_181928] 7 day s prior to randomization.
2. Endpoint: UAS7 ≤ 6 response at Week 12.

[COMPANY_001] Confidential Page 31of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
3. Treatment of interest: the randomized study  treatment (remibrutinib 25 mg b.i.d. or 
placebo) regardless of treatment compliance, with background medication of locally label 
approved dose second generation H1 -antihistamine, and a different second generation 
H1-antihistamine as rescue medication.
4. Summary Measurement: the odds ratio between treatm ent groups.
5. Handling of intercurrent events:
Discontinuation of study  treatment due to any reason
non-compliance (dose 
interruption): Treatment policy  strategy
Intake of strongl y confounding prohibited medication (e.g .,biologics treatment at any  
time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 
8): Composite strategy  (irrespective of potential occurrence of other intercurrent 
events)
Intake of rescue medication, switch of background medi
cation, intake of other 
prohibited medication: Treatment policy  strategy
Secondary estimand on the secondary endpoint UAS7 = 0 response at week 12
Similar Estimand approach will be implemented for UAS7= 0 as for UAS7 ≤ 6.
Other secondary estimand on the other secondary endpoints as defined in Table 2-1and 
Table 2 -
2.
Similar Estimand approach will be implemented for these endpoints as the primary  Estimand 
or co -primary  Estimand
.
3 Study  design
This is a global, multicenter, randomized, double -blind, parallel -group, placebo- controlled 
Phase 3 study  investigating the safet y, tolerabilit y, and efficacy  of remibrutinib (25 mg b.i.d.) 
in adult participants with CSU inadequatel y control led by [CONTACT_157061] H1-antihistamines. 
The study  consists of four periods, the total study  duration is up to 60 weeks ( Figure 3 -1):
Screening period: up to 4 weeks.
Double -blind treatment period: 24 weeks of double
-blind treatment with remibrutinib 
(25 mg b.i.d.) or placebo.
Open -label treatment period: 28 weeks of open -label treatment with remibrutinib (25 
mg b.i.d.).
Follow -up period: [ADDRESS_181929] completed Week 24 or 
discontinued earlier and when a minimum of 150 participants across both Phase 3 pi[INVESTIGATOR_157037] (a second, nearl y identical Phase 3 study  will be conducted in parallel) have completed 
the treatment period at Week 52 (se e Section 4.4). All participants will be on a stable, locally 
label approved dose of a second generation H1-antihistamine (“background therapy”) 
throughout the entire study (starting a minimum of 7 days prior to randomization until 
the end of the study) . To treat unbearable symptoms of CSU, participants will be allowed to 
use another second generation H1-antihistamine on an as-needed basis (“rescue therap y”). 
Eligible participants will be randoml y assigned to the treatment arm
s in a 2:1 ratio. The study 

[COMPANY_001] Confidential Page 32of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
population will consist of approximately  450 female and male adult participants (300 in the 
active arm and 150 in the placebo arm) with CSU inadequatel y controlled by [CONTACT_157061] 
H1-antihistamines at least at locally  label approved dose. Participants will be stratified based 
on prior exposure to anti-IgE biologics and geographic region.
An extension study  is in development. Eligible participants may roll over at Week 52 (after 
completing 52 weeks of treatment and all sched uled assessments planned at this visit). The 
details of the study  design and procedures of the extension, if implemented, will be described 
in a separate protocol.
Figure 3-1 Study  Design
D-1: Day 1, b.i.d.: bis in die/twice a day, mg: milligram(s), Pbo: placebo, PA: Primary Analysis, PE: 
Primary Endpoint, Scr: Screening, W: Week
[ADDRESS_181930] not adequatel y responded toprior treatment 
with H1 -antihistamines and other CSU therapi[INVESTIGATOR_157038]. This Phase 3 study  is 
designed to confirm and further evaluate the efficacy and safet y of remibrutinib at a dose of 25 
mg b.i.d. (as determined by [CONTACT_16646] 2b dose-range finding study  CLOU064A2201, see also 
section Section 4.2) in adult CSU patients. I t is a randomized, double -blind, parallel -group, and 
placebo
-controlled study  that consists of four periods:
1.Screening period: the screening period of up to four weeks will allow the assessment of 
eligibility  of participants and the determination of baseline disease activity .

[COMPANY_001] Confidential Page 33of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
2.Double -blind treatment period: a placebo -controlled, double -blind treatment period until 
Week 24. The placebo -controlled , double -blind design is mandatory  to enable a robust 
assessment of the efficacy  of remibrutinib without bias by [CONTACT_157071] 
(and the resulting significant placebo effect). Furthermore, it is required for a robust 
assessment of the safety profile of remibrutinib in comparison to placebo over an adequate 
period of time (for further details please seeSection 4.3). This design is in line with other 
major Phase 3 
trials in the field of CSU, e.g., with ligelizuma b ([STUDY_ID_REMOVED] and 
[STUDY_ID_REMOVED]), which ensures comparabilit y. In order to limit the number of participants 
exposed to placebo while maintaining the scientific validity of the stud y, the randomization 
ratio will be 2:1 of active vs. placebo treatment. A placebo comparison up to Week 24 
(which is beyond the primary endpoint at Week 12) will provide a background incidence in 
the study  population for possible safety  findings and will ensure a valid assessment of the 
durability  of the treatment response. It will support a more robust characterization of the 
safet y profile of remibrutinib, i.e.,if safety  events are observed in both the placebo and 
remibrutinib arms, it may be inferred that the events are not necessaril y related to the study  
treatment. To limit 
the duration of placebo treatment, the placebo -controlled treatment 
period will stop at Week 24, since a period of 24 weeks allows a reliable and valid 
assessment of efficacy  and safet y in patients with CSU.
3.Open -label treatment period: during this treatment period of 28 weeks, all participants 
will receive open -label remibrutinib (25 mg b.i.d.). Together with the preceding double -
blind, placebo- controlled period, a total of up to 52 weeks of remibrutinib (25 mg b.i.d.) 
treatment will be studied within this trial. This is in line with current CSU treatment 
guidelines (Zuberbier et al 2018) and will provide adequate long-term efficacy  and safet y 
data to fully characterize the value of remibrutinib (25 mg b.i.d.) in CSU treatment. 
Switching placebo treated participants to active treatment with remibrutinib at Week 24 
gives all participants the opportunity  to receive active treatment with remibrutinib within 
the course of this stud y.
4.Follow -up period: a treatment- free follow -upperiod of four weeks at the end of the study 
will be implemented for all participants who do not enroll into the extension study  (currentl y 
in planning stage). This allows the assessment of safet y of treatment discontinuation as well 
as the dynamics of potential re-occurrence of CSU signs and symptoms after treatment 
discontinuation.
The study  population consists of participants with CSU (UAS7 score ≥ 16, with HSS7 score ≥ 
6 and ISS7 score ≥ 6), who have a duration of CSU of ≥ [ADDRESS_181931] inadequatel y responded to or did not tolerate 
anti-IgE biologic treatments are also eligible for this study . Thus, CSU patients with a high 
unmet medical need are the target population for t his study .
Historically , the treatment paradigm for CSU focused primaril y on the key symptom itch, as 
assessed by [CONTACT_157072] y Itch Severit y Score (ISS7). Over the past several years, the emphasis 
and target of therapy , as described in the current CSU treatm ent guidelines 
(Zuberbier et al 2018), have evolved to also integrate the second key  symptom of CSU, which 
is hives. Therefore, UAS7, which is a composite of I SS7 and the weekly  Hives Severit y Score 
(HSS7), is now recom mended, rather than using ISS7 alone. Thus, the primary endpoint of this 

[COMPANY_001] Confidential Page 34of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
study  is change in UAS7 from baseline at Week 12 or a co-primary  endpoint of change from 
baseline in I SS7 and HSS7 at Week 12. Two separate statistical analyses will be used to enable
the two different primary  and consecutive secondary  endpoints, in order to fulfill regional health 
authority  requests. They  will be assessed in independent testing strategies for all participants. 
Furthermore, a primary  endpoint at Week 12ensures adequat e comparability  of the efficacy 
outcomes with other major Phase 3 trials in the field of CSU, e.g.,with omalizumab 
(Maurer et al 2013) or ligelizumab ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]). UAS7 -based 
responder analyses (UAS7 ≤6and UAS7=0), the assessment of the impact of remibrutinib 
treatment on itch (ISS7) and hives (HSS7), the assessment of the impact of remibrutinib 
treatment on dermatology -related qualit y of life (DLQI -response of 0/1), and the assessment of 
the impact of remibrutinib treatment on the number of weeks without occurrence of angioedema 
(AAS7=0) have 
been selected as secondary  endpoints to further assess the efficacy  of 
remibrutinib.
Assessing remibrutinib (25 mg b.i.d.) as add-on to background medication consi sting of a 
locally  approved second generation H1-antihistamine follows the recommendations of the 
current treatment guidelines ( Zuberbier et al 2018 ).
Apply ing a treatment policy  strategy  for treatment non-compliance, the use of rescue 
medication (a second generation H1-antihistamine 
that differs from the background medication), 
and most other intercurrent events aims to assess remibrutinib as a CSU therapy  (as an add -on 
to background medication) close to a "real -life" situation. Only  intercurrent events that are 
likely  to impose a strong bias on the efficacy  readout (such as use of highly  effective biologics 
with a long half -life) will be handled using a composite strategy .
Taken together, the study  design will allow the investigation of the efficacy  and safet y of 
remibrutinib in CSU as per current scientific, medical, ethical and regulatory  standards, while 
limiting the burden for participants as much as possible.
4.1.[ADDRESS_181932]- line therap y to H1-antihistamine background therapy  in CSU patients 
who are not adequatel y controlled by H1 -antihistamines (Zuberbier et al 2018 ). Furthermore, it 
allows active treatment of participants in the placebo arm, including the use of additional rescue 
medication. Thus, participants in the placebo arm are not left without CSU treatment.
4.2 Rationale for dose/regimen and duration of treatment
In this study, remibrutinib will be given in a dosing regimen of 25 mg b.i.d. for a duration of up 
to 52 weeks. A treatment duration of
up to 52 weeks is in line with the current treatment 
guidelines ( Zuberbier et al 2018) and in line with other current major Phase 3 trials in the CSU 
indication, e.g. ,with ligelizumab ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]). Th erefore, it allows the 
collection of efficacy  and safet y data for remibrutinib over a treatment duration, which is 
applied in real-world clinical practice and which allows comparison to 
other Phase 3 trials in 
the same indication. Furthermore, a treatment duration of up to 52 weeks is covered by [CONTACT_094]-
clinical toxicity  data and is used in the Phase 2b extension study  CLOU064A2201E1.

[COMPANY_001] Confidential Page 35of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
The target population of this trial includes difficult -to-treat patients, such as patients with 
concomitant CINDU, long disease history  and patients with prior inadequate response to anti-
IgE biologics. In such cases a treatment duration of up to [ADDRESS_181933] the opportunity  to 
roll over after completing 52 weeks of stud y treatment in this trial.
Based on the safet y data from the completed and ongoing remibrutinib trials, the clinical safety 
profile of remibrutinib is favorable and supports the selected dose of 25 mg b.i.d. In the prima ry 
endpoint analy sis of the dose-range finding Phase 2b study  CLOU064A2201 (cut-off date at 
14-Jan-2021), most adverse events (AEs) were mild in severit y, without patterns of clustering 
or dose-dependency . 
Ongoing clinical safety  review of CLOU064A2201E1, a long-term 
extension study  of CLOU064A2201, with a 52-week treatment period with 100 mg remibrutinib 
b.i.d. did not reveal any  safety  signals. In addition, the clinical safety  data from the completed 
Phase 1 studies, which tested doses of remibrutinib 
up to 600 mg q.d. and 200 mg b.i.d., was 
favorable and did not raise an y concerns. For more detailed information on the safety profile of 
remibrutinib, please see Section 4.5 and the Investigator's Brochure.
In the dose -range finding study  CLOU064A2201, the efficacy  of remibrutinib as an add-on to 
background therapy  of second generation H1-antihistamines was assessed versus placebo for 
the following dose regimens: 10 mg q.d., 35 mg q.d., 100 mg q.d., 10 mg b.i.d., 25 mg b.i.d., 
100 mg b.i.d. The treatment duration was 12 weeks and the primary  endpoint was change in 
UAS7 score from baseline at Week 4. The key  secondary  endpoints were defined as change in 
UAS7 score from baseline at Week 12, change in UAS7 score from baseline over time, 
percentage of participants with UAS7 = 0 (complete absence of hives and itch) over time, and 
percentage of participants with UAS7 ≤6 (disease activity control) over time. At the time of the 
primary  endpoint analysis, there were 301 participants (40-
47per arm) among 309 under full 
analysis set with a UAS7 score at Week 4, and 233 participants (29-37 per arm) with a UAS7 
score at Week 12. The treatment groups were overall well balanced in terms of demograph y 
and baseline disease characteristics.
The study demonstrated clinical efficacy  of remibrutinib in the treatment of CSU, with all tested 
doses showing superior efficacy  over placebo at Week 4. A dose-response relationship was 
established for the q.d. and b.i.d. remibrutinib dosing regimens compared toplacebo with 
respect to the change from baseline in UAS7 score at Week 4, with the dose-response plateau 
alread y achieved at 10 mg for q.d. dosing (=10 mg total dail y exposure) and at 25 mg for b.i.d. 
dosing (=50 mg total daily  exposure).

[COMPANY_001] Confidential Page 36of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Figure 4-[ADDRESS_181934] repeated measurement analy sis, by  [CONTACT_1570] (FA S)
Figure 4-2 UAS7 = 0 and UA S7 <= 6 response rate over time by  [CONTACT_1570] 
(as observed) (FA S)
Assessing the higher hurdle UAS7 ≤ 6 (disease activity  control) and UAS7 = 0 (total absence 
of itch and hives) response rates enabled further differentiation between the tested doses 
(Figure 4
-1and Figure 4-2): At Week 4, the remibrutinib 25 mg b.i.d. dosing regimen achieved 
numericall y higher UAS7 ≤ 6 response rates than all other tested doses: 55.8% under 25 mg 
b.i.d. compared to 43.2%, 40.9%, 
42.6%, 34.1%, 44.4%, 4.8% under 10 mg q.d., 35 mg q.d., 

[COMPANY_001] Confidential Page 37of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
100 mg q.d., 10 mg b.i.d., 100 mg b.i.d., placebo (non -responder imputation). I n line with that, 
the 25 mg b.i.d. dosing regimen also achieved considerabl y higher UAS7=0 response rates than 
all other tested doses at Week 4: 41.9% under 25 mg b.i.d. compared to 18.2%, 22.7%, 17.0%, 
18.2%, 
22.2%, 0.0% under 10 mg q.d., 35 mg q.d., 100 mg q.d., 10 mg b.i.d., 100 mg b.i.d, 
placebo (non-responder imputation). The numerically  higher efficacy  of the 25 mg b.i.d. dosing 
regimen compared to all other doses was observed consistently over time, with higher UAS7 ≤ 
6 and UAS7 = 0 response rates from Week 2 throughout Week 12 (Figure 4-2). Furthermore, 
the [ADDRESS_181935] onset of action, with high response rates 
alread y achieved at Week 2 ( Figure 4 -2).
At Week 12, the UAS7 ≤ 6 and UAS7 = 0 respo nse rates for placebo treated participants were 
relativel y high (31.3% and 15.7%), reflecting the fluctuating nature of CSU (Figure 4-2). While 
still showing numerical superiority , the q.d. dosing regimens (10 mg q.d., 
35 mg q.d., 100 mg 
q.d.) showed a tendency towards weaker differentiation vs placebo in UAS7 ≤ 6 and UAS7 = 0 
response at Week 12 (UAS7 ≤ 6: 43.2%, 40.9%, 42.6%; UAS7 = 0: 29.4%, 29.4%, 32.4%) (as 
observed), whereas the 25 mg b.i.d. regimen was able to maintain a notable difference (UAS7 
≤ 6: 63.6%, UAS7 = 0: 48.5%). B.i.d. dosing is also supported from a pharmacokinetics, 
pharmacod ynamics and mode -
of-action perspective, in order to ensure sustained BTK 
inhibition over [ADDRESS_181936] turn-over of the covalent BTK -
remibrutinib complex in tissue (see Investigator´s Brochure for details).
Taken together, all tested remibrutinib dosing regimens demonstrated superior efficacy  in 
treating signs and symptoms of CSU compared to placebo, when assessing the mean change 
from baseline in UAS7. However, when analyzing higher hurdle efficacy  endpoints with higher 
discriminatory  power (UAS7 ≤ 6or UAS7 = 0) and later time points with higher placebo 
response rates, the 25 mgb.i.d. treatment regimen showe d notably  higher efficacy  than the other 
tested regimens, especially  than the q.d. regimens.
A lower b.i.d. dose (10 mg b.i.d.) or once daily dosing (35 mg q.d.), does not enable participants 
to achieve the maximum efficacy , which can be achieved with 25 mg b.i.d. dosing, especiall y 
when considering the UAS7 ≤ 6 and UAS7 = 0 response rates. At the same time, higher dosing 
regimens, such as 100 mg b.i.d., are not required to reach maximum efficacy .
As the safet y data also support the 25 mg b.i.d. dosing regimen (seeSection
4.5and the 
Investigator's Brochure) with a favorable safety  profile and no dose-dependent safet y signals, 
remibrutinib 25 mg b.i.d. was selected as the optimal dose for this Phase 3 study .
4.3 Rationale for cho
ice of control drugs (comparator/placebo) or 
combination drugs
Placebo was chosen as a comparator for this trial to adjust for the fluctuating nature of CSU, 
which can result in a pronounced placebo effect. Therefore, comparison to placebo allows a 
robust and scientifically valid efficacy  assessment. Furthermore, comparison to placebo allows 
a meaningful safet y assessment. The use of placebo in this study  population is considered to be 
appropriate since participants will additionally  receive background therapy of 
H1-antihistamines (see Section 6.1.2) and will have access to additional rescue medication (see 
Section
6.2.4). Although it is an inclusion criterion of the study  to be inadequat ely controlled 
by H1-antihistamines, this does not mean that participants do not benefit from 

[COMPANY_001] Confidential Page 38of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
H1-antihistamines at all. The allowed H1-antihistamine background treatment still alleviates 
participants´ symptoms to a certain degree. Thus, participants in the placebo arm are not left 
without treatment during the placebo -controlled period. Furthermore, participants in the 
placebo arm will be switched to active treatment with remibrutinib at Week 24, giving all 
participants the opportunity  to receive treatment with remibrutinib during the course of the trial.
As the target patient population is hard -to-treat CSU patients with a prior inadequate response 
to second generation H1-antihistamines, the only potential active comparator according to the 
current treatment guidelines would be omalizumab (Zuberbier et al 2018). CSU patients, who 
have alread y been treated with, and potentially  failed to respond to, omalizumab, have a high 
unmet medical need, since they are currently  left without approved treatment options. Adding 
omalizumab as an active comparator to the study  would significantly  restrict the study 
population, as these omalizumab (or any other anti-IgE biologics) pretreated patients would 
need to be excluded from the study  in order to prevent a potential prior treatment bias and allow 
a fair comparison, thus preventing the collection of efficacy  and safet y dat a for this population. 
Additionally , the burden for enrolled participants would increase as the administration routes
of remibrutinib (oral) and omalizumab (subcutaneous (s.c.)) would mandate a double -dumm y 
design with placebo injections for participants in the remibrutinib arm and 4-weekl y visits 
throughout the entire study  duration (instead of extended periods between visits after Week 24 
as per the current study design). Furthermore, the long half -
life of omalizumab (approximately 
4 weeks vs a half -life of approximately  1 hour for remibrutinib) would mandate a significantly 
longer treatment -free follow -up period after the end of the treatment period. Due to differences 
in the route of administration (s.c. vs. oral), different PK-PD profiles and speed of onset kinetics, 
omalizumab is not considered an ideal comparator for remibrutinib. Lastl y, historical 
comparisons of the data from the confirmatory  omalizumab trials to the current remibrutinib 
trial will be possible, given their similarities with regard to patient population, background 
medication, endpoints and the use of placebo as the control arm in the omalizumab stu dies.
Taken together, a placebo comparison over [ADDRESS_181937] and scientifically valid assessment of the safet y and efficacy of remibrutinib. 
The additional comparative information which could be gained by [CONTACT_157073].
4.4 Purpose and timing of interim analy ses/design adaptations
A primar y anal ysis may be conducted wh en all participants have completed their Week [ADDRESS_181938] completed the treatment period (a second, nearl y identical Phase 3 study  will be 
conducted in paral lel). The minimum of 150 participants reaching week 52 should enable 
analysis on a minimum of 100 participants exposed to remibrutinib for 52 weeks considering 
the initial randomization to either the remibrutinib or the placebo arm (2:1). The results of the 
primary  analysis will further inform decision making for the remibrutinib development 
program.
After the primary  analysis and/or after all participants have entered the open label treatment 
period, additional optional interim analy ses may be conducted to support potential Health 

[COMPANY_001] Confidential Page 39of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Authority  interactions and requests (these interim anal yses are not expected to have an y impact 
on the conduct or scientific integrit y of the study).
4.[ADDRESS_181939] cell degranulation with release 
of inflammatory  mediators including histamine (Ferrer 2015, Saini andKaplan 2018). Bruton’s 
tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that is indispensable forFcεR1 signaling 
and a central signaling kinase in mast cell activation. It has been demonstrated that 
BTK inhibition can effectively  inhibit mast cell activation and reduce wheal sizes in skin prick 
tests (Regan et
al2017; Dispenza et al2018; Kaul et al 2019). In Phase 1, remibrutinib was 
well-tolerated at all doses without any dose-limiting toxicity  and showed encouraging blood 
and skin pharmacod ynamics with a favorable safet y profile, fully supporting further 
development for diseases driven by [CONTACT_157066], 
basophils, or B cells, such as CSU. Furthermore, 
remibrutinib has been shown to effectively reduce wheal size in skin prick tests 
(Kaul et al 2021). The Phase 2b clinical trial CLOU064A2201 (primary endpoint analy sis) 
demonstrated clinical efficacy  of remibrutinib in the treatment of CSU patients with a fast onset 
of action and a favor able safet y profile.
Based on this data, 25 mg b.i.d. has been selected as the optimal dosing regimen for the 
treatment of CSU patients. Treatment with remibrutinib 25 mg b.i.d. resulted in a substantial 
reduction of the UAS7 score, which measures frequenc y/intensity  of hives and itch, the two 
key 
symptoms defining the burden of CSU for affected participants. The benefit for CSU patients 
treated with remibrutinib 25 mg b.i.d. was also reflected by [CONTACT_157074]-
related quality  of life (HRQoL ), as measured by [CONTACT_157075] (see Investigator´s Brochure 
for details).
BTK inhibition is a new therapeutic principle for the treatment of CSU that significantl y differs 
from currentl y available treatment options in terms of its mode of action and route of 
administration. Remibrutinib may therefore offer a treatment option for patients with 
contraindications against or inadequate response to approved treatment options for CSU 
including anti-IgE directed biologics. These patients, for whom a high unmet need for new 
treatments exists, are part of the eligible patient population of this study. In the above -
mentioned Phase 2b trial CLOU064A2201, remibrutinib showed a rapid onset of action alread y 
after the first week of treatment, which is of significan t benefit for CSU patients, who often 
have a high current symptom burden. Furthermore, the oral route of administration of 
remibrutinib offers additional convenience compared to injectable biologics.
Taken together, the benefit for study  participants is that treatment with remibrutinib could 
substantially  improve their CSU signs and s ymptoms and lead to a better quality  of life.
The available clinical safety  experience has documented favorable safety  and tolerability  of 
remibrutinib. As of 10-Mar- 2022, approximately  903 participants (healthy  volunteers (HVs) 
and patients suffering from CSU, asthma, Sjoegren’s Sy ndrome (SjS), atopic dermatitis (AD), 
and relapsing multiple sclerosis (RMS)) have been exposed to remibrutinib at doses ranging 
from 0.5 mg to 600 mg, placebo or comparator. A maximum tolerated dose has not been 
identified.

[COMPANY_001] Confidential Page 40of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
In the final analysis of the Phase 2b trial CLOU064A2201 in patients with CSU, 309 
participants (safet y set(SAF) ) received remibrutinib at doses/regimens up to [ADDRESS_181940] adverse events (AEs) were mild in severity , without clustering of specific 
AEs and no apparent dose related pattern was identified. The most frequent adverse events were 
reported in the following System Organ Classes (SOC): I nfections and infestations (24.0% an y 
remibrutinib dose vs 21.4% in placebo arm), Skin and subcutaneous tissue disorders (16.9% vs 
4.8%), Nervous system disorders (13.1% vs 16.7%), and Gastrointestinal disorders (11.2% vs 
11.9%). The most frequent AEs (defined b y Me dDRA Preferred Term (PT), occurring in ≥ 5% 
of participants in either Any  remibrutinib or placebo arm) were:
Headache: 9.7% in an y remibrutinib arm vs. 14.3% in placebo arm
Nasophary ngitis: 8. 6% in any  remibrutinib arm vs. 7.1% in placebo arm
Chronic spont aneous urticaria: 6.0% in any  remibrutinib arm vs. 2.4% in placebo arm (the 
events of chronic spontaneous urticaria were flares primarily  reported b y participants 
during the treatment- free follow -up period)
In interim analysis 2 (IA2; cut-off May-2021) of the Phase 2b long-term open -label extension 
trial CLOU064A2201E1, data from [ADDRESS_181941] common SOCs (≥ 10% of subjects) were Infections and 
infestations (23%), Skin and subcutaneous tissue disorders (17.5%), Gastrointestinal disorders 
(14.2%) and Nervou s systems disorders (10.4%). The [ADDRESS_181942] commonly  reported PTs were 
headache (6.6%), COVID -19 (4.9%), and diarrhea (4.9%). Based on the mode of action of 
remibrutinib, pre-clinical safet y information, drug-drug-interaction studies, and the review of 
current ly available literature as well as safet y information of approved BTK inhibitors (e.g.,
ibrutinib, acalabrutinib and zanubrutinib), the following potential risks of remibrutinib have 
been identified (see below). Of note, many  safety  risks identified for ibrutinib and acalabrutinib, 
two BTK inhibitors approved for the treatment of B -cell malignancies (mantle cell l ymphoma, 
chronic lymphocy tic leukemia, Waldenstroem´s macroglobulinemia), are less likely  related to 
the pharmacology  of BTK inhibition, but rathe r to the underly ing hemato -oncologic diseases 
being treated and their associated comedications and complications, such as tumor lysis 
syndrome, second primary  malignancies, etc. Therefore, when comparing the safet y risks 
between the approved BTK inhibitors and remibrutinib, the underl ying condition of the treated 
patient population must be taken into consideration. Furthermore, ibrutinib and acalabrutinib 
have a different target selectivity  profile compared to remibrutinib ( Angst et al2020).
Infections: BTK is an important signaling kinase downstream of cell surface receptors and 
expressed in a number of cell t ypes of the adaptive and innate immune s ystem, including B 
cells, 
macrophages, basophils and mast cells. Thus, a dministration of remibrutinib might be 
associated with an increased risk for infections and participants should be monitored for 
signs and symptoms of infections and be evaluated promptly . In the completed and ongoing 
clinical trials with remibrutinib, infections were well balanced between the remibrutinib and 
placebo arms. Most of the infections observed were mild to moderate and did not lead to a 
change in study  treatment. In the final analysis of the Phase 2b study  CLOU064A2201, 
infection rates (defined as MedDRA SOC Infections and infestations) were comparable 
between any remibrutinib arm (24.0%) and the placebo arm (21.4%). Most infections 

[COMPANY_001] Confidential Page 41of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
reported in the remibrutinib arms were mild in severity  and did not lead to treatment 
discontinuation. 
All partici pants in remibrutinib clinical trials are monitored closel y for si gns and symptoms 
of infections while in the trial. Patients with a known history  of chronic recurrent or active 
ongoing infections are excluded from the trial (refer to Section 5.2for details). In addition, 
the use of live attenuated vaccines should be avoided [ADDRESS_181943] dose of the study treatment (see Section 6.2.3).
Response to vaccination : In general, immunomodulatory  treatments may  diminish vaccine 
efficacy  (Farez et 
al 2019 ). BTK inhibition is expected to affect the response to vaccinations 
and result in reduced vaccination efficacy . Due to its immunomodulatory effects, treatment 
with remibrutinib might be associated with reduced efficacy  of vaccinations. There are 
limited data available on vaccination response in patients treated with BTK inhibitors and 
primaril y reported in patients with hematologic malignancies (Pleyer et al 2021, Weber et 
al 2021). In ongoing studies with remibrutinib, participants are advised to complete 
necessary  vacc
ination before starting treatment with remibrutinib. If necessary, vaccination 
with non- live vaccines is allowed during the stud y.
Effect on platelet function - risk for bleeding :BTK is a signaling molecule in one of 
several platelet activation pathway s, and clinically  relevant effects of remibrutinib on 
platelet functions were observed in the remibrutinib preclinical toxicology  program. The 
mode of action b y which remibrutinib could potentially cause bleeding is currentl y not 
fully  understood. In vitro as sessments suggest a target -related impact on platelets, similar 
to effects induced b y the BTK inhibitor ibrutinib, which has been shown to inhibit clot 
retraction ( Bye et al 2015 ). 
In CSU, in the completed core CLOU06 4A2201 Phase 2b study , 18 (6.7%) non-serious 
bleeding events were reported in any remibrutinib arm 
compared to one event on placebo 
(2.4%); none of the AEs was serious or severe. All the bleeding AEs events reported were 
mild, except 2 moderate AEs: gingival bleeding and hematuria. Two bleeding events 
(petechiae and hematuria) led to study  treatment discontinuation. There were no notable 
clinically  relevant abnormalities for coagulation parameters, hemoglobin levels and platelet 
counts noted in these studie s. In the interim analysis of the open -label long-term (up to 52 
weeks) extension trial CLOU064A2201E1, the rate of bleeding events (4.4%) was 
comparable to that seen in the core trial; all events were non-serious, all but 2 events (the 
purpura and heavy  menstrual bleeding in the setting of leiomy oma) were mild in severity . 
Potential effects of remibrutinib on hemostasis should be monitored both clinically  and by 
[CONTACT_38183], validated laboratory  measures including complete blood count and standard 
coagulation parameters. Clinical monitoring should focus on skin (bruising, petechiae) and 
mucosa (e.g., gastro -intestinal (GI) tract bleeding including 
gingival, rectal, and 
conjunctival bleeding). Patients with a known history  of bleeding disorders, or with a histo ry 
of clinically  relevant gastrointestinal bleeding and patients requiring anti-platelet or 
anticoagulant therap y (other than aspi[INVESTIGATOR_155752] 100 mg/d or clopi[INVESTIGATOR_157034] 75 mg/d) are 
excluded from the trial; the use of dual anti-platelet therap y (e.g.,acetylsalicy lic acid + 
clopi[INVESTIGATOR_7745]) is prohibited (see details in Section 5.2 and Table 6 -3).In case of a significant 
bleeding event, study  treatment must be discontinued immediately . Please, refer to the 
current IB for further details.

[COMPANY_001] Confidential Page 42of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Effects on QT interval : Remibrutinib is a mild inhibitor of the human ether -a-go-go related 
gene (hERG) channel (IC50 = 1.4 µM; unbound Cmax -based average safety  margin of 43 -
fold based on 100 mg b.i.d. in humans) , without affecting other ion channels in a relevant 
manner .Close ECG monitoring via Holter recordings in the FIH studies (CLOU064X2101 
and CLOU064X1101) documented a minor exposure dependent increase in QTcF with no 
outliers (i.e., QT -interval with a fre quency  correction according to Fridericia (QTcF) > 480 
msec or increases equal or greater than 60 msec) up to the maximal dose of 600 mg. At the 
projected supratherapeutic exposure calculated based on the observed Cmax at 25 mg b.i.d., 
assuming severe organ impairment and comedication with a strong CYP3A4 inhibitors such 
as ritonavir (“worst case” scenario), the calculated mean QTcF effect is 2.[ADDRESS_181944]. The predicted upper 90% 
confide nce limit of the QTcF changes is well below [ADDRESS_181945] threshold for cardiac repolarization, indicating a low probability  of clinicall y 
significant repolarization effects even at 2-fold higher exposure than that of the “wors t -case” 
scenario. In the interim and final analyses of ongoing and completed Phase 2 studies in 
participants with CSU, SjS and asthma, no notable trend was observed for the change of 
ECG over time; no finding in ECG recordings or AEs suggestive of pro -arrh ythmic events 
were noted. Patients with a history  of major cardiovascular events are excluded from the 
trial. In addition, triplicate sequential ECG monitoring is implemented in the study  to 
monitor potential effects of remibrutinib on QTc and other ECG pa rameters.
Myelomodulation :Treatment emergent grade 3 or 4 cytopenias (neutropenia, 
thrombocytopenia and anemia) were reported in participants with hematologic malignancies 
treated with ibrutinib and acalabrutinib. Again, the underl ying hemato -oncologic diseases 
of these participants and their frequent association with such events should be taken into 
consideration here. All cytopenias reported in the final analysis of CLOU064A2201 were 
mild. Participants are closely  monitored for signs and symptoms of cytopenia while in the 
trial, and those with a history  of hematological disorders or with markedl y altered 
hematologic parameters at baseline are excluded from the study (see details in Section 5.2).
Drug -drug interactions : Oxida tive metabolism is the 
major clearance pathway  of 
remibrutinib and expected to be predominantly  mediated by [CONTACT_097]3A4 with minor 
contribution of other cytochrome P450 (CYP) enzy mes (e.g.,CYP2C9, CYP1A1). At the 
dose used in this study  (25 mg remibrutinib b.i .d.), co-administration of CYP3A4 inhibitors 
(even of strong ones) will not result in exposure levels of remibrutinib that are associated 
with clinically  relevant QT prolongation. Likewise, co-administration of even strong 
CYP3A4 inhibitors with 25 mg remibrutinib b.i.d. will not increase exposure levels of 
remibrutinib bey ond exposure levels that can be reached with 100 mg remibrutinib b.i.d., a 
dose that was well-tolerated in CLOU064A2201 and was not associated with any safety 
signals, based on the interim analysis. Therefore, only co-administration of strong CYP3A4 
inhibitors is prohibited in this study . Concomitant administration of moderate and strong 
inducers of CYP3A4 is also prohibited during the study  (see Table 6-3). Remibrutinib can 
be co-administered with oral contraceptives such as ethiny lestradiol or levonorgestrel 
without a major impact on their exposure and efficacy .Remibrutinib has been shown to 
inhibit some efflux and uptake transporters (such as P
-glycoprotein, OATP1B, Mate1, 
OAT3, organic cation transporter [ADDRESS_181946] cancer resistance protein (BCRP)). However ,
at a dose of 25 mg b.i.d. ,only inhibition of BCRP remains as a minor risk which is planned 

[COMPANY_001] Confidential Page 43of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
to be investigated in a clinical drug-drug interaction study.Therefore, concomitant 
administration of remibrutinib with respective BCRP substrates with a small safety  margin 
may be administered with caution (see Table 6-2)
Reproductive toxicity : Remibrutinib is not genotoxic or muta genic in in vitro or in vivo
studies. No effects on fertility  or embry o-fetal development were observed in rats up to the 
highest dose, while in rabbits a no-observed - adverse- effect -level at 100 mg/kg/day  was 
established. At doses ≥300 mg/kg/day  body weight loss, marked low food consumption, 
and moribundity  were noted, as well as a higher incidence of external fetal malformations 
(see details in Investigator's Brochure). For the approved BTK inhibitors, embry o-fetal 
toxicity  in 
animals is reported (see national prescribing information). Highl y effective 
methods of contraception must be practiced. Women of child- bearing potential will be 
informed that taking the study  treatment may involve unknown risks to the fetus if 
pregnancy  were to occur during the trial and must agree that in order to participate in the 
trial they must adhere to the contraception requirements outlined in the exclusion criteria. 
If there is any question that the participant will not reliabl y compl y, they should not be 
entered or continue in the study .
For detailed information on potential risks associated with remibrutinib, please refer to the 
Investigator’s Brochure.
In summary , CSU patients with inadequate response to H1 -antihistamines (and other available 
treatment options if applicable ) participating in this clinical trial may significantly benefit from 
treatment with remibrutinib. Additionally , this trial will help to improve the understanding of 
remibrutinib in the management of CSU and potentially  enable the development of a novel, 
innovative, oral drug that could improve the quality  of life of CSU patients bey ond the limited 
treatment modalities currently  available. Potential risks are mitigated as far as possible by 
[CONTACT_157076]/exclusion criteria, study  procedures, very close clinical and 
laboratory  monitoring, periodic review of safet y data by [CONTACT_105231] (DMC), and study  drug discontinuation rules. As with investigational drugs in 
general, not all safet y risks are known. Participants and investigators participating in this trial 
will be informed should important new safety  information become available.
Considering all aspects, the risk-benefit assessment fully  supports this trial with remibrutinib 
25 mg b.i.d.
4.6 Rationale for Public Health Emergency  mitigation procedures
During a Public Health emergency as declared b y Local or Regional authorities, i.e., pandemic , 
epi[INVESTIGATOR_6519], mitigation procedures to ensure participant safety  and trial integrit y 
are listed in relevant secti ons. Notification of the Public health emergency  should be discussed 
with [COMPANY_001] prior to implementation of mitigation procedures and permitted/approved by 
[CONTACT_6588].
[ADDRESS_181947] of approximately  450 
randomized female and male adult 
participants (300 in the active arm and 150 in the placebo arm) with CSU inadequatel y 
controlled by  [CONTACT_157061] H1- antihistamines (at least at locall y label approved dose).

[COMPANY_001] Confidential Page 44of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
The screen failure rate is estimated to be 30%, meaning approximately  645 participants are 
expected to be screened.
Participants will be stratified based on prior exposure to anti-IgE biologics and geographic 
region; maximum number of participants with prior exposure to anti-IgE biologics will be 
limited to approximately  30% of the total study  population.
Participants who drop out after they  have been randomized will not be replaced.
5.[ADDRESS_181948] meet allof the following criteria:
1.
Signed informed consent must be obtained prior to participation in the study
2.Male and female adult participants ≥18 y ears of age at the time of screening
3.CSU duration for ≥ 6 months prior to screening (defined as th e onset of CSU determined 
by [CONTACT_157077])
4.Diagnosis of CSU inadequately  controlled by  [CONTACT_157061] H1-antihistamines at the 
time of randomization defined as:
The presence of itch and hives for ≥6 consecutive weeks prior to screening despi[INVESTIGATOR_157039] H1 -antihistamines during this time period
UAS7 score (range 0 -42) ≥16, I SS7 score (range 0 -21) ≥ 6 and HSS7 score (range 0 -
21) ≥ 6 during the 7 day s prior to randomization (Day  1)
5.Docu mentation of hives within three months before randomization (either at screening 
and/or at randomization; or documented in the participants` medical history)
6.Willing and able to complete an Urticaria Patient Daily  Diary  (UPDD) for the duration of 
the study and adhere to the study  protocol
7.Participants must not have had more than one missing UPDD entry  (either morning or 
evening) in the 7 day s prior to randomization (Day 1)
5.[ADDRESS_181949] be based on 
central laboratory  results. In case eligibility  criteria are not met for specific laboratory  
parameters, these may  be re -tested a maximum of once during the screening period.
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study  
population will be representative of all eligible participants.
1. Use of other investigational drugs within 5 half -lives or within 30 day s (for small 
molecules) prior to Screening or until the expected pharmacod ynamic (PD) effect has 
returned to baseline (for biologics), whichever is longer; or longer if required by  [CONTACT_13125]
2.Previous use of remibrutinib o r other BTK inhibitors
3.History  of hypersensitivity  to any  of the study  treatments or its excipi[INVESTIGATOR_157040] 45of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
4.Participants having a clearly  defined predominant or sole trigger of their chronic urticaria 
(chronic inducible urti caria) including urticaria factitia (sy mptomatic dermographism), 
cold- , heat -, solar -, pressure -, delay ed pressure -, aquagenic- , cholinergic -, or contact -
urticaria
5.Other diseases with sy mptoms of urticaria or angioedema, including but not limited to 
urtica ria vasculitis, urticaria pi[INVESTIGATOR_1802], ery thema multiforme, mastocy tosis, hereditary  
urticaria, or drug -induced urticaria
6.Any other skin disease associated with chronic itching that might influence in the 
investigator’s opi[INVESTIGATOR_157041], e .g., atopic dermatitis, bullous 
pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
7.Participants taking medications prohibited by  [CONTACT_760] (see Table 6-3)
8.Known history  or evidence of ongoi ng alcohol or drug abuse within the last 6 months 
before randomization
9.History  of malignancy  of any  organ s ystem (other than localized basal cell carcinoma of 
the skin or in situ cervical cancer), treated or untreated, within the past 5 y ears, regardless 
of whether there is evidence of local recurrence or metastases
10.Pregnant or nursing (lactating) women
11.Women of child
-bearing potential (WoCBP), defined as all women ph ysiologically  
capable of becoming pregnant, unless they  are using highl y effective methods of 
contraception during dosing and for 7 day s after stoppi[INVESTIGATOR_157042]. Highl y 
effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
participant). Periodic abstinence (e .g.,calendar, ovulation, sy mptothermal, post -
ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) total h ysterectom y or bilateral tubal ligat ion at least six weeks before 
taking investigational drug. In case of oophorectomy  alone, onl y when the 
reproductive status of the woman has been confirmed by  [CONTACT_96036] 
Male sterilization (at least 6 months prior to screening). Fo r female participants on the 
study , the vasectomized male partner should be the sole partner for that participant
Use of oral(estrogen and progesterone), injected or implanted hormonal methods of 
contraception  
 
In case of use of oral contraception women should have been stabl e on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_181950] had 12 months of natural 
(spontaneous) amenorrhea with an appropriate clinical profile (e. g., age appropriate, 
history  of vas
omotor symptoms). Women are considered not of child-bearing potential if 
they are post- menopausal or have had surgical bilateral oophorectomy  (with or without 
hysterectom y), total h ysterectom y or bilateral tubal ligation at least six weeks ago. In the 

[COMPANY_001] Confidential Page 46of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
case of oophorectom y alone, only  when the reproductive status of the woman has been 
confirmed b y follow- up hormone level assessment is she considered not of child -bearing 
potential.
If local regulations deviate from the contraception methods listed above to pr event 
pregnancy , local regulations apply  and will be described in the informed consent form 
(ICF).
12.Major surgery  within 8 weeks prior to screening or planned surgery  for the duration of the 
study
13.a History  of live attenuated vaccine within 6 weeks prior to randomization or 
requirement to receive these vaccinations at an y time during the study
14.Evidence of clinically  significant cardiovascular (such as but not limited to my ocardial 
infarction, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, 
arrhythmia and uncontrolled hy pertension within 12 months prior to Visit 1), neurological, 
psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders, 
gastroint estinal disease or immunodeficiency  that, in the investigator's opi[INVESTIGATOR_1649], would 
compromise the safety of the participant, interfere with the interpretation of the study  
results or otherwise preclude participation or protocol adherence of the participant
15.Uncontrolled disease states, such as asthma, or inflammatory  bowel disease, where flares 
are commonl y treated with oral or parenteral corticosteroids
16.Hematology  parameters at screening:
Hemoglobin: < 10 g/dl
Platelets: < 100 000/mm3
Leucocy tes: < 3 000/mm3
Neutrophils: < 1 500/mm3
17.Significant bleeding risk or coagulation disorders
18.a History  of gastrointestinal bleeding, e .g., in association with use of nonsteroidal anti -
inflammatory  drugs (NSAID), that was clinicall y relevant (e.g., where intervention was 
indica ted or requiring hospi[INVESTIGATOR_157043])
19.a Requirement for anti- platelet medication, except for acet ylsalicy lic acid up to 100 
mg/d or clopi[INVESTIGATOR_157034] 75 mg/d. The use of dual anti -platelet therap y (e.g., 
acetylsalicy lic acid + clopi[INVESTIGATOR_7745]) is prohibited. 
20.Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti -
Coagulants (NOAC))
21.History  or current hepatic disease including but not limi ted to acute or chronic hepatitis, 
cirrhosis or hepatic failure or Aspartate Aminotransferase (AST)/ Alanine 
Aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or 
International Normalized Ratio (INR) of more than 1.[ADDRESS_181951], or estimated Glomerular 
Filtration Rate (eGFR) <45ml/min (using the Cockcroft -Gault equation) at screening
23.Evidence of an ongoing Hepatitis C infection (e.g., defined b y the detection of hepatitis C-
ribonucleic acid (HCV -RNA) at screening) and/or an ongoing Hepatitis B infection 
(defined b y the detection of Hepatitis B virus surface antigen (HBsAg) and/or hepatitis B 
virus (HBV) -DNA at screening; participants who are positive for anti -hepatiti s B co re 

[COMPANY_001] Confidential Page 47of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
(HBc) antibodies but who are negative for antibodies against HBsAg and HBV -DNA can 
be included into the study if they  agree to monitoring for HBsAg and HBV -DNA re -
activation)
24. Known or suspected ongoing, chronic or recurrent infectious disease including but not 
limited to opportunistic infections ( e.g., tuberculosis , atypi[INVESTIGATOR_2855] m ycobacterioses, listeriosis 
or aspergillosis) and/or known positivity  for Human I mmunodeficiency  Virus (HIV) 
infection. HIV antigen/antibody  tests will be performed to determine HIV status if 
required according to local regulations.
6 Treatment
6.1 Stud y treatment
[COMPANY_001] Global Clinical Supply  (GCS) will supply  the following IMPs in the trial in 
appropriatel y labeled bottles:
-LOU064 25mg (blinded)
-LOU064 25mg placebo (blinded)
-LOU064 25m g (open -label)
No other supplies apart from these would be provided by  [CONTACT_157078]  (GCS).

[COMPANY_001] Confidential Page 48of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
6.1.1 Investigational and control drugs
Table 6-1 Investigational and control drug
Investigational/ 
Control DrugPharmaceutical 
Dosage FormRoute of 
AdministrationPresentation Sponsor (global 
or local)
LOU064 25 mg Film coated tablet Oral use Double blind [COMPANY_001] Pharma 
AG
LOU064 25 mg 
matching PlaceboFilm coated tablet Oral use Double blind [COMPANY_001] Pharma 
AG
LOU064 25 mg Film coated tablet Oral use Open label [COMPANY_001] Pharma 
AG
6.1.2 Additional study treatments
No other treatment beyond investigational drug and control drug (remibrutinib and placebo) are 
included in this trial.
Participants will take background medication (second generation H1-antihistamines at locall y 
label approved doses) with a stable regimen during the study  (Section 6.2.1). For rescue 
medication, see Section 6.2.4 .
6.1.3 Treatment arms/group
Participants will be assigned at Day 1 to either remibrutinib 25 mg b.i.d. or matching placebo 
in a ratio of 2:1. At week 24 participants in the placebo arm will be switched to active treatment. 
Each partici pant will take one film-coated tablet in the morning and one film-coated tablet in 
the evening  
.
6.1.4 Treatment duration
The planned duration of treatment is52 weeks. Participants may discontinue from study  
treatment earlier at the discretion of the investigator or the 
participant, e.g.,due to adverse 
events (see Section 9.1) or lack/loss of efficacy . Eligible participants may roll over into the 
planned extension study  at Week 52 (after completing all scheduled assessments planned at 
these visits). The details of the study  design and procedures of the extension, if implemented, 
will be describ ed in a separate protocol.
There are a total of [ADDRESS_181952] dispensing visit occurs at Week 40.
6.2 Other treatment(s)
6.2.[ADDRESS_181953] take a second generation H1 -antihistamine at a locally 
label approved dose (background therap y). Background therap y should not be changed until the 
Week 12 visit and should only be changed thereafter if medically  required (i.e.,advers e 
reactions that are attributable to background therapy as per investigator judgment). For detailed 

[COMPANY_001] Confidential Page 49of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
information on the background medication, refer to the corresponding national prescribing 
information.  
Prior medication for treatment of CSU will berecorded in the Electronic Case Report Forms 
(eCRF). In addition, all concomitant medication at screening and prior medication that has been 
terminated within [ADDRESS_181954] 
the participant tonotify  the study  site about any new medications (including medications that 
are not related to the treatment of CSU) he/she takes after the participant was enrolled into the 
study , ideall y before initiating a new treatment.
All medications, procedures, and significant non-drug therapi[INVESTIGATOR_014] (including physical therap y and 
blood transfusions) administered after the participant was enrolled into the study  must be 
recorded on the appropriate eCRFs.
Each concomitant medication must be individually  assessed against all exclusion 
criteria/prohibited medication. I f in doubt, the investigator should contact [CONTACT_157079] a participant or allowing a new medication to be started. If the 
participant is alread y enrolled, contact [CONTACT_157080].
6.2.2 Permitted concomitant therapy  requiring caution and/or action
Remibrutinib has been shown to inhibit the BCRP transporter at the intestinal level. As a 
consequence, co-administration with remibrutinib can lead to exposure increases area under the 
curve of >1.5-fold. Therefore, concomitant administration of remibrutinib with respective 
BCRP substrates may be accomplished with caution. BCRP substrates with a small safet y 
margin may  be administered 2 hours before or after remibrutinib (staggered dosing).
Table 6-2 Permitted concomitant therapy  requiring caution and/or action
Medication Period Guidance
Oral BCRP substrates that may 
have increased exposure when 
co-administered with 
remibrutinib (pi[INVESTIGATOR_2830], 
rosuvastatin, sulfasalazine and 
ubrogepan)[ADDRESS_181955] 
medication or administer 2 hr 
before or after remibrutinib 
(staggered dosing)
6.2.3 Prohibited medication
Use of the treatments display ed in the below table are not allowed during the specified time 
period.
Table 6-3 Prohibited medication
Medication Prohibition period Action taken
Biologics for treatment of CSU 
(including omalizumab and 
ligelizumab)4 months prior to 
randomization until end of 
treatmentDiscontinue biologic treatment 
and closely monitor for 
potential associated adverse 
events.

[COMPANY_001] Confidential Page 50of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Medication Prohibition period Action taken
Routine (more than 3 doses 
over a 5 day period) oral 
corticosteroids30 days prior to screening until 
end of treatment
Oral corticosteroids are only 
allowed as an additional 
rescue therapy for CSU 
AFTER Week 12 , on an as -
needed basis for unbearable 
symptoms as per Section 6.2.4 . 
Other preparations of 
corticosteroids (CS) with limited 
systemic exposure for non -
CSU indications (e. g., intra -
nasal or any topi[INVESTIGATOR_157044]) can be 
used 
on an as -needed basis.Discontinue routine 
corticosteroids if medically 
justifiable and closely monitor 
for potential associated 
adverse events. If 
discontinuation of routine 
corticosteroids is not possible, 
discontinue study treatment.
i.v./IM/IA cortico steroids 30 days prior to screening until 
end of treatmentDiscontinue i.v./IM/IA 
corticosteroids if medically 
justifiable and closely monitor 
for potential associated 
adverse events. If 
discontinuation of i.v./IM/IA 
corticosteroids is not possible, 
discon tinue study treatment.
Leukotriene antagonists 
(including montelukast and 
zafirlukast)From  screening until end of 
treatmentDiscontinue Leukotriene 
antagonists and closely monitor 
for potential associated 
adverse events.
H2-antihistamines From  screening until end of 
treatmentDiscontinue H2-antihistamines 
and closely monitor for 
potential associated adverse 
events.
First generation antihistamines From  screening until end of 
treatmentDiscontinue first generation 
antihistamines and closely 
monitor for po tential associated 
adverse events.
Second generation 
antihistamines other than the 
participant's defined 
background medication and 
rescue medicationFrom  7 days prior to 
randomization until end of 
treatmentDiscontinue all second 
generation H1 -antihistam ines 
but the defined background 
and rescue medication and 
closely monitor for potential 
associated adverse events.
Other 
immunosuppressive/immunom
odulating medication with or 
without known effect on CSU 
including but not limited to 
hydroxychloroquine, 
methotrexate, cyclosporine A, 
cyclophosphamide, tacrolimus 
and m ycophenolate mofetil30 days or 5 half -lives 
(whichever is longer) prior to 
screening until end of treatmentDiscontinue immunosuppressiv
e/immunomodulating 
medication if medically 
justifiable and closely monitor 
for potential associated 
adverse events. If 
discontinuation not possible, 
discontinue study treatment.

[COMPANY_001] Confidential Page 51of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Medication Prohibition period Action taken
Intravenous (i.v.) 
immunoglobulins or 
plasmapheresis30 days prior to screening until 
end of treatmentDiscontinue i.v. 
immunoglob ulins or 
plasmapheresis if medically 
justifiable and closely monitor 
for potential associated 
adverse events. If 
discontinuation not possible, 
discontinue study treatment.
Ultraviolet (UV) therapy From  screening until end of 
treatmentDiscontinue UV thera py and 
closely monitor for potential 
associated adverse events.
Any other therapy intended for 
the treatment of urticaria 
including but not limited to 
herbal therapi[INVESTIGATOR_157045]  [ADDRESS_181956] 
dose of study treatmentDiscontinue study treatment.
Strong inhibitors of CYP3A4 From  2 weeks prior 
randomization until end of 
treatmentDiscontinue CYP3A4 inhibitor if 
medically justifiable and closely 
monitor for potential associated 
adverse events. If 
discontinuation not possible, 
discontinue study treatment
Moderate and strong inducers 
of CYP3A4From  2 weeks prior 
randomization until end of 
treatmentDiscontinue CYP3A4 inducers 
if medically justifiable and 
closely monitor for potential 
associated adverse events. If 
discontinuation not possible, 
discontinue s tudy treatment.
Anticoagulant medication (for 
example, warfarin, or Novel 
Oral Anti -Coagulants (NOAC) )From  screening until end of 
treatmentOnly if medically justifiable, 
discontinue anticoagulant 
medication and interrupt study 
medication until anticoagu lant 
effects have ended. Otherwise 
discontinue study treatment. 
Closely monitor coagulation 
parameters and associated 
adverse events.
Clinical monitoring should 
focus on skin (bruising, 
petechiae) and mucosa (e.g. ,
gastro -intestinal tract bleeding 
includin g gingival and rectal, or 
conjunctival bleeding). In case 
of a significant bleeding event, 
study treatment must be 
discontinued immediately.

[COMPANY_001] Confidential Page 52of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Medication Prohibition period Action taken
Anti-platelet medication except 
for acetylsalic ylic acid up to 
100 mg/d or clopi[INVESTIGATOR_157034] 
75 mg/d. The use of d ual anti -
platelet therapy (e.g., 
acetylsalicylic acid + 
clopi[INVESTIGATOR_7745]) is prohibited.From  screening until end of 
treatmentOnly if medically justifiable, 
discontinue anti -platelet 
medication and interrupt study 
medication until anti -platelet 
effects have en ded. Otherwise 
discontinue study treatment. 
Closely monitor coagulation 
parameters and associated 
adverse events. Clinical 
monitoring should focus on skin 
(bruising, petechiae) and 
mucosa (e.g. ,gastro -intestinal 
tract bleeding including gingival 
and recta l, or conjunctival 
bleeding). In case of a 
significant bleeding event, 
study treatment must be 
discontinued immediately.
6.2.4 Rescue medication
H1-antihistamines: In addition to being used as background medication, second generation 
H1-antihistamines are allow ed as rescue medication, used on an as needed basis for participants 
with CSU flare-ups of unbearable symptoms during screening, treatment and follow -up periods. 
The selection of the rescue medication H1-antihistamine should be made only once for an 
indivi dual participant and recorded in the source document. For each individual participant, the 
H1-antihistamine used as rescue medication must differ from the H1-antihistamine used 
as background medication . The daily  dose of H1 -antihistamine rescue medication should not 
exceed 4-fold of the approved dose, as recommended by [CONTACT_157081] (Zuberbier et
al2018). For detailed information on the rescue medication, refer to 
the corresponding national prescribing information. A change of the rescue medication for an 
individual participant is only permitted in case of adverse reactions that are, in the judgment of 
the investigator, attributable to rescue medication.
Oral corticosteroids: Prior to Week 12, any corticosteroid use for CSU is prohibited. After 
the Week 12 primary endpoint , participants will be permitted to use oral corticosteroids such 
as prednisone or its equivalent, as rescue medication if needed for CSU flare -ups of unbearable 
symptoms. The selection of the oral corticosteroid to be used as rescue medication after Week 
12, should be made only  once for an individual participant. A switch of oral corticosteroids as 
rescue medication for an individual is not permitted except due to an AE. Rescue oral 
corticosteroid use will be limited to 3 days in a 30 -day period and a maxi mum of 9 days in 
total after Week 12to avoid any confounding suppression of signs and symptoms of CSU. The 
recommended dose is 20 - 50 mg prednisone or equivalent per day, which is in line with the 
current urticaria treatment guidelines ( Zuberbier et al 2018).
Rescue medication will be sourced locall y. Us e of H1 -antihistamine rescue medication only for 
CSU must be recorded in the eDiary  by [CONTACT_2299] (number of tablets taken) and the name 
[CONTACT_157128] (eCRF). All relevant 
information for oral corticosteroid rescue therap y will be captured in the appropriate eCRF.

[COMPANY_001] Confidential Page 53of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
6.3 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under investigational 
and control drugs section.
A unique medication number is printed on the study
 medication label.
Investigator staff will identify  the study  medication kits to dispense to the participant by 
[CONTACT_6598]  (IRT) and obtaining the medication number(s). 
The study  medication has a 2-part label (base plus tear-off label), immediately  before dispensing 
the medication kit to the participant, site personnel will detach the outer part of the label from 
the packaging and affix it to the source document.
As per Section
4.6, during a Public Health emergency  as declared by [CONTACT_6620], i.e. ,pandemic, epi[INVESTIGATOR_6519], that limits or prevents on-sitestudy 
visits, delivery  of Investigational Medicinal Product (IMP) directly  to a participant’s home may 
be permitted (if allowed by [CONTACT_157082]) in the event the Investigator has decided that anon-site visit by [CONTACT_157083], and that it is in the interest of the participant’s health to 
administer the study  treatment even without performing an on-site visit. The dispatch of IMP 
from the site to the particip
ant’s home remains under the accountability  of the Investigator. 
Each shipment/provisioning will be for a maximum of 1-months suppl y. In this case, phone 
calls, virtual contacts (e.g.,tele consult) or visits by  [CONTACT_6624]/home nursing to the participant's
home at the time of a planned on-site visit will occur for instructional purposes, safety 
monitoring, investigation of any  adverse events, ensuring participants continue to benefit from 
treatment, and discussion of the participant's health status until itis safe for the 
participant to 
visit the site again.
6.3.1 Handling of study  treatment and other treatment
[IP_ADDRESS] Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, all study  treatment must be stored according to the 
instructions specified on the labels.
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints 
are to be reported to the respective [COMPANY_001] Country  Organization Quality  Assurance.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage co nditions for the study  treatment but no information about 
the participant except for the medication number.
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability will be performed by 
[CONTACT_157084], and at the completion of the trial.
Participants will be asked to return all unused study  treatment and packaging at each site visit 
during the study  and at the end of the study , or at the time of discontinuation of study  treatment.

[COMPANY_001] Confidential Page 54of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
The site may destro y and document destruction of unused study  treatment, drug labels and 
packaging as appropriate in compliance with site processes, monitoring processes, and per local 
regulati on/guidelines. Otherwise, the investigator will return all unused study  treatment, 
packaging, drug labels, and a copy of the completed drug accountabilit y log to the field monitor 
or to the [COMPANY_001] address provided in the investigator folder at each site.
[IP_ADDRESS] Handling of other treatment
Not applicable.
6.3.2 Instruction for prescribing and taking study treatment
Every  participant should take one film-coated tablet of remibrutinib 25 mg or placebo in the 
morning and in the evening, respectivel y, with a 12 hour interval at approximately  the same 
time every  day. The study  medication may be taken with or without a meal but participants 
should adhere to their choice throughout the stud y. If taken without food, the study  medication 
should be taken with a glass of water (250 milliliters (ml)) at least [ADDRESS_181957] meal 
and 1 hour before the next meal. Participants should be instructed to swallow whole tablets and 
not to chew or break them.
 
 
If vomiting occurs during the course of treatment, participants should not take the study 
treatment again before the next scheduled dose.
Participants should be instructed not to make up missed doses. A missed dose is defined as a 
case when the full dose is not taken within 6 hours after the approximate time of the usuall y 
morning/evening dosing. That dose should be omitted and the participant should continue 
treatment with the next scheduled dose.
H1-antihistamines taken as either as background medication or rescue medication, respectivel y, 
should be taken according to the local treatment instructions.
All kits of study  treatment assigned by  [CONTACT_157085].
6.4 Participant numbering, treatment assignment, randomization
6.4.1 Participant numbering
Each participant is identified in the study  by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening and is retained for the participant 
throughout his/her participation in the trial. A new Participant No. will be assigned at every  
subsequent enrollment if the participant is re-screene d. The Participant No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential 
participant number suffixed to it, so that each participant’s participation is numbered uniquely 
across the entire datab ase. Upon signing the informed consent form, the participant is assigned 
to the next sequential Participant No. available.

[COMPANY_001] Confidential Page 55of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
A new I CF will need to be signed if the investigator chooses to re -screen the participant after a 
participant has screen failed, and the participant will be assigned a new Participant No.
6.4.2 Treatment assignment, randomization
At the randomization visit, all eligible participants will be randomized via IRT to one of the 
treatment arms. The investigator or his/her delegate will contact [CONTACT_157086]/exclusion criteria. The IRT will assign a randomization 
number to the participant, which will be used to link the participant to a treatment arm and will 
specify  a unique medication numbe r for the first package of study treatment to be dispensed to 
the participant.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from participants and investigator staff. A 
participant randomization list will be produced by [CONTACT_6609] a validated system 
that automates the random assignment of participant numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication list will beproduced by [CONTACT_157087]  (GCS) using a validated system that automates the random assignment of medication 
numbers to packs containing the stud y treatment.
Randomization will be stratified by [CONTACT_157088]-IgE biologic use and geographic 
region; maximum number of participants with prior exposure to anti-IgE biologics will be 
limited to approximately  30% of the total study  population.
The randomization scheme for participants will be reviewed and approved by  a member of the 
Randomization Office.
6.[ADDRESS_181958] of the trial will remain blinded to the identity of the treatment during 
the double -blind treatment period (i.e. ,up to week 24) from the time of randomization until the 
final database lock.
The following methods will be used to maintain the blind:
(1) Randomization data will be kept strictly  confidential until the time of final database lock, 
and will not be accessible by  [CONTACT_37242]:
The designated [COMPANY_001] study  team members involved in the primary  analy sis
The bioanal yst  (to avoid the unnecessary  analy sis of placebo samples)
An independent anal ysis team who need to prepare DMC reports.
(2) The identity  of the treatments will be concealed by [CONTACT_37243], labeling , schedule of administration, appearance, taste, and odor.
At the time of the primary anal ysis, a selected [COMPANY_001] Team will create and review unblinded 
interim reports. No access 
will be given to the study  team conducting the ongoing trial until 
final da tabase lock.

[COMPANY_001] Confidential Page 56of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
 
Unblinding a single participant at the study  site for safety reasons (necessary  for participant 
management) will occur via an emergency  system in place at the site. As a result, the participant 
should be discontinued from the study  treatment.
The DMC will review semi -blinded interim reports created by [CONTACT_157089]. 
More details will be provided in the DMC charter.
6.6 Dose escalation and dose modification
Investigational or other study
 treatment dose adjustments are not permitted.
Study  treatment interruptions are permitted in order to manage the follow ing events:
Management of bleeding events: in case of planned surgery
 with clinical significant 
bleeding risk, interruption of study  treatment 7 day s before the surgery  is required; after 
recovery , participant may  re-start study  treatment after 7 day s.
Management of participants in case of Hepatitis B re-activation (new appearance of 
detectable HBV -DNA or positive HBsAg): participants should start antiviral treatment 
according to local clinical practice and interrupt study  treatment until HBV- DNA and 
HBsAg reach an undetectable level, and then re -start study  treatment.
Study  treatment interruption for other than the above reasons is only permitted if, in the opi[INVESTIGATOR_8574], a participant is deemed to be at a significant safet y risk unless admini stration 
of investigational treatment is temporaril y interrupted. In such cases study  treatment should be 
interrupted only during the time that this risk is present and ongoing. Study  treatment can be re-
started at the next scheduled visit after resolution of the safet y risk.
6.6.[ADDRESS_181959] promote compliance by [CONTACT_157090] y as prescribed and b y stating that compliance is necessary for the participant’s 
safet y and the validity  of the study .The participant must also be instructed to contact [CONTACT_121942]/she is unable for any reason to take the study  treatment as 
prescribed. Compliance will be assessed by [CONTACT_1755]/or study  personnel at each visit 
using tablet counts (if applicable) and information provided by [CONTACT_2299]. This information 
should be captured in the source document at each visit. All study  treatment dispensed and 
returned must be recorded in the Drug Accountability  Log.
 

[COMPANY_001] Confidential Page 57of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
6.7.[ADDRESS_181960] often, discontinuation from study  treatment and knowledge of the possible treatment 
assignments are sufficient to treat a study  participant who presents with an emergency  condition. 
Emergency  treatment code breaks are performed using the IRT. When the investigator contacts 
the system to break a treatment code for a participant, he/she must provide the requested 
participant identify ing information and confirm the necessit y to break the treatment code for 
the participant. The investigator will then receive details of the investigational drug treatment 
for the specified participant and a fax or email confirming this information. The system will 
automatically  inform the [COMPANY_001] monitor for the site and the study  team that the code has been 
broken. If the IRT s ystem is not available for technical reasons, the IRT help desk can facilitate 
emergency  code break requests.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The investigator 
will provide:
protocol number
participant number
In addition, oral and written information to the participant must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at an y time.
The appropriate personnel from the study  site and [COMPANY_001] will assess whet her study treatment 
should be discontinued for an y participant whose treatment code has been broken inadvertentl y 
for an y reason.
Study  treatment must be discontinued after emergency  unblinding and the participant will be 
withdrawn from the trial and would not be eligible for enrollment into the planned open -label 
extension study .
6.7.3 Treatment of overdose
No clinical data are available to assess the risk of overdose. Based on preclinical data it is 
concluded that remibrutinib has a low potential to cause acute toxicity , e.g., in case of accidental 
overdosing. Single and multiple ascending doses of remibrutinib up to 600 mg were studied in 
healthy  volunteers with no dose-limiting toxicities identified. With the 25 mg b.i.d. dose used 
in this study , the potential of remibrutinib to cause acute toxicity  is assessed as low.
There is no specific antidote to remibrutinib; therefore, adverse events will be managed 
symptomaticall y according to standard of care and applicable clinical guidelines.
In the event of an overd ose, the Investigator should:
Contact [CONTACT_10990] .
Closely  monitor the participant for an y AE/SAE and laboratory  abnormalities.
Document the quantit y of the excess dose as well as the duration of the overdose.

[COMPANY_001] Confidential Page 58of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
7 Informed consent procedures
Eligible participants may only be included in the study  after providing (witnessed, where 
required by [CONTACT_6617]), Institutional Review Board (IRB)/Independent Ethics 
Committee (I EC)-approved informed consent.
If applicable, in cases wher e the participant's representative(s) gives consent (if allowed 
according to local requirements), the participant must be informed about the study to the extent 
possible given his/her level of understanding. If the participant is capable of doing so, he/sh e 
must indicate agreement by [CONTACT_37249] y signing and dating the written informed consent 
document.
Informed consent must be obtained before conducting any study -specific procedures (e.g.,all 
of the procedures described in the protocol). The process of obtaining informed consent must 
be documented in the participant source documents.
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the International Council for Harmonization of Technical Requir ements for 
Pharmaceuticals for Human Use (ICH) E6 good clinical practice (GCP) guidelines and 
regulatory  requirements and is considered appropriate for this study . Any changes to the 
proposed consent form suggested by [CONTACT_157091] I RB/IEC.
Information about common side effects already
 known about the investigational treatment can 
be found in the Investigator's Brochure (IB). This information will be included in the participant 
informed consent and shou ld be discussed with the participant during the study as needed. An y 
new information regarding the safet y profile of the investigational drug that is identified 
between IB updates will be communicated as appropriate, for example, via an investigator 
notifi cation or an aggregate safet y finding. New information might require an update to the 
informed consent and then must be discussed with the participant.
The following informed consents are included in this study :
Main study  consent, which also includes: 
  
 
As applicable, Pregnancy Outcomes Reporting Consent for female participants who took 
study treatment


Women of child- bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
 
 
 

[COMPANY_001] Confidential Page 59of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
 
 
A copy of the approved version of all consent forms must be provided to [COMPANY_001] after IRB/IEC 
approval.
Participants might be asked to complete an optional questionnaire to provide feedback on their 
clinical trial experience.
As per Secti on 4.6, during a Public Health emergency  as declared by [CONTACT_6620] i.e., pandemic, epi[INVESTIGATOR_6519], that may  challenge the ability  to obtain 
a standard written informed consent due to limits that prevent an on -site visit, I nvestigator may 
conduct the informed 
consent discussion remotely  (e.g., telephone , videoconference) if 
allowable b y a local Health Authority.
Guidance issued by [CONTACT_157092] y documen ted (e.g., the presence of an impartial witness, sign/dating separate I CFs 
by [CONTACT_6622], etc.).
8 Visit schedule and assessments
The Assessment Schedule (Table 8-1) lists all of the assessments and when they are performed. 
All data obtained from 
these assessments must be supported in the participant’s source 
documentation.
Participants should be seen for all visits/assessments as outlined in the assessment schedule 
(Table 8-1) or as close to the designated day/time as possible. Missed or rescheduled visits 
should not lead to automatic discontinuation.
For participants who discontinue from study  treatment refer to Section 9.1.1.
Participants who discontinue from the study  or withdraw their consent/oppose the use of their 
data/biological samples should be scheduled for a final 
evaluation visit, if they agree, as soon 
as possible, at which time all of the assessments listed for the final visit will be performed. At 
this final visit, all dispensed investigational product should be reconciled, and the adverse event 
and concomitant medications not previously reported must be recorded on the CRF.
The "X" in the table denot es the assessments to be recorded in the clinical database or received 
electronically  from a vendor. The "S" in the table denotes the assessments that are only in the 
participant's source documentation and do not need to be recorded in the clinical databas e.
As per Section 4.6, during a Public Health emergency  as declared by [CONTACT_6620] i.e., pandemic , epi[INVESTIGATOR_157046]-site study  visits, 
alternative methods of providing continuing care may be implemented by [CONTACT_157093]. If allowed by [CONTACT_157094], phone calls, virtual contacts (e.g., tele consult) or visits by  [CONTACT_6624]/ home nursing 
staff to the participant´s home, can replace on-site study  visits, for the duration of the disruption 
until it is safe for the participant to visit the site again.

[COMPANY_001] Confidential Page 60of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
The preferred sequence of assessments during study visits is PRO completion, ECG collection, 
followed b y vital signs, and blood sampling.

[COMPANY_001] Confidential Page 61of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Table 8-1 Assessment Schedule
Period Screening Treatment Follow -up Unscheduled visit
Visit Name [CONTACT_157129]/ 
Randomization1
week 21
week 4
week 8
week 121
week 16
week 20
week 24 week 32
week 40Early  
treatment 
discontinu -
ationweek 
52/Study  
discontinu -
ation1week 
56/Safety  
FU/Study  
completionUnscheduled visit
Days -28 to -1 1 15 29 57 85 113 141 169 225 281 - 365 394 -
Informed consent X
IRT transaction X X X X X X X X X X X X
Inclusion / 
Exclusion criteriaX X
Randomization X
Demography X
Pregnancy and 
assessments of 
fertility2XS S S S S S S S S S S S S S
Evidence of 
urticariaS S
Hepatitis screen X
Relevant medical 
historyX
Dispense 
participants' 
eDiary3S S S
CSU History and 
prior urticaria 
treatmentX
Cardiovascular 
historyX

[COMPANY_001] Confidential Page 62of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Period Screening Treatment Follow -up Unscheduled visit
Visit Name [CONTACT_157129]/ 
Randomization1
week 21
week 4
week 8
week 121
week 16
week 20
week 24 week 32
week 40Early  
treatment 
discontinu -
ationweek 
52/Study  
discontinu -
ation1week 
56/Safety  
FU/Study  
completionUnscheduled visit
Days -28 to -1 1 15 29 57 85 113 141 169 225 281 - 365 394 -
Physical 
Examination4 S S S S S S S S S S S S S S S
Height and 
Weight5 XXXXX X X X
Vital Signs X X X X X X X X X X X X X X X
Electrocardiogram 
(ECG)X X X6X6X X X6X X
Subject's eDiary 
review7 S S S S S S S S S S S S S
DLQI8X X X X X X X
Study drug 
dispensationX X X X X X X X X
Background 
medication 
dispensation and 
compliance 
assessmen t17X X X X X X X X X X X X X
Rescue 
medication X X X X X X X X X X X X

[COMPANY_001] Confidential Page 63of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Period Screening Treatment Follow -up Unscheduled visit
Visit Name [CONTACT_157129]/ 
Randomization1
week 21
week 4
week 8
week 121
week 16
week 20
week 24 week 32
week 40Early  
treatment 
discontinu -
ationweek 
52/Study  
discontinu -
ation1week 
56/Safety  
FU/Study  
completionUnscheduled visit
Days -28 to -1 1 15 29 57 85 113 141 169 225 281 - 365 394 -
dispensation and 
usage10
Clinical Chemistry X X X X X X X X X X X X X X X
Hematology X X X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X X X
Coagulation Panel X X X X X X X X X X
Hepatitis B re -
activation 
monitoring15X X X X X X X X X X X X

[COMPANY_001] Confidential Page 64of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Period Screening Treatment Follow -up Unscheduled visit
Visit Name [CONTACT_157129]/ 
Randomization1
week 21
week 4
week 8
week 121
week 16
week 20
week 24 week 32
week 40Early  
treatment 
discontinu -
ationweek 
52/Study  
discontinu -
ation1week 
56/Safety  
FU/Study  
completionUnscheduled visit
Days -28 to -1 1 15 29 57 85 113 141 169 225 281 - 365 394 -
Eligibility 
assessment for 
extension stud y18X
Prior and 
concomitant 
medicationX
Adverse Events X
Study completion 
informationX
1Participant to come fasting for ≥8 h (ideally overnight) to visits: Baseline/Randomization, week 2, week [ADDRESS_181961] done by [CONTACT_157095]. Urine pregnancy results are reported as 
source. 
3Participants eDiary will be returned to site at either W eek 52/study discont inuation
4Complete physical exam at screening, short physical exam at all subsequent visits including body temperature monitoring (per local practice)
5Height collected at screening visit only
6pre and post dose
7eDiary includes UPDD (Urticaria Patien t Daily Diary) with UAS (Urticaria Activity Score, part of UPDD) and AAS (Angioedema Activity Score), eDiary to be completed 
from screening to week 52/study discontinuation
8Completed in the patient’s eDiary during site visit. Order of completion: DLQI . All questionnaires should be completed prior to 
any other physician assessment.
  
14At selected sites only

[COMPANY_001] Confidential Page 65of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Period Screening Treatment Follow -up Unscheduled visit
Visit Name [CONTACT_157129]/ 
Randomization1
week 21
week 4
week 8
week 121
week 16
week 20
week 24 week 32
week 40Early  
treatment 
discontinu -
ationweek 
52/Study  
discontinu -
ation1week 
56/Safety  
FU/Study  
completionUnscheduled visit
Days -28 to -1 1 15 29 57 85 113 141 169 225 281 - 365 394 -
15Hepatitis B re -activation monitoring only for p articipants who were HBsAg negative and HBcAb (anti-HBc) positive with a negative HBV DNA test at Screening.
17Dispen sation for background medication covers prescription, dispensation and/or instruction of the participant on dosing and use of background medication and 
protocol requirements, considering different procedures for the provision of background medication at in vestigational sites. At W eek 56/Safety FU/Study completion visit 
only compliance to be checked 
[ADDRESS_181962] completed W eek 52 visit, not applicable at Study discontinuation visit

[COMPANY_001] Confidential Page 66of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
8.[ADDRESS_181963] been assessed and the participant is eligible for enrollment in 
the study  the baseline visit can be scheduled (this may be prior to the maximum 28 day screening 
period duration).
Evaluation of participant eligibility  for laboratory  parameters listed in Section 5.[ADDRESS_181964] number. The investigator/qualified site staff will record if the 
participant was re-screened on the re-screening eCRF and any applicable screening numbers 
the participant was issued prior to the current screening number.
The date of the new informed consent signature [CONTACT_157130]. For re -screening, all screening assessments 
must be performed per protocol.
8.1.1 Information to be collected on screening failures
Parti cipants who sign an informed consent form and are subsequentl y found to be ineligible 
prior to randomization will be considered a screen failure. The reason for screen failure should 
be recorded on the appropriate Case Report Form. The demographic informat ion, informed 
consent, and Inclusion/Exclusion pages must also be completed for screen failure participants. 
No other data will be entered into the clinical database for participants who are screen failures, 
unless the participant experienced a serious adverse event (SAE) during the screening phase 
(see SAE section for reporting details). If the participant fails to be randomized, the IRT must 
be notified within 2 days of the screen fail that the participant was not randomized.
Participants who are randomiz ed and fail to start treatment, e.g.,participants randomized in 
error, will be considered an early terminator. The reason for early  termination should be 
recorded on the appropriate Case Report Form.
8.2 Participant demographics/other baseline characteristics
Baseline CSU activit y will be assessed using the eDiary  from Day -[ADDRESS_181965] on the 

[COMPANY_001] Confidential Page 67of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
safet y and efficacy  parameters in the study . Relevant medical history  (including evaluation of 
inclusion/exclusion criteria, CSU history  and cardiovascular history ) and current medical 
condition present before signing the informed consent will be captured. Where possible, 
diagnoses, and not symptoms, will be recorded. Data on participants’ family  history  of 
malignancies will be colle cted on the respective eCRF page, only when a participant has a 
malignancy  event reported during the study , to assess possible risk factors related to any 
malignancies.
Country -
specific regulations should be considered for the collection of demographic and
baseline characteristics in alignment with CRF.
8.3 Efficacy
8.3.1 eDiary  assessments
All participants will be provided with an electronic device (eDiary ) that contains the following 
Patient Reported Outcomes (PRO) assessments: Urticaria Patient Daily  Diary (UPDD) and 
Angioedema Activity  Score (AAS).
Site and participants will receive appropriate training and guidance on the use of the eDiary  and 
will receive clear instructions on the completion of the assessments.
Assessments will be completed twice daily  (UPDD), o nce dail y (AAS, if triggered by  [CONTACT_157096]) from screening to week 52/study  discontinuation.
In general, participants complete eDiary  questionnaires at home and independent of study  visits. 
Participants will be instructed to complete eDiary  entries after they took their study  medication 
throughout the treatment period.
The DLQI, questionnaires will be administered 
during respective visits on site and should be completed prior to any other study  specific 
procedure. Site personnel must allow participants to complete the questionnaire on their own 
without any  assistance from the site staff. In the case that participants cannot come to site (see 
Section 4.6), the DLQI,  will be available on their 
electronic device.
[IP_ADDRESS] Urticaria Patient Daily Diary  (UPDD)
UPDD includes Urticaria Activity  Score (UAS) which assesses twice daily severit y of itch and 
number of hives, use of rescue medication, sleep a
nd activity  interference, angioedema 
occurrence, its management and records the calls to a healthcare professional (HCP) (see 
Section 16.4). The components are presented in the Table 8-2and the relevant weekl y scores 
are described below.
Table 8
-2 UPDD
Diary component When assessed
Urticaria Activity Score (UAS)
Itch severity
Number of hivesMorning and evening

[COMPANY_001] Confidential Page 68of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Diary component When assessed
Sleep interference Morning
Daily activity interference Evening
Rescue medication use Evening
Angioedema:
Whether patient had an epi[INVESTIGATOR_1865]
If patient had an epi[INVESTIGATOR_1865], how did they 
manage itEvening
Contact [CONTACT_157097]
[IP_ADDRESS].1 Weekly Hives Severity Score (HSS7)
The hives (wheals) severity  score, defined by [CONTACT_157098], will be recorded by [CONTACT_157099] , on a scale of 0 (none) to 3 (> 12 hives/12 hours; 
Table 8-3). A weekl y score (HSS7) is derived by [CONTACT_157100] 7 
days preceding the visit. The possible range of the weekl y score is therefore 0 – 21.
Table 8-3 Hives Severity  Score
Score Hives (Wheals) (every 12 hours)
0 None
1 1-6 hives/12 hours
2 7-12 hives/12 hours
3 >12 hives/12 hours
[IP_ADDRESS].2 Weekly Itch Severity Score (ISS7)
The severit y of the itch will be recorded by [CONTACT_157101] , on a scale 
of 0 (none) to 3 (severe) ( Table 8-4). A weekly  score (ISS7) is derived by [CONTACT_157102] 7 days preceding the visit. The possible range of the weekly  score is therefore 
0 - 21.
Table 8
-4 Itch Severity  Score
Score Pruritus (Itch) (every 12 hours)
0 None
1 Mild (minimal awareness, easily tolerated)
2 Moderate (definite awareness, bothersome but 
tolerable)
3 Severe (difficult to tolerate)
[IP_ADDRESS].3 Weekly Urticaria Activity Score (UAS7)
The UAS7 is the sum of the HSS7 score and the ISS7 score. The possible range of the weekly 
UAS7 score is 0 –42 (highest activity ).

[COMPANY_001] Confidential Page 69of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
[IP_ADDRESS].7 Angioedema occurrence
Angioedema occurrence is recorded once dail y in the evening in the eDiary by  [CONTACT_2299]. 
Reporting the occurrence of angioedema will be used as opening question for the assessment of 
the AAS (see Section
[IP_ADDRESS] ). Actions and/or treatments related to those angioedema 
occurrences will be also r ecorded in the eDiary  as follows (multiple answers possible):
Did nothing
Took some prescription or non-prescription medication
Called my  doctor, nurse or nurse practitioner
Went to see my  doctor, nurse or nurse practitioner
Went to the emergency  room at the hospi[INVESTIGATOR_307]
Was hospi[INVESTIGATOR_157047] 70of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
[IP_ADDRESS].8 Number of calls to doctor or nurse
The number of calls to doctor, nurse or nurse practitioner because of the participant’s skin 
condition will be recorded once dail y in the eDiary b y the participant.
[IP_ADDRESS] Angioedema A ctivity Score (AAS)
AAS is recorded once daily  in the evening in the eDiary  by [CONTACT_2299]. This validated tool 
assesses occurrence of epi[INVESTIGATOR_157048]. As an opening question, the occurrence of 
angioedema in the UPDD (see Section [IP_ADDRESS].7) will be used. If participants answer this 
opening question in the UPDD with “no”, AAS score for this day 
is 0. If “yes” is the answer to 
the opening question in the UPDD, the participant will continue to answer questions about the 
durati on, severit y and impact on daily  functioning and appearance of the angioedema (see 
Section 16.4). A score between 0 and 3 is assigned to every  answer field. The AAS score in this 
study  will be reported as weekl y AAS (AAS7). Minimum and maximum possible AAS7 scores 
are 0 −105. A higher score means higher severit y.
8.3.2 Other Patient Reported Outcomes (PRO) assessments
[IP_ADDRESS] Dermatology  Life Quality  Index (DLQI)
The Dermatology  Life Quality  Index (DLQI) is a 10-item (grouped in 6 domains) dermatology -
specific quality  of life (QoL) measure (Finlay andKhan 1994). The DLQI  was validated for 
patients aged [ADDRESS_181966] 
of their skin conditio n on various aspects of their lives thinking about the previous 7 day s.
An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease -
related QoL). Domain scores are calculated for: Symptoms and Feelings (0 -6), Daily Activities
(0-6), Leisure (0- 6), Work and School (0 -3), Personal Relationships (0- 6), Treatment (0 -3).
The overall DLQI score range was split into score bands (Hongbo et al 2005 ) and validated in 
terms of their meaning/relevance to patients as follows:
Table 8-[ADDRESS_181967] on patient's life
DLQI band Significance of score
0-[ADDRESS_181968] on patient's life
2-[ADDRESS_181969] on patient’s life
6-[ADDRESS_181970] on patient’s life
11-[ADDRESS_181971] on patient’s life
21-[ADDRESS_181972] on patient’s life
A DLQI score of > [ADDRESS_181973] on patients’ life and justification for a 
biologic prescription for example in psoriasis (Finlay 2005 ). The DLQI questionnaires are 
completed at visits detailed in Table 8-1in the eDiary. The DLQI should be completed prior to 
any other asses sment and prior to administration of investigational medication.

[COMPANY_001] Confidential Page 71of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 72of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
 
1.
8.3.3 Appropriateness of efficacy  assessments
UAS7: The UAS7 score is a unified, simple, well
-established and validated tool, recommended 
by [CONTACT_157103] e assessment of disease activity and treatment response 
in real-world clinical practice as well as in clinical trials with urticaria patients 
(Młyneket al 2008, Hawro et al 2018, Zuberbier et al2018). It is based on the assessment of 
the two key urticaria signs and symptoms, wheals and pruritus, which are documented by [CONTACT_4677], making this score especiall y valuable. The use of the UAS7 facili tates 
comparison of 
study  results across different trials, since it is used in other major Phase 3 trials in the CSU 
indication as well (e.g. ,with ligelizumab).
AAS7: The AAS7 score is a unified, simple and validated tool, recommended by [CONTACT_157104] (Weller et
al2013, Zuberbier et al2018 ). The use of the AAS7 facilitates 
comparison of study  results across different trials, since it is used in other major  Phase 3 trials 
in the CSU indication as well (e.g. ,with ligelizumab).
 
 
8.3.4 Other assessments: evidence of urticaria
The investigator must confirm the presence of urticaria (i.e.,the presence of hives) in each 
participant before randomization by [CONTACT_157105]. In the absence of active 
disease at the screening and/or randomization visit, the following will be acceptable: (a) a 
clearly identifiable photograph of the participant that is no older than 3 months showing the 
presence of urticaria, (b) the investigator must have seen the participant with active CSU in the 
past 3 months, or (c) the presence of hives/wheals must have been documented in the medical 
record of the participant by a physician trained in the management of urticaria in the past 3 
months.

[COMPANY_001] Confidential Page 73of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
8.4 Safet y
Safety  assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.

[COMPANY_001] Confidential Page 74of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
For details on AE collection and reporting, refer to AE section.
As per Section 4.6, during a Public Health emergency  as declared by [CONTACT_6620] i.e.,pand emic, epi[INVESTIGATOR_6519], that limits or prevents on-site study 
visits, regular phone or virtual calls can occur (every 4 weeks or more frequently if needed) for 
safet y monitoring and discussion of the participant´s health status until it is safe
for the 
participant to visit the site again.
Table 8-8 Physical assessments
Assessment Specification
Physical examination A complete physical examination (performed at 
Screening) will include the examination of 
general appearance, skin, neck (including 
thyroid), eyes, ears, nose, throat, lungs, heart, 
abdom en, back, ly mph nodes, extremities, 
vascular, neurological and body te mperature 
measurement (per local practice). If indicated 
based on medical histor y and/or sy mptoms, 
rectal, external genitalia, breast, and pelvic 
exams will be performed.
A short phy sical exam (performed at all visits 
except Screening) will include the exa mination 
of general appearance, assessment of the skin 
for signs of urticaria and other skin lesions, body 
temperature measurement (per local practice) 
and vital signs (blood pressure (BP) [systolic 
blood pressure (SBP) and diastolic blood 
pressure (DBP)] and pulse).
Information for all physical examinations must 
be included in the source documentation at the 
study site. Clinically relevant findings that are 
present prior to signing informed consent must 
be recorded on the appropriate CRF that 
captures med ical histor y. Significant findings 
made after signing informed consent which meet 
the definition of an Adverse Event must be 
recorded as an adverse event.
Vital signs Vital signs include BP and pulse measurements. 
After the participant has been sitting fo r five 
minutes, with back supported and both feet 
placed on the floor, systolic and diastolic blood 
pressure will be measured three times using an 
automated validated device, e.g., OMRON, with 
an appropriately sized cuff. The repeat sitting 
measurements wi ll be made at 1 -2 minute 
intervals and the mean of the three 
measurements will be used. In case the cuff 
sizes available are not large enough for the 
participant's arm circumference, a 
sphygmomanometer with an appropriately sized 
cuff may  be used.

[COMPANY_001] Confidential Page 75of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Assessment Specification
Clinic ally notable vital signs are defined in 
Section 16.1.
Height and weight Height in centimeters (cm) and body weight (to 
the nearest 0.1 kilogram (kg) in indoor clothing, 
but without shoes) will be measured as specified 
in Table 8-1.
8.4.1 Laboratory  evaluations
A central laboratory  will be used for analy sis of all specimens detailed in this section (Table 8-9) 
unless noted otherwise. Details on the collections, shipment of samples and reporting of results 
by [CONTACT_157106].
If participants cannot visit the site for protocol specified safety  lab assessments (per Section 4.6), 
an alte rnative lab (local) collection may  be used.
Clinically  notable laboratory  findings are defined in Section 16.1.
Clinically  significant abnormalities must be recorded on the relevant section of the eCRF 
capturing medical hist ory/current medical conditions/AEs.
Table [ADDRESS_181974] Name
[CONTACT_157131], Hemoglobin, [in the case of clinically 
significant anemi a the following parameters will 
be assessed: Ery. Mean Corpuscular 
Hemoglobin (MCH), Er y. Mean Corpuscular 
Hemoglobin Concentration (MCHC), Er y. Mean 
Corpuscular Volume (MCV)], Platelets, 
Erythrocytes, Leukocytes, and Differential 
(Basophils, Eosinophils, Ly mphocy tes, 
Monoc ytes, Neutrophils, Bands)
Chemistry Albumin, Alkaline phosphatase (ALP), Alanine 
Aminotransferase (ALT), Aspartate 
Aminotransferase (AST), Gamma -glutam yl 
transferase (GGT), Lactate dehydrogenase 
(LDH), Calcium, Magnesium, Phosphate, 
Chloride, Sodium, Potassium, Creatinine, 
Creatine Kinase (CK), Direct Bilirubin, Indirect 
Bilirubin (in case of clinically significant 
elevation), Total Bilirubin, Total Cholesterol, Low 
Density Lipoprotein (LDL) Cholesterol, High 
Density Lipoprotein (HDL) Cholesterol, Total 
Protein, Triglycerides, Urea Nitrogen or Urea, 
Uric Acid, Am ylase, Lipase
C-reactive protein (CRP), estimated Glomerular 
Filtration Rate (eGFR): in all patients at 
screening, baseline, weeks 12, 24 and 52 and 
when deemed necessar y by [CONTACT_3433] e investigator at 
later visits.

[COMPANY_001] Confidential Page 76of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Test Category Test Name
[CONTACT_157132], 
weeks 2, 12 and 52.
Urinalysis Done on site: Macroscopic Panel (Dipstick) 
(Color, Bilirubin, Occult Blood, Macroscopic 
Blood, Glucose, Ketones, Leukocy tes esterase, 
Nitrite, pH, Pr otein, Specific Gravity, 
Urobilinogen)
Coagulation Prothrombin time (PT), International normalized 
ratio (INR), Activated partial thromboplastin time 
(APTT)
Hepatitis screening Hepatitis B screening: Antibodies against 
Hepatitis B virus core antigen (HBc Ab or anti -
HBc); antibodies against Hepatitis B virus 
surface antigen (anti-HBs or HBs -Ab); Hepatitis 
B virus surface antigen (HBsAg) .
Hepatitis B -Deoxy ribonucleic acid (HBV -
DNA, only in participants who are positive 
foranti-Hepatitis B virus Core HBc -Abor anti -
HBc).
Hepatitis C screening: Hepatitis C virus 
antibodies (anti -HCVAb) and Hepatitis C -
Ribonucleic acid (HCV -RNA, only in participants 
who are positive for anti-HCVAb)
Hepatitis B re -activation monitoring Only in participants who are positive for HBc-Ab 
(anti- HBc positive) and negative for anti -HBsAg 
and HBV -DNA at screening: HBsAg, HBV -DNA
HIVtesting HIV test performed at screening, only when 
required by [CONTACT_427].
Additional tests
Follicle -stimulating hormone (FSH) (for female 
participants with unclear fertility status)
Pregnancy Test Serum / Urine pregnancy test for WoCBP (refer 
to Section 8.4.3 )
8.4.2 Electrocardiogram (ECG)
Electrocardiograms (ECGs) must be recorded according to the ECG investigator manual. The 
preferred sequence of cardiovascular data collection during stud y visits is ECG collection first, 
followed by [CONTACT_18651], and blood sampling. The Fridericia QT correction formula (QTcF) 
should be used for clinical decisions.
Triplicate 12-lead ECGs are to be collected approximately  [ADDRESS_181975]-
dose assessments should be collected (refer to Table 8-1), post dose assessment should be 
measured  

[COMPANY_001] Confidential Page 77of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
 and the mean QTcF value for each timepoint will be calculated from the triplicate 
ECGs for each participant.
All ECGs, including unscheduled safet y ECGs with clinically  relevant findings collected during 
the study  needs to be transmitted to the central ECG laboratory  for review.
A monitoring or review process should be in place for clinicall y significant ECG findings 
throughout the stud y and especiall y at baseline before administ ration of study  treatment.
In the event that a clinically  significant ECG abnormality  is identified at the site (e.g.,severe 
arrhythmia, conduction abnormality  of QTcF > 450 ms (males)/ 460 ms (females)), a copy of 
the assessment is sent to the core labor atory  for expedited review if applicable, and the ECG is 
repeated to confirm the diagnosis. If the participant is hemody namicall y compromised, the 
investigator or a medically qualified person must initiate appropriate safet y procedures without 
delay  (for e xample cardioversion).
Additional, unscheduled, safety  ECGs may be repeated at the discretion of the investigator at 
any time during the study  as clinicall y indicated. For any ECGs with participant safet y concerns, 
two additional ECGs must be performed to confirm the safet y finding. 
Clinically  significant abnormalities must be recorded on the CRF as either medical 
history /current medical conditions or adverse events as appropriate.
8.4.[ADDRESS_181976] pregnancy  testing at 
screening (serum), at randomization (Day  1, before administration of study  medication (urine)), 
and every  4 weeks thereafter (urine). Where the visit interval is greater than [ADDRESS_181977], in the case that participants cannot visit the site an alternative (local lab) 
can be used. If positive the participant must be discontinued from study  treatment.
A communication process should be established with the participant so that the siteis informed 
and can verify  the pregnancy  test results (e.g., following country -specific measures).
Additional pregnancy testing might be performed if requested by  [CONTACT_5277].
Assessments of fertility
Medical documentation of oophorectom y, hysterectomy , or bilateral tubal ligation must be 
retained as source documents. Subsequent hormone level assessment to confirm the woman is 
not of child- bearing potential must also be available as source documentation in the following 
cases:
1.Surgical bilateral oophorectomy  without a hy sterectomy
2.Reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile.

[COMPANY_001] Confidential Page 78of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
In the absence of the above medical documentation, FSH testing is required of any female 
participant regardless of reported reproductive/menopausal status at screening/baseline.
8.4.4 Appropriateness of safety  measurements
The selected safet y monitoring assessments (including laboratory  assessments covering clinical 
chemis try, hematology , coagulation status , as well as clinical and 
physical assessments, triplicate ECG monitoring and general AE assessments) are reliable and 
well-established standard measures which allow valid and close safet y monitoring o f the trial´s 
patient population, with regards to their disease, to the compound they are treated with, 
remibrutinib, and also to their overall medical safety .
8.5 Additional assessments
8.5.1 Clinical Outcome A ssessments (COA s)
Trial Feedback
This study  includes a n optional anony mized questionnaire, the ‘Trial Feedback Questionnaire’ 
for trial participants to provide feedback on their clinical trial experience at 3 timepoints: at the 
start, during and at the end of the trial. Individual trial participant responses will not be reviewed 
by [CONTACT_431]. Responses may be used by [CONTACT_157107]. This questionnaire does not ask questions about the trial 
participant’s disease, symptoms, treatment effect or adverse events and therefore is not 
considered as trial data.

[COMPANY_001] Confidential Page 79of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 80of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
9 Discontinuation and completion
9.1 Discontinuation from study  treatment and from study
9.1.1 Discontinuation from study  treatment
Discontinuation of study  treatment for a participant occurs when study  treatment ispermanentl y 
stopped for an y reason (prior to the protocol planned completion of study  drug administration) 
and can be initiated by  [CONTACT_6633].
The investigator must discontinue study  treatment for a given participant if, he/she believes that 
continuation would negatively  impact the participant's well- being.
Discontinuation from study  treatment is required under the following circumstances:
Participant decision (requested in writing or verbally )
Pregnancy
Use of prohibited tr eatment requiring study  treatment discontinuation as detailed in 
Table 6-3or discontinuation of highl y effective methods of contraception as detailed 
inSection
5.2

[COMPANY_001] Confidential Page 81of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Any situation in which continued study  participation might result in a safety  risk to the 
participant
Following emergency  unblinding
Emergence of the following AEs: 
any adverse events that in the judgement of investigator, taking into consideration the 
participant's overa ll status, prevents the participant from continuing participation in 
the study , including: 
hypersensitivity  reactions,
severe/serious infections
clinically  significant spontaneous bleeding events
new confirmed diagnosis of malignancy  of any  organ s ystem 
(other than localized basal cell carcinoma of the skin or in situ cervical cancer)
Platelets < 75 000/mm3
Abnormal renal laboratory results requiring discontinuation (see Section 16.3)
Abnormal liver laboratory  results requi ring discontinuation (see Section 16.2)
Any other laboratory  abnormalities that in the judgment of the investigator, taking 
into consideration the participant’s overall status, prevents the participant from 
continuing partic ipation in the study
participant received a live virus vaccination during the stud y
If discontinuation from study  treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the participant’s discontinuation from study  treatment and 
record this information.
All participants who discontinue from study treatment prematurely should complete the 
Early treatment discontinuation visit at the time of treatment discontinuation.
For participants who discontinue from study  treatment prior to week 12, where possible they 
should be requested to return for visits after the Early  treatment discontinuation visit as per the 
Assessment Schedule (Table 8-1) up to and including the week 12 timepoint. At the week 12 
timepoint the study  discontinuation visit should be performed . If 
the 
participant declines to continue with assessments as per the visit schedule up to week 12, 
then they should complete the safet y follow -up visit after the Early treatment discontinuation 
visit.
Participants who discontinue from study  treatment after week 12 should complete the safet y 
follow -up visit indicated in the Assessment Schedule ( Table 8-1) whenever possible.
If theparticipant cannot or is unwilling to attend any visit(s), the site staff should maintain 
regular telephone contact [CONTACT_151525], or with a person pre-designated by [CONTACT_2299]. 
This telephone contact [CONTACT_37283] y be done according to the study  visit schedule.
After discontinuation from study  treatment, at a minimum, in abbreviated visits, the following  
data should be collected at clinic visits or via telephone/email contact:
New / concomitant treatments
Adverse Events / Serious Adverse Ev ents

[COMPANY_001] Confidential Page 82of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
The investigator must also contact [CONTACT_6637]’s discontinuation from 
study  treatment.
If discontinuation occurs because treatment code has been broken, please refer to Emergenc y 
breaking of treatment code section.
9.1.2 Discontinuat ion from study
Discontinuation from study  is when the participant permanently  stops receiving the study 
treatment, and further protocol -required assessments or follow -up, for any reason , including 
participant’s decision (requested in writing or verbally ).
If the participant agrees, a final evaluation at the time of the participant’s study discontinuation 
should be made as detailed in the assessment table (refer to Section 8).
9.1.[ADDRESS_181978] to follow -up
For participants whose status is unclear because they fail to appear for study  visits without 
stating an intention to discontinue from study  treatment or discontinue from study  or withdraw 
consent/oppose to the use of their data/biological samples, the investigator must show "due 
diligence" by [CONTACT_6638], e.g. ,
dates of telephone calls, registered letters, etc. A participant should not be considered as lost to 
follow -up until due diligence has been completed or until the end of the study .
9.2 Withdrawal of informed consent/Opposition to use 
data/biological samples
Withdrawal of consent/opposition to use data/biological samples occurs when a participant:
Explicitly  requests to stop use of their biological samples and/or data (oppositi
on to use 
participant’s data and biological samples)
and
No longer wishes to receive study  treatment
and
Does not want an y further visits or assessments (including further stud y-related contacts)
This request should be in writing or verbally  (depending on local regulations) and recorded in 
the source documentation.
In this situation, the investigator should make a reasonable effort (e.g.,telephone, e-mail, letter) 
to understand the primary  reason for the participant’s decision to withdraw their 
consent/opposition to use data/biological samples and record this information.  
Where consent to the use of Personal and Coded Data is not required in a certain country 's legal 
framework, the participant therefore cannot withdraw consent. However, they still retain the 
right to object to the further collection or use of their Personal Data.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.

[COMPANY_001] Confidential Page 83of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Further attempts to contact [CONTACT_131359] -up.
If the participant agrees, a final evaluation at the time of the participant’s withdrawal of 
consent/opposition to use data/biological samples sh ould be made as detailed in the assessment 
table (refer to Section 8).
[COMPANY_001] will continue to retain and use all research results (data) that have alread y been 
collected for the study  evaluation, including processing of biological samples that has alread y 
started at time of consent withdrawal/opposition. No new Personal Data (including biological 
samples) will be collected following withdrawal of consent/opposition.
9.[ADDRESS_181979] been documented and followed- up 
appropriatel y by t he Investigator, enrolls into the planned open -label extension study  following 
completion of the 52-week treatment period or, in the event of an early  study termination 
decision, the date of that decision. 
Participants who complete participation in the 52
-week treatment period of this trial may be 
eligible to receive remib rutinib as part of an open- label extension study  (under development) if 
they meet the eligibility  criteria defined in the extension study  protocol.
The open -label extension will require endorsement in participating countries and sites as per 
local laws and regulations.
For participants not willing or ineligible to roll over into the extension study and who want to 
continue receiving remibrutinib every  effort will be made to continue provision of study 
treatment prior to the investigational treatment becomin g available in the respective country, if 
in the opi[INVESTIGATOR_871], they  are still deriving clinical benefit from remibrutinib.
9.4 Early study  termination by  [CONTACT_157108].
Reasons for earl y terminat ion:
Unexpected, significant, or unacceptable safet y risk to participants enrolled in the study
Decision based on recommendations from applicable board(s) after review of safet y and 
efficacy  data
Discontinuation of study  drug development
In taking the decision to terminate, [COMPANY_001] will alway s consider participant welfare and safet y. 
Should early termination be necessary , participants must be seen as soon as possible and treated 
as a participant who discontinued from study  treatment. Following instruction from [COMPANY_001], 
investigators must contact [CONTACT_157109] (as appropriate) and provide instruction regarding study  drug intake. The 
investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the participant’s interests. The investigator 

[COMPANY_001] Confidential Page 84of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the 
early termination of the trial.
10 Safety  monitoring, reporting and committees
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a clinical 
investigation participant after providing written informed consent for participation in the study . 
Therefore, an AE may or may not be temporally  or causall y associated with the use of a 
medicinal (investigationa l) product.
The investigator has the responsibility  for managing the safet y of individual participant and 
identify ing adverse events.
[COMPANY_001] qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by [CONTACT_105]-directive questioning of the participant 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by [CONTACT_157110], laboratory 
test findings, or other assessments .
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, 
accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to
Section
10.1.2):
1.The severit y grade:
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.Its relationship to the study  treatment. If the event is due to lack of efficacy or progression 
of underl ying illness (i. e.,progression of the stud y indication) the assessment of causalit y 
will usually  be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a 
lack of efficacy  or progression of underly ing illness are not caused by  [CONTACT_6645], they  
happen in spi[INVESTIGATOR_6532]/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by [CONTACT_49430], not on a 
single participant
3.
Its duration (start and end dates or ongoing) and the outcome must be reported
4.Whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5.Action taken regarding with study  treatment.
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:

[COMPANY_001] Confidential Page 85of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Dose not changed
Drug interrupted/permanently  discontinued
6.Its outc ome (i.e.,recovery  status or whether it was fatal)
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history of the participant.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least [ADDRESS_181980] be f ollowed until its resolution or until it is judged to 
be permanent (e.g.,continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the interv entions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator's Brochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typi[INVESTIGATOR_157049]. See Section
16.[ADDRESS_181981] abnormalities.
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]: 

[COMPANY_001] Confidential Page 86of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
elective or pre -planne d treatment for a pre-existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respi[INVESTIGATOR_157050]’s 
general condition
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g. ,defined as an event that jeopardizes the participant or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be imme diately 
life threatening or result in death or hospi[INVESTIGATOR_157051]. Such events should be 
considered as “medicall y significant.” Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospi[INVESTIGATOR_37209] (please refer to the ICH-
E2D Guidelines ).
All new mali gnant neoplasms will be assessed as serious under “medicall y significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred (see Section 10.1.5 ).
10.1.[ADDRESS_181982] be reported to [COMPANY_001] safety  immediately , without undue delay , but under no 
circumstances later than withi n 24 hours of obtaining knowledge of the events (Note: If more 
stringent, then local regulations regarding reporting timelines prevail). Detailed instructions 
regarding the submission process and requirements are to be found in the investigator folder 
provided to each site. Information about all SAEs is collected and recorded on the electronic 
serious adverse event (eSAE) (with paper backup if required) Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report.
1.Screen Failures (e.g. ,a participant who is screened but is not treated or randomized): 
SAEs occurring after the participant has provided informed consent until the time the 
participant is deemed a Screen Failure must be r eported to [COMPANY_001] with 24 hours of 
learning of its occurrence.
2.Randomized OR Treated Participants: SAEs collected between time participant signs ICF 
until 30 day s after the participant has discontinued from study treatment.

[COMPANY_001] Confidential Page 87of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_18536] , without undue delay , but under no circumstances later thanwithin 24 hours of the 
investigator receiving the follow -up information (Note: If more stringent, then local regulations 
regarding reporting timelines prevail) . An SAE occurring at a different time interval or 
otherwise considered completely  unrelated toa previously  reported one must be reported 
separately  as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, a Chief Medical Office and
Patient Safety  (CMO & PS) Department associate may urgentl y require further information 
from the investigator for health authority reporting. [COMPANY_001] may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study  with the same study  treatment 
that this SAE has been reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_181983] administration of study  
treatment should only be reported to [COMPANY_001] Safety  if the investigator suspects a causal 
relationship to study  treatment, unless otherwise specified b y local law/regulations.
10.1.[ADDRESS_181984] 
be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded and reported by [CONTACT_157111] y (CMO&PS) . Pregnancy  follow -up should be recorded on the Targeted 
Follow -up pregnancy  -Infant status form and should include an assessment of the possible 
relationship to the study treatment any pregnancy  outcome. Any SAE experienced during 
pregnancy  must be repor ted.
After consent is provided, the pregnancy reporting will occur up to one y ear after the estimated 
date of delivery .

[COMPANY_001] Confidential Page 88of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or 
consumer (European Medicines Agency  definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespec tive of it being associated with an AE/SAE within 24 hours of 
Investigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dosing 
CRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
10.2 Additional Safety  Monitoring
10.2.1 Liver safety monitoring
To ensure participant safety  and enhance reliability  in determining the hepatotoxic potential of 
an investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
Please refer to Table 16-1in Section 16.2 for complete definitions of liver laboratory  triggers.
Once a participant is exposed to study  treatment, every  liver event defined in Table 16-1 should 
be followed up by [CONTACT_6648], as summarized below. 
Additional details 
on actions required in case of liver events are outlined in Table 16-2 and 
Table 16-3. Repeat liver chemistry  tests (i.e.,ALT, AST, TBL, PT/INR, ALP a nd GGT) to 
confirm elevation.
These liver chemistry  repeats will be performed using the central laboratory. I f results will not 
be available from the central laboratory , then the repeats can also be performed at a local 
laboratory  to monitor the safet y of the participant. If a liver event is subsequently reported, an y 
local liver chemistry  tests previously  conducted that are associated with this event should have 
results recorded on the appropriate CRF.

[COMPANY_001] Confidential Page 89of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
If the initial elevation is confirmed, close observati on of the participant will be initiated, 
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to Section 9.1 and Section 16.2), if 
appropriate
Hospi[INVESTIGATOR_6539]
Causality  assessment of the liver event
Thorough follow -up of the liver event should include, based on investigator's discretion: 
serology  tests, imaging and pathology  assessments, hep
atologist’s consultancy ; 
obtaining more detailed history  of symptoms and prior or concurrent diseases, history  
of concomitant drug use, exclusion of underly ing liver disease
All follow -up information and procedures performed must be recorded as appropriate in the 
CRF.
10.2.2 Renal safety  monitoring
Once a participant is exposed to study  treatment, the following two categories of abnormal renal 
laboratory  alert values should be assessed during the study  period:
Serum creatinine increase ≥ 25% compared to baseline during normal h ydration status
Any one of the following: 
Urine protein
-creatinine ratio (PCR) ≥1g/g or ≥100 mg/mmol, OR
New onset dipstick proteinuria ≥ 3+, OR
New onset dipstick hematuria ≥ 3+ (after excluding menstruation, UTI, extreme 
exercise, or trau ma)
Abnormal renal event findings must be confirmed after ≥24 hours but ≤ [ADDRESS_181985] 
assessment.
Once a participant is exposed to study  treatment, renal laboratory  alerts or renal safet y events 
as defined in Table 16-4 should be followed up by [CONTACT_157112] 16-5.
10.3 Committees
10.3.1 Data Monitoring Committee
This study  will include a data monitoring committee (DMC) which will funct ion independentl y 
of all other individuals associated with the conduct of this clinical trial, including the site 
investigators participating in the study . The DMC will assess at defined intervals the progress 
of a clinical trial, safet y data, and critical efficacy  variables and recommend to the sponsor 
whether to continue, modify , or terminate a trial.
Specific details regarding composition, responsibilities, data monitoring, and meeting 
frequency , and documentation of DMC reports, minutes, and recommendations will be 
described in a separate charter that is established between the sponsor and the DMC.

[COMPANY_001] Confidential Page 90of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
10.3.[ADDRESS_181986] been trained. Automatic validation programs check for data discrepancies in the 
eCRFs, allow modification and/or verification of the entered data by  [CONTACT_6649].
The investigator/designee is responsible for assuring that the data (entered into eCRF) is 
complete, accurate, and that entry  and updates are performed in a timely  manner. The 
Investigator must certify  that the data entered are complete and accurate.
After final datab ase lock, the investigator will receive copi[INVESTIGATOR_157052].
All data should be recorded, handled, and stored in a way that allows its accurate reporting, 
interpretation, and verification.
11.2 Database manag ement and quality  control
[COMPANY_001] personnel (or designated Contract Research Organization (CRO)) will review the data 
entered by [CONTACT_5375] . Electronic data queries stating 
the nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC s ystem. Designated investigator 
site staff are required to respond promptly to queries and to make an y necessary  changes to the 
data.
Concom itant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employ s the Anatomical 
Therapeutic Chemical (ATC) classification system. Medical history /current medical conditions 
and adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA) terminology .
Dates of screenings, randomizations, screen failures and study  completion, as well as 
randomization codes and data about all study  treatme nt(s) dispensed to the participant and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 

[COMPANY_001] Confidential Page 91of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
will be supplied by a  vendor, who will also manage the database. The data will be sent 
electronically  to [COMPANY_001] (or a des ignated CRO) at specific timelines.
Each occurrence of a code break via I RT will be reported to the clinical team and monitor. The 
code break functionality  will remain available until study  shut down or upon request of [COMPANY_001].
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatment codes will be unblinded and made 
available for data analysis. Any  changes to the database after that time can only be made after 
written agreement b y [COMPANY_001] development management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a 
[COMPANY_001] /delegated CRO representative will review the protocol and data capture requirements 
(i.e.,electronic source (eSource) DDE or eCRFs) with the investigators and their staff. During 
the study , [COMPANY_001] employ s several methods of ensuring protocol and GCP compliance and the 
quality /integrity  of the sites’ data. The field monitor will visit the site to check the completeness 
of participant records, the accuracy  of data capture / data entry , the adherence to the protocol 
and to Good Clinical Practice, the progress of enrollment, and to ensure that study  treatment is 
being stored, dispensed, and accounted for according to specifications. Key study personnel 
must be available to assist the field monitor during these visits. Continuous remote monitoring 
of each site’s data may be performed by a  c entralized [COMPANY_001]/delegated CRO/CRA 
organization. Additio nally, a central analytics organization may analyze data & identify  risks 
& trends for site operational parameters, and provide reports to [COMPANY_001] clinical teams to assist 
with trial oversight.
The investigator must maintain source documents for each participant in the study , consisting 
of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
participant's file. The investigator must also keep the original informed consent form signed b y 
the participant (a signed copy  is given to the participant).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 
study -
specific monitoring plan. No information in source documents about the identity  of the 
participants will be disclosed.
12 Data analy sis and statistical methods
The analysis will be conducted at the time of the primary  analysis and on all participants' data 
at the time the trial ends. Any data analysis carried out independently  by [CONTACT_157113].

[COMPANY_001] Confidential Page 92of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
12.1 Analysis sets
The following anal ysis sets will be used in this trial:
Randomized set (RAS): The RAS set consists of all randomized participants, regardless of 
whether or not they  receive a dose of study drug. Participants will be analyzed according to 
the treatment they  are assigned.
The Full Anal ysis Set (FAS) comprises all participants to whom study  treatment has been 
assigned by [CONTACT_17628]. FAS will be used for all efficacy  variables, unless otherwise 
stated. Mis-randomized participants (mis- randomized in IRT) will be included in the 
Randomized set but will be excluded from FAS.
Mis-randomized participants are defined as cases where IRT contacts were made by [CONTACT_157114] y prior to confirmation of the participant’s final 
randomization eligibility  and no study  medication was administered to the participant.
The Safet y Set (SAF) includes all participants who received at least one dose of study  
treatme nt, whether or not being randomized. Participants will be analy zed according to the 
study  treatment received. The safety  set will be used in the analysis of all safet y variables. 
The actual treatment will be defined as the treatment received over the study . In case of 
error in dispensation, the actual treatment will correspond to the treatment which was given 
most often.
12.[ADDRESS_181987] deviation, median, 25th and 
75th percentiles, minimum, and maximum will be presented.
The duration of exposure in weeks to remibrutinib and placebo will be summarized by [CONTACT_6490], by [CONTACT_157115] . The duration of study  will also be summarized by  
[CONTACT_1570].
Concomitant medications and significant non-drug therapi[INVESTIGATOR_157053] (ATC) 
classification s ystem, by  [CONTACT_1570].

[COMPANY_001] Confidential Page 93of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
12.4 Analysis supporting primary  objectives
This section will detail the statistical analy sis of the primary  estimand. Details of the hypothesis 
testing strategy  including primary  and secondary  endpoints to handle multiplicity  are provided 
in Section
12.5.1.
12.4.1 Definition of primary  endpoint(s)
Primary estimand for scenario with UAS [ADDRESS_181988] is: What is the effect of remibrutinib treatment versus 
placebo on the change from baseline in UAS7 score at Week 12 after treatment in adult 
participants with CSU who are inadequ
ately controlled by H1-antihistamine and receiving a 
stable locally  label approved dose of a second generation H1-antihistamine, regardless of 
treatment discontinuation for any reason and regardless of intake of a different second 
generation H1-antihistami
ne as rescue medication and considering strongl y confounding 
prohibited medication as an unfavourable outcome?
The primary efficacy endpoint is the absolute change from baseline in UAS7 score at Week 12, 
which is the UAS7 score at Week 12 minus the UAS7 sc ore at baseline. The UAS7 is the sum 
of the HSS7 score and the ISS7 score, and ranges from 0-42. Weekl y scores (HSS7 and ISS7 
scores) will be derived by [CONTACT_157100] [ADDRESS_181989] is: What is the effect of remibrutinib treatment versus 
placebo on the change from baseline in I
SS7 and change from baseline in HSS7 score at Week 
12 after treatment in adult participants with CSU who are inadequately  controlled by 
H1-antihistamine and receiving a stable locall y label approved dose of a second generation 
H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of 
intake of a different second generation H1 -antihistamine as rescue medication and considering 
strongl y confounding prohibited medication as an unfavourable outcome?
The co-primary  efficacy  endpoints are the absolute change from baseline in ISS7 score at Week 
12 and absolute change from baseline in HSS7 score at Week 12, which is the ISS7 score 
(respectively  HSS7 score) at Week 12 minus the ISS7 score (respectively  HSS7 score at 
baseline). The weekl y scores ISS7 and HSS7 range from 0-21, and will be derive d by [CONTACT_157116] y scores of the [ADDRESS_181990] for the primary  endpoint being tested is that the absolute change 
from baseline in UAS7 score at Week 12 in remibrutinib is not superior to the placebo group 
i.e.:
H01: µ remibrutinib ≥µPlacebo versus H A1: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in UAS7 at Week 12.

[COMPANY_001] Confidential Page 94of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
A linear mixed model with repeated measures (MMRM) will be used to estimate treatment 
differences for change from baseline in UAS7 score at Week 12, based on the FAS. The MMRM 
model will include treatmen t group, baseline UAS7 score, randomization strata variables, week 
and both interaction of treatment by [CONTACT_157117]7 score by [CONTACT_157118]. Repeated measures within participant are modeled using an unstructured 
covariance of the error terms. Additional important covariates may  be added to the model. For 
the primary  analy sis, data up to Week 12 will be used in the model.
The detailed testing strategy  including the primary  endpoint analysis is provided in Section 12.5.
Statistical model, hypothesis, and method of analysis for scenario with ISS7/HSS7 as the 
co-primary efficacy endpoints
The statistical hy pothesis test for the co -primary  endpoints tests the union null hy pothesis that 
the absolute change from baseline in ISS7 score at Week 12 in remibrutinib is not superior to 
the placebo group or the absolute 
change from baseline in HSS7 score at Week 12 in 
remibrutinib is not superior to the placebo group i.e.:
H01a: µ remibrutinib ≥µPlacebo versus H A1a: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in ISS7 at Week 12.
H01b: µ remibrutinib ≥µPlacebo versus H A1b: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in HSS7 at Week 12.
The union null hypothesis is rejected if both elementary  null hypotheses (H01a, H01b) are rejected.
A linear mixed model with repeated measures (MMRM) will be used to estimate treatment 
differences for change from baseline in ISS7 score (respectivel y HSS7) at Week 12, based on 
the FAS. The MMRM model will include treatment group, baseline ISS7 score (respectively 
HSS7), randomization strata variables, week and both interaction of treatment by [CONTACT_157119]7 score (respectivel y HSS7) by [CONTACT_157120]. Repeated 
measures within participant are modeled using an unstructured covariance of the error terms. 
Additional important covariates may be added to the model. For the primary  analysis, data up 
to Week 12 will be used in the model.
The detailed testing strategy  including the primary  endpoint analy sis is provided inSection 12.5.
12.4.3 Handling of intercurrent events of primary estimand
Participants who discontinue from study  treatment early  due to any  reas on will be encouraged 
to stay in the study  following the procedures. Every  effort will be made to continue to follow 
participants who discontinued from study  treatment up to Week 12. These are considered as 
Retrieved drop out (RDO) participants.
The anal ysis will account for different intercurrent events as explained in the following:
Discontinuation of study  treatment prior to Week 12 
due to an y reason: ignore (Treatment 
policy  strategy ), i.e., data collection will be maintained and available measurements post-
treatment discontinuation will be used as if they  had been obtained under the treatment 
assigned at randomization: RDO data collected after study  treatment discontinuation will 
be used for anal ysis.

[COMPANY_001] Confidential Page 95of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Intake of rescue medication as per protocol, or switch of background medication, or intake 
of other prohibited medication, or participants non -compliant to treatment prior to Week 
12: ignore (Treatment policy  strategy ), data collected after these events will be used for 
analysis.
Intake of strongl y confounding prohibited medication (e .g.,biologics treatment at any  
time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8): 
(Composite strategy ) measurements after this event will be excluded from the anal ysis and 
will be imputed using the worst value of the endpoint (e.g. ,42 for UAS7 score at week 12 
and 21 for co -primary  endpoints I SS7 score or HSS7 score at week 12).
12.4.4 Handling of missing values not related to intercurrent event
The UAS7 score is derived from the sum of the HSS7 sc ore and the ISS7 score. The HSS7 and 
ISS7 score will be derived by  [CONTACT_157121] I SS scores of the 7 day s preceding 
the visit, respectively . The daily score (HSS and ISS) will be calculated by [CONTACT_157122] I SS sco re, respectively . If one of the morning or evening scores 
is missing, the non-missing score for that day (morning or evening) will then be used as the 
daily  score.
For each weekl y score from the UPDD (i.e., HSS7, ISS7), if one or more of the daily scores a re 
missing, the following principles will be applied to handle the missing data:
The weekly  UAS7 is the sum of both the HSS7 score and the ISS7 score and will be missing 
if at least one of them is missing.
If a participant has at least 4 
non-missing daily  (morning or evening) scores within the 7 
days prior to the study  visit, the weekly  score for HSS or I SS will be calculated as the sum 
of the available eDiary  scores of that week, divided by [CONTACT_154562]
-missing days, 
multiplied by  7.
If there are lessthan 4 non-missing daily scores within the prior 7 days, then the weekl y 
score for HSS or ISS will be considered as missing for that week. Accordingl y, no UAS7 
can be calculated.
Participants who discontinue from study  treatment early  due to any  reason will be encouraged 
to stay in the study  following the procedures. Every  effort will be made to continue to follow 
participants who discontinued from study  treatment. These are considered as RDO participants.
For any intercurrent events handled with treatment policy  strategy : If no RDO data was 
collected after study  treatment permanent discontinuation, missing data will be imputed based 
on the following rules:
For participants in the active treatment arms, if sufficient RDO data, missing data will be 
imputed using MI based on observed RDO data in the corresponding active arm. If not 
feasible (e.g., very limited RDO data), missing 
data will be imputed based on observed data 
in the placebo arm under the assumption of jump to reference (J2R) using MI .
For participants in the placebo arm, if sufficient RDO data, missing data will be imputed 
using MI based on observed RDO placebo arm data. If not feasible (e.g. ,very limited RDO 
data), missing data will be imputed using MIunder the MAR assumption based on the 
observ ed placebo arm data.

[COMPANY_001] Confidential Page 96of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
12.4.5 Sensitivity analy ses
The following sensitivity  analy siswill be performed for the primary  estimand to assess the 
robustness of the estimation in the presence of deviations from the assumptions specified in the 
primary  anal ysis. The sen sitivity  anal ysiswill be implemented with the same target population, 
the primary  variables and the summary  measure as for the primary  estimand, but using the 
different assumptions or handling of intercurrent events.
Sensitivity analysis : The change from baseline in UAS7, ISS7 and HSS7 score at week 12 will 
be imputed using zero (i.e., no clinical improvement from baseline) for the intercurrent event 
of “Intake of strongl y confounding prohibited medication (e.g., biologics treatment at an y time 
before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8)” handled 
with composite strategy .
12.4.[ADDRESS_181991] is: What is the effect of remibrutinib treatment versus placebo 
on the change from baseline in UAS7 score (respectivel y for co-primary  endpoints ISS7 and 
HSS7) after 12 weeks treatment in adult patients with CSU who are inadequately controlled b y 
H1-antihistamine and receiving a stable locall y label approved dose of a second generation 
H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of 
intake of a different second generation H1-antihistamine and rescue 
medication, andasifstrongl y confounding prohibited medication was not taken?
Thesup
plementary estimand is described b y the following attributes:
1.Population : patients with inadequately  controlled CSU despi[INVESTIGATOR_157036] H1-antihistamine who have CSU duration ≥6 months, a UAS7 score ≥16, ISS7 score 
≥6 and HSS7 score ≥[ADDRESS_181992] 7 day s prior to randomization.
2.Endpoint: Change in UAS7 (respectivel y for co-primary  endpoints ISS7 and HSS7) from 
baseline at Week 12.
3.Treatment of interest: the randomized study  treatment (remibrutinib 25 mg b.i.d. or placebo) 
regar dless of treatment compliance, with background medication of local approved second 
generation H1-antihistamine, and a different second generation H1-antihistamine as rescue 
medication.
4.Summary Measurement: the mean difference between treatment groups.
5.Handling of intercurrent events:
Discontinuation of study  treatment due to an y reason: Treatment policy  strategy
Intake of strongl y confounding prohibited medication (e.g. ,biologics treatment at any  
time before Week 12, cyclosporin after Week 8, systemi c corticosteroids after Week 
8):Hypothetical strategy (irrespective of potential occurrence of other intercurrent events)
Intake of rescue medication, switch of background medication, intake of other prohibited 
medication: Treatment policy  strategy

[COMPANY_001] Confidential Page 97of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
12.5 Analysis supporting secondary  objectives
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s)
Improvement of UAS7, assessed as absolute change from baseline in UAS7 score at Week 
12 (For scenario with I SS7/HSS7 as the co- primary  efficacy  endpoints).
The absolute change from baseline in UAS7 score at Week 12 will be analy zed using MMRM 
modeling including treatment group, baseline UAS7 score, randomization strata variables, week 
and both interaction of treatment by [CONTACT_157117]7 score by [CONTACT_157118].
Disease activity  control at Week 12, assessed as % of participants achieving UAS7 ≤ 6.
The proportion of participants with UAS7 ≤ 6 at Week 12 will be analy zed using a logistic 
regression model including treatment group, region, prior exposure to anti-IgE biologics and 
baseline UAS7 score as covariate.
Complete absence of hives and itch at Week 12, assessed as % of participants achieving 
UAS7 = 0.
The proportion of participants with UAS7 = 0 at Week 12 will be analy zed using a logistic 
regressio n model including treatment group, region, prior exposure to anti-IgE biologics and 
baseline UAS7 score as covariate.
Improvement of severit y of itch, assessed as absolute change from baseline in I SS7 score 
at Week 12 (For scenario with UAS7 as the primary efficacy  endpoint).
The absolute change from baseline in ISS7 score at Week [ADDRESS_181993] ion of baseline ISS7 score by [CONTACT_157118].
Improvement of severit y of hives, assessed as absolute change from baseline in HSS7 
score at Week 12 (For scenario with UAS7 as the primary  efficacy  endpoint).
The absolute change from baseline in HSS7 s core at Week 12 will be analy zed using MMRM 
modeling including treatment group, baseline HSS7 score, randomization strata variables, week 
and both interaction of treatment by [CONTACT_157123]7 score by [CONTACT_157118].
Disease act ivity control at Week 2, assessed as proportion of participants achieving 
UAS7 ≤ 6.
The proportion of participants with UAS7 ≤ 6 at Week 2 will be analy zed using a logistic 
regression model including treatment group, region, prior exposure to anti-IgE biologics and 
baseline UAS7 score as covariate.
No impact on participants’ dermatology  quality  of life at Week 12, assessed as proportion 
of participants achieving DLQI = 0 -1.
An overall score will be calculated according to the scoring manual. The proportion of 
participants with overall DLQI scores ≤ 1 at Week 12 will be analyzed using a logistic 
regression model which includes treatment group, region, prior exposure to anti -IgE biologics 
and baseline DLQI score.

[COMPANY_001] Confidential Page 98of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Cumulative number of weeks that participants ac hieve UAS7 ≤ 6 responses between 
baseline and Week 12.
The cumulative number of weeks achieving UAS7 ≤ 6 response between baseline and Week 12 
will be derived based on the eDiary . The cumulative number of weeks achieving UAS7 ≤ 6 
response between baseline and Week 12 will be modelled using a negative binomial regression 
model with log link, using treatment group, region, and prior exposure to anti-IgE biologics. 
The number of weeks stay on the trial will be used as an offset.
Cumulative number of weeks that participants achieve AAS7 = 0 responses between 
baseline and Week 12.
The cumulative number of weeks achieving AAS7 = 0 response between baseline and Week 12 
will be derived based on the AAS eDiary  and UPDD diary . A weekl y AAS7 score will be 
derived by [CONTACT_157124] 7 days preceding the visit, and ranges from 0 to 
105. If the AAS7 assessment is missing, it will be considered as a non-response for the 
cumulative number of weeks that participants achieve AAS7 = 0 response calculation.
Thecumulative number of weeks achieving AAS7 = 0 response between baseline and Week 12 
will be modelled using a negative binomial regression model with log link, using treatment 
group, region, prior exposure to anti- IgE biologics and baseline AAS7 = 0 status .
Statistical model, hypothesis, and method of analysis for scenario with UAS7 as the 
primary efficacy endpoint
Testing strategy
The following null h ypotheses (H0) will be tested against the respective alternative h ypotheses 
(HA) in a closed testing proced ure (Bretz et al 2009 ), thus controlling the family -wise type I 
error which is set to 0.025 (one -sided):
Primary:
UAS7 score change from baseline at Week 12
H01: µ remibrutinib ≥µPlacebo versus H A1: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in UAS7 at Week 12,
Secondaries:
UAS7 ≤ 6 at Week 12
H02: premibrutinib ≤pPlacebo versus H A2: premibrutinib >pPlacebo
where p is the proportion of participants achieving UAS7 ≤ 6 at Week 12,
UAS7 = 0 at Week 12
H03: premibrutinib ≤pPlacebo versus H A3: premibrutinib >pPlacebo
where p is the proportion of participants achieving UAS7 = 0 at Week 12,
ISS7 score change from baseline at Week 12
H04: µ remibrutinib ≥µPlacebo versus H A4: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in ISS7 at Week 12,

[COMPANY_001] Confidential Page 99of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
HSS7 score change from baseline at Week 12
H05: µ remibrutinib ≥µPlacebo versus H A5: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in HSS7 at Week 12,
UAS7 ≤ 6 at Week 2
H06: premibrutinib ≤pPlacebo versus H A6: premibrutinib >pPlacebo
where p is the proportion of participants achieving UAS7 ≤ 6 at Week 2,
DLQI = 0/1 at Week 12
H07: premibrutinib ≤pPlacebo versus H A7: premibrutinib >pPlacebo
where p is the proportion of participants achieving DLQI = 0/1 at Week 12,
Cumulative number of weeks with an UAS7 ≤6 response between baseline and Week 
12
H08: µ remibrutinib ≤µPlacebo versus H A8: µ remibrutinib > µ Placebo
where µ is the mean cumulative number of weeks that participa nts achieve UAS7 ≤ 6 response 
between baseline and Week 12,
Cumulative number of weeks with an AAS7= 0 response between baseline and Week 
12
H09: µ remibrutinib ≤µPlacebo versus H A9: µ remibrutinib > µ Placebo
where µ is the mean cumulative number of weeks that participants achieve AAS7 =[ADDRESS_181994] represents the significance level. The arrow and value inside the square 
represent the "alpha -propagation".
The first hypothesis istested with full level alpha (0.025 one-sided). If significant, the second 
hypothesis is tested with full- level alpha; otherwise, the testing procedure stops. The testing is 
strictly  hierarchical, so that null hypotheses can be tested along the pre-define d order at the level 
assigned until a null hypothesis cannot be rejected, at which point the testing stops. Furthermore, 
the testing strategy  reflects the separation of primary  and secondary endpoints, so that 
hypotheses related to secondary  endpoints willonly be tested if the null hypothesis related to 
the primary  endpoint is rejected.
Statistical model, hypothesis, and method of analysis for scenario with ISS7/HSS7 as the 
co-primary efficacy endpoints
Testing strategy

[COMPANY_001] Confidential Page 100of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
The following null hy potheses (H 0) will be tested against the respective alternative hy potheses 
(HA) in a closed testing procedure (Bretz et al 2009 ), thus controlling the famil y-wise type I 
error which is set to 0.025 (one -sided):
Co-Primary:
ISS7 score change from baseline at Week 12
H01a: µ remibrutinib ≥µPlacebo versus H A1a: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in ISS7 at Week 12,
HSS7 score change from baseline at Week 12
and H 01b: µ remibrutinib ≥µPlacebo versus H A1b: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in HSS7 at Week 12,
Secondaries:
UAS7 score change from baseline at Week 12
H02: µ remibrutinib ≥µPlacebo versus H A2: µ remibrutinib < µ Placebo
where µ is the mean change from baseline in UAS7 at Week 12,
UAS7 ≤ 6 at Week 12
H03: premibrutinib ≤pPlacebo versus H A3: premibrutinib >pPlacebo
where p is the proportion of participants achieving UAS7 ≤6 at Week 12,
UAS7 = 0 at Week 12
H04: premibrutinib ≤pPlacebo versus H A4: premibrutinib >pPlacebo
where p is the proportion of participants achieving UAS7=0 at Week 12,
UAS7 ≤ 6 at Week 2
H05: premibrutinib ≤pPlacebo versus H A5: premibrutinib >pPlacebo
where p is the proportion of participants achieving UAS7 ≤6 at Week 2,
DLQI = 0/1 at Week 12
H06: premibrutinib ≤pPlacebo versus H A6: premibrutinib >pPlacebo
where p is the proportion of participants achieving DLQI = 0/1 at Week 12,
Cumulative number of weeks with an UAS7 ≤6 response between baseline and Week 
12
H07: µ remibrutinib ≤µPlacebo versus H A7: µ remibrutinib > µ Placebo
where µ is the mean cumulative number of weeks that participants achieve UAS7 ≤6 response 
between baseline and Week 12,
Cumulative number of weeks with an AAS7= 0 response between baseline and Week 
12
H08: µ remibrut inib≤µPlacebo versus H A8: µ remibrutinib > µ Placebo

[COMPANY_001] Confidential Page 101of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
where µ is the mean cumulative number of weeks that participants achieve AAS7=0 response 
between baseline and Week 12,
A graphical representation of the testing strategy  is presented in Figure 12-2
Figure 12-
2 Testing strategy  with ISS7/HSS7 as the co -primary endpoints
The value inside the circle represents the significance level. The arr ow and value inside the square 
represent the "alpha -propagation".
The first two hypotheses are tested: both H1aand H1baretested with full level alpha (0.025 one-
sided) and only if both are rejected, then H2hypothesis is tested with full-level alpha; otherwise, 
the testing procedure stops. The testing is strictly  hierarchical, so that null hypotheses can be 
tested along the pre-defined order at the level assigned until a null hypothesis cannot be rejected, 
at which point the testing stops. Furthermore, the testing strategy  reflects the separation of 
primary  and secondary  endpoints, so that hypotheses related to secondary  endpoints will only 
be tested if both null hy potheses related to the co -primary  endpoints are rejected.
12.5.2 Safety  endpoints
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_1570].
Safety  summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where a ppropriate (e.g.,change from 
baseline summaries). In addition, a separate summary  for death including on treatment and post 
treatment deaths will be provided. In particular, summary  tables for adverse events (AEs) will 
summarize only on-treatment events, with a start date during the on-treatment period 
(treatment -emergent AEs).
The on -treatment period lasts from the date of first administration of study  treatment to [ADDRESS_181995] on:
the date of the last actual dose intake of remibrutinib double -blind
the date of first dose intake of open -label treatment
Adverse events
All information obtained on adverse events will be display ed by [CONTACT_131373].
The number (and percentage) of participants with treatment emergent adverse events (events 
started after the first dose of study  medication or events present prior to start of double -blind 
treatm ent but increased in severit y based on preferred term) will be summarized in the following 
ways:

[COMPANY_001] Confidential Page 102of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
by [CONTACT_3148], primary  system organ class and preferred term.
by [CONTACT_3148], primary  system organ class, preferred term and maximum severity .
by [CONTACT_3148], Stand ardized MedDRA Query  (SMQ) and preferred term.
Separate summaries will be provided for study  medication related adverse events, death, serious 
adverse events, other significant adverse events leading to discontinuation by [CONTACT_157125].
The number (and proportion) of participants with adverse events of special interest for 
remibrutinib (related to identified and potential risks) will be summarized by [CONTACT_157125].
A participant with multiple adverse events within a pri mary  system organ class is only  counted 
once towards the total of the primary  system organ class.
Vital signs
All vital signs data will be listed by [CONTACT_1570], participant, and visit/time and if ranges 
are available, abnormalities (and relevant chang es) will be flagged. Summary  statistics will be 
provided b y treatment and visit.
12-lead ECG
PR, QRS, QT, QTcF, and RR intervals will be obtained from 12-lead ECGs for each participant 
during the stud y. ECG data will be read and interpreted centrall y.
All ECG data will be listed by [CONTACT_1570], participant and visit/time, abnormalities will be 
flagged. Summary  statistics will be provided by  [CONTACT_10659]/time.
Clinical laboratory  evaluations
All laboratory  data will be listed by [CONTACT_1570], p articipant, and visit and if normal ranges 
are available abnormalities will be flagged. Summary  statistics for the change from baseline 
will be provided by [CONTACT_10659]. Shift tables using the low/normal/high/ (low and 
high) classification will be u sed to compare baseline to the worst on
-treatment value.
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 103of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dermatology Life Quality Index (DLQI)
For DLQ I total score, summary statistics will be provided for absolute change from baselin e as 
well as for percent change from baseline b y treatment group and visit.
The proportion of participants achieving DLQI = 0-1 will be provided by  [CONTACT_29013].
Angioedema Activity Score (AAS)
For AAS7 score, summary statistics will be provided for absolute change from baseline as well 
as for percent change from baseline over time by [CONTACT_1570], in participants with 
angioedema at baseline (AAS7 >0) and in all participants.

[COMPANY_001] Confidential Page 104of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
The proportion of participants achieving AAS7 = 0 will be provided over time by [CONTACT_6490].
For angioedema burdened days, summary  statistics will be provided for absolute change from 
baseline as well as for percent change from baseline over time b y treatment group.
 
 
 
 
 

[COMPANY_001] Confidential Page 105of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
12.[ADDRESS_181996] completed the treatment period (a second, nearly  identical Phase 3 study  will be 
conducted in parallel). The minimum of 150 participants reaching week 52 should enable 
analysis on a minimum of 100 participants exposed to remibrutinib for 52 weeks, considering 
the initial randomization to e ither the remibrutinib or the placebo arm (2:1). The results of the 
primary  analysis will further inform decision- making for the remibrutinib development 
program. Formal testing of the primary  endpoint and key secondary  endpoints will only be 
performed at the primary anal ysis time point; thus, no adjustment for multiplicity  is required.
After the primary  anal ysis and/or after all participants entered the open -label treatment period, 
additional optional interim analyses may be conducted at the discretion of the Sponsor to 
support potential Health Authority  requests and interactions (these interim analy ses are not 
expected to have an y impact on the conduct or scientific integrity of the study). The decision to 
conduct optional interim analyses and the timing of these analyses will be documented in the 
Statistical Analy sis Plan prior to the conduct of any interim analysis.These interim analyses 
will be performed and interpreted b y members of the [COMPANY_001] clinical team.
12.8 Sample size calculation
12.8.1 Primary  endpoint(s )
In order to fulfill registration and ICH E1 requirements 
on the number of participants treated 
for 6 months and 12 months in the development program, a sample size of 300 participants in 
the active arm and 150 in the placebo arm is targeted. Hence, the total sample size is 450 
randomized participants.
From an efficacy  point of view, the sample size justification is based on UAS7 change from 
baseline (for scenario with one primary  endpoint), ISS7 and HSS7 change from baseline (for 
scenario with co-primary endpoints) and achievement of UAS7 ≤6 and UAS7=0 at Week 12. 
To avoid assigning an unnecessary large number of participants to placebo, participants will be 
randomized in a 2:1 ratio to remibrutinib 25 mg b.i.d. and placebo arms, respectivel y.
All calculations were performed with nQuery  Advisor [IP_ADDRESS] and Ri386 4.0.2 softwares.
For scenario with UAS7 as the primary efficacy endpoint
UAS7 change from baseline at Week 12
Approximately  10% drop-out is expected at week 12, thus with 270 participants in the active 
arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to 
detect a difference between remibrutinib and placebo if the mean change of UAS7 from baseline 
to Week [ADDRESS_181997] deviation of 
approximately  12 (based on the primary endpoint analysis of Phase 2b study 
(CLOU064A2201)), based on a t -test, assuming t ype I error 0.025 (one -sided).
For scenario with ISS7/HSS7 as the co -primary efficacy endpoints
ISS7 change from ba seline at Week 12

[COMPANY_001] Confidential Page 106of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Approximately  10% drop-out is expected at week 12, thus with 270 participants in the active 
arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to 
detect a difference between remibrutinib and placebo if the mean change of ISS7 from baseline 
to Week [ADDRESS_181998] deviation of 
approximately  6 (based on the primary  endpoint analy sis of Phase 2b study  (CLOU064A2201)), 
based on a t -test, assuming t ype I erro r 0.025 (one -sided).
HSS7 change from baseline at Week 12
Approximately  10% drop-out is expected at week 12, thus with 270 participants in the active 
arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to 
detect a difference between remibrutinib and placebo if the mean change of HSS7 from baseline 
to Week [ADDRESS_181999] deviation of 
approximately  6 (based on the primary  endpoint analy sis of Phase 2b study  (CLOU064A2201)),
based on a t -test, assuming t ype I error 0.025 (one -sided).
With 300 participants in the active arm and 150 participants in the placebo arm randomized in 
this study , this gives a power of more than >90% to detect a difference between remibrutinib 
and placebo inboth mean change of ISS7 and HSS7 from baseline to Week 12 when correlation 
between endpoints is 0 (conservative assumption, as higher the correlation is, higher the power 
is).
12.8.2 Secondary  endpoint(s)
Achievement of UAS7 = 0 at Week 12
Similarly , with approximately  10% drop-out at week 12, then with 270 participants in the active 
arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to 
detect a difference between remibrutinib and placebo arm assuming a proportion of complete 
response (UAS7=0) of 0.[ADDRESS_182000] with a 0.025 one -sided significance level.
Achievement of UAS7 ≤6 at Week 12
Similarly , with approximately  10% drop-out at week 12, then with 270 participants in the active 
arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to 
detect a difference between remibrutinib and placebo arm assuming a proportion of disease 
activity  control response (UAS7 ≤6) of 0.[ADDRESS_182001] with a 0.025 one-sided significance level.
The primary  and secondary  endpoints anal yses are planned to use the multiple testing strategy 
to control the family -wise error at α=0.025 (one-sided). It is considered, however, this 
hierarchical approach could impact the sample size compared to the separate endpoint approach, 
which depends on how the recycled alpha will be used. In both scenarios, the “family -wise” 
power (power to reject all null hypotheses) is >90% when correlation between endpoints is 0 
(Higher the correlation is, higher the power is).

[COMPANY_001] Confidential Page 107of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, participant recruitment procedures (e.g. ,
advertisements) and an y other written information to be provided to participants. Prior to study  
start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement 
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] 
monitors, auditors, [COMPANY_001] Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority , the investigator must inform [COMPANY_001] immediately  that this 
request has been made.
13.[ADDRESS_182002]. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study report the results of this trial will be submitted for publication and 
posted in a publicly  accessible database of clinical trial results, such as the Novart is clinical trial 
results website and all required Health Authority websites (e.g.,Clinicaltrials.gov, EudraCT 
etc.).
For details on the [COMPANY_001] publication policy  including authorship criteria, please refer to the 
[COMPANY_001] publication policy  training materials that were provided at the trial investigator 
meetings.
13.[ADDRESS_182003] Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compl iance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk -based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes.

[COMPANY_001] Confidential Page 108of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
13.5 Participant Engagement
The following participant engagement initiatives are included in this study  and will be provided, 
as available, for distribution to study  participants at the timepoints indicated. If compliance is 
impacted by [CONTACT_6664], sites may discuss modifications to 
these requirements with [COMPANY_001].
Thank You letter
Plain language trial summary  -after CSR publication
Individual stud y results -after CSR public ation
Trial Feedback Questionnaires - 3 timepoints: at the start, during and at the end of the 
trial.
[ADDRESS_182004] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and Health Authorities, where required, it cannot be implemented.
14.[ADDRESS_182005] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for participa nt safety  may be implemented immediately 
provided the health authorities are subsequently  notified by [CONTACT_37306]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expecte d to take any immediate action required for the safet y of any participant included in this 
study , even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

[COMPANY_001] Confidential Page 109of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
[ADDRESS_182006] D, Gessier F, Janser P, et al (2020) Discovery of LOU064 (Remibrutinib), a Potent and 
Highl y Selective Covalent I nhibitor of Bruton's Ty rosine Kinase. J Med Chem p. 5102 -5118.
Bernstein JA, Lang DM, Khan DA, et al (2014) The diagnosis and management of acute and 
chronic urticaria: 2014 update. J Allergy  Clin I mmunol p. 1270 -7.
 
Bretz F, Maurer W, Brannath W, et al (2009) A graphical approach to sequentially  rejective 
multiple test procedures. Stat Med p. 586-604.
Brukinsa®Prescribing Information (2021) BeiGene, Brukinsa (zanubrutinib) 80 mg capsule 
(Internet). Available from: <https://www.brukinsa.com/prescribing- information.pdf> 
(Accessed 22- Mar-2022).
Brukinsa®SmPC (2022) BeiGene, Brukinsa (zanubrutinib) 80 mg capsule (Internet). Available 
from: <https://www.ema.eur opa.eu/en/documents/product -information/brukinsa -epar-product -
information_en.pdf> (Accessed 22 -Mar-2022).
Bye AP, Unsworth AJ, Vaiy apuri S, et al (2015) Ibrutinib inhibits platelet integrin αIIbβ3 
outside -in signaling and thrombus stability  but not adhesion to collagen. Arterioscler Thromb 
Vasc Biol; 35(11):2326-35.
Calquence® Prescribing Information (2019) [COMPANY_008], Calquence (acalabrutinib) 100 mg 
capsules (Internet). Available from: <https://www.azpi[INVESTIGATOR_24309].com> (Accessed 26 -Apr-2022).
Calquence® SMPC (2021) [COMPANY_008], Calquence (ascalabrutinib) 100 mg capsules (Internet). 
Available from: <https://www.ema.europa.eu/en/documents/product- information/calquence -
epar-product -information_en.pdf> (Accessed 26- Apr-2022).
Dispenza MC, Pongracic JA, Singh AM, et al (2018) Short -term ibrutinib therap y suppresses 
skin test responses and eliminates IgE -mediated basophil activation in adults with peanut or 
tree nut allergy . J. Allergy  Clin. I mmunol. p. 1914 -1916.e7.
Dispenza MC, Regan JA, Bochner BS (2017) Potential applications of Bruton's t yrosine 
kinase inhibitors for the prevention of allergic reactions. Expert Rev Clin Immunol p. 921 -
923.
Ferrer M (2015) Immunological events in chronic spontaneous urticaria. Clin Transl Allergy  
p. 30.
Farez et al (2019) Practice guideline update summary : Vaccine -preventable infections and 
immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and 
Implementation Subcommittee of the American Academ y of Neurology. Neurology. 2019 Sep 
24;93(13):584 -594
Finlay  AY (2005) Current severe psoriasis and the rule of tens. Br. J. Dermatol. p. 861 -7.

[COMPANY_001] Confidential Page 110of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Finlay  AY, Khan GK (1994) Dermatology  Life Quality  Index (DLQI) --a simple practical 
measure for routine clinical use. Clin. Exp. Dermatol. p. 210-6.
Futatani T, Watanabe C, Baba Y, et al (2001) Bruton's t yrosine kinase is present in normal 
platelets and its absence identifies patients with X -linked agammaglobulinaemia and carrier 
females. Br J Haematol p. 141 -
9.
Gabizon R, L ondon N (2020) A Fast and Clean BTK Inhibitor. J Med Chem p. 5100-5101.
Gonçalo M, Gimenéz -Arnau A, Al -Ahmad M, et al (2021) The global burden of chronic 
urticaria for the patient and society . Br J Dermatol p. 226 -236.
Greaves MW (2003) Chronic idiopathic urticaria. Curr Opin Aller gy Clin Immunol p. 363-8.
Guillén- Aguinaga S, Jáuregui Presa I, Aguinaga - Ontoso E, et al (2016) Updosing nonsedating 
antihistamines in patients with chronic spontaneous urticaria: a s ystematic review and meta -
analysis. Br J Dermatol p. 1153-1165.
 
Hawro T, Ohan yan T, Schoepke N, et al (2018) The Urticaria Activit y Score -Validity , 
Reliability , and Responsiveness. J Allergy  Clin I mmunol Pract p. 1185 -1190.e1.
Hendriks RW, Yuvaraj S, Kil L P (2014) Targeting Bruton's t yrosine kinase in B cell 
malignancies. Nat Rev Cancer p. 219 -32.
Hongbo Y, Thomas CL, Harrison MA, et al (2005) Translating the science of quality  of life 
into practice: What do dermatology  life quality  index scores mean? J. I nvest. Dermatol. p. 
659-64.
Imbruvica® Prescribing Information (2020) JanssenCilag International NV, Imbruvica 
(ibrutinib) 
[ADDRESS_182007] capsules (Internet). Available from: 
<https://www.imbruvica.com/files/prescribing-i nformation.pdf> (Accessed on 26- Apr-2022).
Imbruvica®SmPC (2022) Janssen- Cilag International NV, Imbruvica (ibrutinib) [ADDRESS_182008] Characteristics. Available from < 
https://www.ema.europa.eu/en/documents/product -information/im bruvica -epar-product -
information_en.pdf> (Accessed on 26 -Apr-2022).
Kaplan A, Ferrer M, Bernstein JA, et al (2016) Timing and duration of omalizumab response 
in patients with chronic idiopathic/spontaneous urticaria. J Allergy  Clin Immunol p. 474 -81.
Kapla n AP, Horáková Z, Katz SI  (1978) Assessment of tissue fluid histamine levels in 
patients with urticaria. J Allergy  Clin Immunol p. 350-4.
Kaul M, Storim J, End P, et al (2019) LOU064: A highl y selective and potent covalent oral 
BTK inhibitor with promising pharmacod ynamic effects in skin p. 333 -376.
Kaul M, End P, Cabanski M, et al (2021) Remibrutinib (L OU064): A selective potent oral 
BTK inhibitor with promising clinical safet y and pharmacod ynamics in a randomized phase I  
trial p. 1-13.

[COMPANY_001] Confidential Page 111of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
 
 
 
Maurer M, Abuzakouk M, Bérard F, et al (2017) The burden of chronic spontaneous urticaria 
is substantial: Real -world evidence from ASSURE -CSU. Allergy  p. 2005- 2016.
Maurer M, Rosén K, Hsieh HJ, et al (2013) Omalizumab for the treatment of chronic 
idiopathic or spontaneous urticaria. N Engl J Med p. 924-35.
 
 
Młynek A, Zalewska -Janowska A, Martus P, et al (2008) How to assess disease activity  in 
patients with chr onic urticaria? Allergy  p. 777-80.
O'Donnell BF, Lawlor F, Simpson J, et al (1997) The impact of chronic urticaria on the 
quality  of life. Br J Dermatol p. 197
-201.
 
Pleyer et al (2021) Effect of Bruton t yrosine kinase inhibitor on efficacy of adjuvanted 
recombinant hepatitis B and zoster vaccines. Blood. 2021 Jan 14;137(2):185-189
Powell RJ, Du Toit GL , Siddique N, et al (2007) BSACI guidelines for the management of 
chronic urticaria and angio -oedema. Clin Exp Allergy  p. 631-50.
Regan JA, Cao Y, Dispenza MC, et al (2017) Ibrutinib, a Bruton's ty rosine kinase inhibitor 
used for treatment of l y
mphoproliferative disorders, eliminates both aeroallergen skin test and 
basophil activation test reactivity . J. Allergy  Clin. I mmunol. p. 875- 879.e1.
Rip J, Van Der Ploeg EK, Hendriks RW, et al (2018) The Role of Bruton's Ty rosine Kinase in 
Immune Cell Signaling and Sy stemic Autoimmunity . Crit Rev I mmunol p. 17 -62.
Saini SS, Kaplan AP Chronic Spontaneous Urticaria: The Devil's Itch. J Alle rgy Clin 
Immunol Pract p. 1097 -1106.
Smiljkovic D, Blatt K, Stefanzl G, et al (2017) BTK inhibition is a potent approach to block 
IgE-mediated histamine release in human basophils. Allergy  p. 1666-1676.
Weber et al (2021) Balancing Potential Benefits and Risks of Bruton Ty rosine Kinase 
Inhibitor Therapi[INVESTIGATOR_157054]
-19 Pandemic. Neurol 
Neuroimmunol Neuroinflamm 2021;8:e1067.

[COMPANY_001] Confidential Page 112of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
 
Weller K, Groffik A, Magerl M, et al (2013) Development, validation, and initial results of 
the Angioedema Activity Score. Allergy  p. 1185- 92.
Zuberbier T, Aberer W, Asero R, et al (2014) The EAACI /GA(2) LEN/EDF/WAO Guideline 
for the definition, classification, diagnosis, and management of urticaria: the 2013 revision 
and update. Allergy  p. 868 -
87.
Zuberbier T, Aberer W, Asero R, et al ( 2018) The EAACI /GA²LEN/EDF/WAO guideline for 
the definition, classification, diagnosis and management of urticaria. Allergy  p. 1393 -1414.
Zuberbier T, Asero R, Bindslev -Jensen C, et al (2009) EAACI/GA(2)LEN/EDF/WAO 
guideline: management of urticaria. Aller gy p. 1427 -43.

[COMPANY_001] Confidential Page 113of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
16 Appendices
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs
The following specific criteria have been identified for this stud y. Should these criteria be met, 
a re-test must be done within [ADDRESS_182009] assessment. Discontinuation of the study  
treatment should be considered if the abnormal hematology  parameter is confirmed:
Hemoglobin: < 10 g/dl
Platelets: < 75 000/mm3
Leukocy tes: < 3 000/mm3
Neutrophils: < 1 500/mm3
For all other laboratory  assessments, the central laboratory  will flag laboratory  values falling 
outside of the normal ranges on the central laboratory  report (which the investigator should 
review and sign-off) and the investigator will report any values considered clinically  significant 
in the eCRF.
Refe r to Section 16.2 for clinically  notable laboratory  values for hepatotoxicity .
Refer to Section 16.3 for clinically  notable laboratory  values for nephrotoxicity .
Notable values for vital signs and change from baseline will be summarized.
Notable values are defined as follows:
heart rate of < 50 or > 100 bpm
systolic blood pressure of < 90 and ≥ 140 mmHg
diastolic blood pressure of < 60 and ≥ 90 mmHg
For ECGs, a notable QTc value is defined as an absolute QTc (Fridericia’s) interval of greater 
than 450 msec for males or greater than 460 msec for females or QTcF increase of ≥60 msec 
compared to baseline QTcF value –all such ECGs will be flagged by [CONTACT_157126]’s 
cardiologist and require assess ment for clinical relevance b y the investigator.

[COMPANY_001] Confidential Page 114of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
16.2 Appendix 2: Liver event and laboratory trigger definitions & 
follow -up requirements
Table 16-1 Liver event and laboratory  trigger definitions
Definition/ threshold
Liver laboratory triggers
If ALT, AST and total bilirubin normal at 
baseline:ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known 
bone pathology)
Total bilirubin > 3 × ULN (in the absence of 
known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or 
AST > 3 × ULN and Total bilirubin > 2 × ULN 
[mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent 
term)
ALT or AST > 3 × ULN accompanied by 
(general) malaise, fatigue, abdominal pain, 
nausea, or vomiting, or rash with 
eosinophilia
Any adverse event potentially indicative of a 
liver toxicity
ALP: Alkaline phosphatase, ALT: Alanine aminotransferase, AS T: Aspartate aminotransferase, ULN: 
upper limit of normal
Table 16-2 Follo w up requirements for liver laboratory  triggers: A LT, A ST and 
TBL
Action Taken
Trigger Liver Symptoms Monitoring Follow -up 
MonitoringStudy Medication
ALT
ALT > [ADDRESS_182010]
TBL normal, or 
no change for 
participants with 
Gilbert’s 
syndromeNone Measure ALT, 
AST, ALP, GGT, 
TBL, INR, 
albumin, CK, and 
GLDH in 48 -72 
hoursFollow up for 
symptomsContinue dosing
ALT > [ADDRESS_182011] 
for more than two 
weeks
TBL normal, or 
no change for 
participants with 
Gilbert’s 
syndromeNone Measure ALT, 
AST, ALP, GGT, 
TBL, INR, 
albumin, CK, and 
GLDH in 48 -72 
hoursFollow -up for 
symptoms
Initiate close 
monitoring and 
workup for 
competing 
etiologiesInterrupt
Study drug can 
be restarted only 
if another etiology 
is identi ﬁed and 
liver enzy mes 
return to baseline

[COMPANY_001] Confidential Page 115of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Action Taken
Trigger Liver Symptoms Monitoring Follow -up 
MonitoringStudy Medication
ALT > [ADDRESS_182012]
TBL normal, or 
no change for 
participants with 
Gilbert’s 
syndromeNone Measure ALT, 
AST, ALP, GGT, 
TBL, INR, 
albumin, CK, and 
GLDH in 48 -72 
hoursFollow -up for 
symptoms
Initiate close 
monitoring and 
workup for 
competing 
etiologiesInterrupt
Study drug can 
be restarted only 
if another etiology 
is identi ﬁed and 
liver enzy mes 
return to baseline
ALT > [ADDRESS_182013]
TBL > [ADDRESS_182014] 
(or INR > 1.5)
For patients with 
Gilbert’s 
syndrome: 
Doubling of direct 
bilirubinNone Measure ALT, 
AST, ALP, GGT, 
TBL, INR, 
albumin, CK, and 
GLDH in 48 -72 
hoursFollow -up for 
symptoms
Initiate close 
monitoring and 
workup for 
competing 
etiologiesInterrupt
Study drug can 
be restarted only 
if another etiology 
is identi ﬁed and 
liver enzy mes 
return to baseline
ALT > [ADDRESS_182015], ALP, GGT, 
TBL, INR, 
albumi n, CK, and 
GLDH in 48 -72 
hoursFollow -up for 
symptoms
Initiate close 
monitoring and 
workup for 
competing 
etiologiesInterrupt
Study drug can 
be restarted only 
if another etiology 
is identi ﬁed and 
liver enzy mes 
return to baseline
Total Bilirubin (isolated)
>1.5 –3.[ADDRESS_182016] Repeat LFTs 
within 48 -72 
hoursMonitor LFTs 
weekly until 
resolution1to ≤ 
Grade 1 or to 
baselineContinue dosing
> 3 -10 × ULN (in 
the absence of 
known Gilbert 
syndrome)Repeat LFT 
within [ADDRESS_182017] the AE 
and contributing 
factors (e.g. ,
conmeds, med 
hx, lab) in the 
appropriate CRFMonitor LFTs 
weekly until 
resolution1to ≤ 
Grade 1 or to 
baseline (ALT, 
AST, total 
bilirubin, Alb, 
PT/INR, ALP and 
GGT)
Test for 
hemolysis (e.g. ,
reticulocytes, 
haptoglobin, 
unconjugated 
[indirect] bilirubin)Interrupt
> [ADDRESS_182018], total 
bilirubin, Alb, 
PT/INR, ALP and 
GGT until 
resolution1(frequDiscontinue 
treatment 
immediately

[COMPANY_001] Confidential Page 116of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Action Taken
Trigger Liver Symptoms Monitoring Follow -up 
MonitoringStudy Medication
Record the AE 
and contributing 
factors(e.g. ,
conmeds, med 
hx, lab) in the 
appropriate CRFency at 
investigator 
discretion)
General Clinical Symptoms
Any AE potentially indicative of a liver 
toxicity including: (General) malaise, 
fatigue, abdominal pain, nausea, or 
vomiting, or rash with eosinophiliaEstablish 
causality
Record the AE 
and contributing 
factors(e.g. ,
conmeds, med 
hx, lab) in the 
appropriate CRFInvestigator 
discretionConsider study 
treatment 
interruption or 
discontinuation
1Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a 
maximum of 6 months, (4) liver transplantation, and (5) death
Alb: Albumin, ALP: Alkaline phosphatase, ALT: Alanine aminotransferase, AST: Aspartate 
aminotransferase, CK: Creatinine kinase, CRF: Case report form, GGT: Gamma -glutam yl transferase, 
GLDH: glutamate dehydrogenase, INR: International Normalized Ratio, LFTs: Liver function tests, Med 
Hx: medical history, PT: Prothrombin time, TBL: Total bilirubin, ULN: upper limit of normal
Table 16-3 Follo w up requirements for liver lab oratory triggers -Isolated 
Hyperbilirubinemia
Criteria Actions required Follow -up monitoring
Total Bilirubin (isolated)
>1.5 –3.[ADDRESS_182019] -Maintain treatment- Repeat 
LFTs within 48 -72 hoursMonitor LFTs weekly until
resolution to ≤ Grade 1 (≤ 1.[ADDRESS_182020])
or to baseline
> 3 -10 × ULN (in the
absence of
known Gilbert syndrome)-Interrupt treatment
-Repeat LFT within [ADDRESS_182021] the AE and 
contributing factors
(e.g., conmeds, med hx, lab) in 
the appropriate CRF-Monitor LFTs weekly until
resolution to ≤ Grade 1 (≤ 1.[ADDRESS_182022]) or to
baseline (ALT, AST, total
bilirubin, Alb, PT/INR, ALP and 
GGT)
-Test for hemoly sis (e.g. ,
reticulocytes,
haptoglobin, unconjugated 
[indirect] bilirubin)
> [ADDRESS_182023], total bilirubin, Alb,
PT/INR, ALP and GGT until 
resolution (frequency at 
investigator discretion)

[COMPANY_001] Confidential Page 117of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Criteria Actions required Follow -up monitoring
Total Bilirubin (isolated)
-Record the AE and 
contributing factors
(e.g., conmeds, med hx, lab) in 
the appropriate CRF
Any AE potentially indicative of 
a liver toxicity-Consider study treatment 
interruption or discontinuation
-Hospi[INVESTIGATOR_157055]
-Establish causality -Record 
the AE and contributing factors 
(e.g., conmeds, med hx, lab) in 
the appropriate CRFInvestigator discretion
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can include: Serology  tests, imaging and pathology  assessments, hepatologist’s consultancy ; 
obtaining more detailed history  of symptoms and prior or concurrent diseases, history  of 
concomitant drug use, exclusion of underl ying liver disease.

[COMPANY_001] Confidential Page 118of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
16.3 Appendix 3: Specific Renal A lert Criteria and A ctions and E vent 
Follow -up
Table 16-4 Specific renal alert criteria and actions
Renal Event Actions
Confirmed serum creatinine increase 25 –49% Consider causes and possible interventions
Follow - up within 2 -5 day s; increase fluid 
intake before assessment if appropriate
Repeat follow -up (every 2 -5 days) until 
creatinine is <125% of baseline value
Serum creatinine increase 50 % 1Consider causes and possible interventions 
and initiate renal investigation
Repeat assessment within 24 -48 h if 
possible
Interruption of study drug
Close follow -up (every 24 -48 h), consider 
participant hospi[INVESTIGATOR_157056] <125% of 
baseline value
New onset dips tick proteinuria ≥ 31
When urine proteins are measured as a follow -
up of positive urine dipstick measurements:
Protein -creatinine ratio (PCR) ≥ 1g/g Cr (or 
mg/mmol equivalent as converted by [CONTACT_157127] y)Consider causes and possible interventions
Assess serum albumin & serum total protein
Repeat assessment to confirm
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
New onset hematuria ≥ 31on urine dipstick Assess and document:
Repeat asse ssment to confirm
Distinguish hemoglobinuria from hematuria
Urine sediment microscopy
Assess sCr
Exclude infection, trauma, bleeding from the 
distal urinary tract/bladder, menstruation
Consider bleeding disorder
[ADDRESS_182024] initiated or contributed to the 
event:
Blood pressure assessment (after 5-minute rest, with an appropriate cuff size)
Signs and s ymptoms like fever, headache, shortness of breath, back or abdominal pain, 
dysuria or hematuria, dependent or periorbital edema
Changes in blood pressure, body  weight, fluid intake, voiding pattern, or urine output

[COMPANY_001] Confidential Page 119of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic 
failure, contrast media or other known nephrotoxin administration, or other diseases or 
causes, eg, deh ydration due to delirium, tumor lysis
Table 16-[ADDRESS_182025] in the CRF:
Urine dipstick and sediment microscopy evidence of Drug -Induced Nephrotoxicity (DIN): 
crystals, red blood cells (dysmorphic/glomerular vs. non -dysmorphic/non -glom erular), white 
blood cells, tubular epi[INVESTIGATOR_1663]
Blood pressure and body weight
Serum creatinine, BUN, electrolytes (sodium, potassium, phosphate, calcium), bicarbonate and 
uric acid
Urine output
Review and record possible contributing factors to the renal event (co -medications, other co- morbid 
conditions) and additional diagnostic procedures (MRI etc.) in the CRF
Monitor participant regularly (frequenc y at investigator's discretion) until:
Event resolution: (sCr within 10% of baseline or PCR < 1 g/g Cr, or ACR <300 mg/g Cr) or
Event stabilization: sCr level with ±10% variability over last 6 months or protein -creatinine ratio 
stabilization at a new level with ±50% variabili ty over last 6 months.
Analysis of urine markers in samples collected over the course of the DIN event

[COMPANY_001] Confidential Page 120of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
16.4 Appendix 4: PRO Tools
Samples of questionnaires provided here are for illustrative purpose only . The text format and 
wording might slightl y vary.
Patie nt Diary : Urticaria Patient Daily  Diary  (UPDD)

[COMPANY_001] Confidential Page 121of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 122of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 123of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 124of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Patient Diary : Angioedema A ctivity Score (AA S)

[COMPANY_001] Confidential Page 125of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
Dermatology  Life Quality  Index (DLQI):

[COMPANY_001] Confidential Page 126of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 127of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 128of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 129of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 130of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 131of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301

[COMPANY_001] Confidential Page 132of 132
Amended Protocol Version No. 01 ( Clean ) Protocol No. CLOU064A2301
